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Abstract 
 
Background: Diagnostic molecular testing in colorectal cancer (CRC) offers a number of 
benefits including predicting prognosis, directing targeted therapies and screening for 
hereditary cancer syndromes. Molecular testing however is expensive, requires specialist 
facilities and staff and is time consuming, limiting its widespread availability. The Idylla 
System is an automated testing platform that could overcome these issues.  
 
Aims: To appraise the suitability of the Idylla System for use in clinical practice by 
evaluating the system’s accuracy and financial impact. 
 
Hypothesis: The Idylla System has high accuracy for detecting mutations in BRAF, KRAS 
and NRAS genes in CRC resection tissue and is a cost-effective alternative to current 
testing platforms.  
 
Methods: Ethical approval was granted by Oxfordshire Research and Ethics Committee A 
(reference: 04/Q1604/21). Diagnostic accuracy was determined for the Idylla System in 
detecting BRAF and KRAS mutations with a comparison against conventional polymerase 
chain reaction (PCR). Further validations were also performed for BRAF, KRAS and NRAS 
mutation testing against NGS and IHC methods. An audit of the molecular diagnostics 
workload was carried out and a cost-analysis performed. 
 
Results: The Idylla system had a sensitivity of 100.0% (95% CI: 88.3% to 100.0%) and a 
specificity of up to 100.0% (95% CI: 94.7% to 100.0%) for detecting BRAF mutations and 
a sensitivity of 100.0% (95% CI: 79.6% to 100.0%) and a specificity of up to 92.9% (95% 
CI: 68.5% to 98.7%) for detecting KRAS Mutations. There was 100% concordance for 
NRAS testing. A cost-analysis estimated that the Idylla System could save from around 
£12,000 to anywhere up to £40,000 per year in some centres.  
 
Conclusions: The results support the hypothesis that the Idylla System is an accurate 
system for detecting relevant mutations in CRC and demonstrate the system to be cost-
effective. The Idylla system is therefore suitable for use in routine clinical practice.  
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Chapter 1: Introduction 
 
1.1 Introduction to the thesis 
This thesis is focused on the diagnostic molecular pathology of bowel cancer. This is a 
disease which is a significant health problem in the United Kingdom (UK) and much 
improvement is still needed.9 Genetic testing of cancer tissue is one way in which the 
outcome for patients is hoped to improve. Mutations in three key genes, BRAF, KRAS and 
NRAS play a significant role, not only in the development of bowel cancer, but also in 
guiding the course of treatment for these patients. Testing for mutations in these genes has 
been recommended for several years now and is therefore increasingly common in 
National Health Service (NHS) laboratories.10-14 However despite guidelines, testing is still 
not universal for some of these genes and this is probably due to a lack of resources and 
facilities.15 The problem could be addressed by any number of the new technologies that 
are constantly being developed in the field of molecular diagnostics, but proper evaluation 
of such new systems is vital if we are to provide valuable and meaningful diagnostic 
information. The aim of this thesis is to investigate a new molecular diagnostics platform 
which could help address the problem of under-testing in bowel cancer across the NHS. 
This work will assess the accuracy of this new technology and the potential for it to 
overcome many of the barriers to universal testing.   
 
1.2 Bowel cancer 
1.2.1 The epidemiology and aetiology of bowel cancer 
Bowel cancer is overall the fourth most common cancer in the UK (excluding non-
melanoma skin cancer). Just over 40,000 cases are diagnosed each year, accounting for 
10-15% of all new cancers. Bowel cancer mortality in the UK is around 30% and causes 
almost one in 10 cancer-related deaths.9 Internationally, there are 1.3 million cases per 
year and these result in over 600,000 deaths.16 The incidence of bowel cancer is slightly 
higher in men, but for both men and women individually it is the third most common type of 
cancer. The incidence rises sharply after the age of 50 years and the mean age of 
presentation is 70.9 
 
The aetiology of bowel cancer is poorly understood but is likely to be a combination of 
genetic and environmental factors.10 There is good evidence that family history is a strong 
risk factor for developing bowel cancer. This familial risk is largely due to polygenic 
inheritance, but a number of inherited cancer syndromes are also directly linked to 
developing bowel cancer.10,17,18 Life-style probably plays a significant role in the 
development bowel cancer as well, with obesity, poor diet (high in fat and red meat, low in 
fiber) and a high intake of alcohol all associated with an increased risk.19-25 Another 
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important group at risk of bowel cancer are those with other pre-existing disorders of the 
gut, such as inflammatory bowel disease.26  
 
1.2.2 Relevant anatomy, histology, and physiology of the large bowel 
The gastrointestinal tract develops from the endoderm layer of the embryonic trilaminar 
disc. From around week four of gestation, the disc undergoes folding during which the 
endoderm forms a tube running the length of the embryo. From this tube the mouth, 
pharynx, oesophagus, stomach, small and large intestine and anus form.27 The gut is 
embryologically divided into the foregut (mouth to duodenum), midgut (duodenum to the 
distal third of the transverse colon) and hindgut (distal transverse colon to anus). Many of 
the accessory glands of the gut (the liver, pancreas etc.) develop from out pouchings of the 
endoderm early in organogenesis.28,29 
 
The bowel is a tube-like structure that comprises the mid and hindgut structures of the small 
intestine (duodenum, jejunum, ileum) and large intestine (caecum and vermiform appendix, 
colon, rectum and anal canal).30 The large bowel begins at the caecum, which is around 
10cm in length and sits in the right iliac fossa. Here, the small bowel (ileum) empties 
through the ileocecal valve into the large bowel. From the caecum the bowel extends 
retroperitoneally for about 20cm superiorly as the ascending colon into the right upper 
quadrant and, at the level of L2, forms the hepatic flexure. The bowel then extends across 
the body, intraperitoneally, for about 45cm as the transverse colon and, at the level of T12, 
forms the splenic flexure in the left upper quadrant. Next, the bowel extends 
retroperitoneally and inferiorly for around 25cm as the descending colon, into the left side 
of the pelvis.31 Once the bowel enters the pelvis it forms a 40cm section known as the 
sigmoid colon, due the S-shape course it takes. The anatomical boundaries of the sigmoid 
colon are not defined consistently however.32 At approximately the level of S3, just above 
the reflection of the peritoneum, the bowel forms a straight 12cm section known as the 
rectum.31,33,34 At the level of the levator ani muscle the bowel is known as the anal canal, a 
portion that extends for around 12cm to the anus.31,35 
 
The colon is attached to the abdominal wall by a fold of fatty connective tissue, known as 
the mesentery. Blood vessels, lymphatics and nerves all traverse the mesentery centrally, 
to supply the wall of the bowel.36 The midgut portions of the large bowel receive a blood 
supply from branches of the superior mesenteric artery and drain by the superior 
mesenteric vein into the portal system. Hindgut structures are largely supplied by the 
inferior mesenteric vessels, with the middle and lower thirds of the rectum supply from the 
internal iliac vessels. The lymphatic system of the bowel is rich and drains in a course that 
follows the vasculature, with lymph nodes scattered at junctional points along this course.37 
Within the bowel wall is a complex network of autonomic nerves, known as the enteric 
nervous system. This system regulates bowel wall muscle tone and the secretions of the 
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bowel during digestion. Although the enteric nervous system functions somewhat 
autonomously, it receives spinal cord input from higher centers which influence digestion.38 
 
The colon is a main site for the absorption of water in the body and, in doing this, functions 
to form and store faecal matter.39 The luminal surface of the bowel is lined by mucosa and 
this comprises a layer of simple (one cell thick) columnar epithelium sitting on a basement 
membrane, overlying lamina propria (loose connective tissue) and a thin layer of smooth 
muscle known as the muscularis mucosae. The epithelium is arranged in test-tube shaped 
intestinal glands that increase the surface area for absorption. This is shown in Figure 1. 
Scattered between epithelial cells are mucous secreting goblet cells, occasional 
neuroendocrine cells which play a role in modulating the enteric nervous system and (in 
the right side of the colon) Paneth cells, which may function as part of the innate immune 
system.40,41 At the junction between the upper two-thirds and lower one-third of the anal 
canal is the dentate or pectinate line, which marks a transition from glandular epithelium to 
squamous epithelium.42 Hilton’s white line marks the progression to keratinisation of the 
squamous epithelium,43 which is continuous with the epidermis of the anal margin skin.35,44 
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Figure 1. Photomicrograph of normal colorectal histology at low power. The mucosa is 
seen side on showing the intestinal glands arranged vertically (blue arrow), often said to 
resemble test tubes in a rack. The underlying pink fibers of the muscularis mucosae are 
also seen (red arrow), along with the lighter underlying connective tissue of the submucosa 
(black arrow). The deeper muscularis propria is not seen in this view. Inset: high power 
view of a normal intestinal gland as seen from above (cross cut) and surrounded by lamina 
propria. The epithelial cells are neatly arranged in a single layer with small regular basal 
nuclei. The gland lumen in seen in the center. H&E staining scanned at x400. H&E = 
haematoxlyin and eosin 
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Below the mucosa is a connective tissue layer known as the submucosa that extends to 
the underlying circular smooth muscle layer known as the muscularis propria.41 This muscle 
layer is involved in the contractile peristalsis that propels bowel contents along its route. A 
second, deeper layer of longitudinal muscularis propria also exists and this is continuous 
with three bands of muscle that extend along the length of the intra-abdominal surface of 
the colon, known as the taenia coli.41 The contractile nature of the taenia causes shortening 
of the overall length of the large bowel, causing the wall to fold in on itself and form pouched 
areas known as haustra. In the distal parts of the rectum, the muscularis propria transitions 
into to skeletal muscle as part of the rectal and anal sphincters.31 In various locations, along 
the bowel length are aggregates of mucosal-associated lymphoid tissue (MALT) present. 
MALT plays an important role in the adaptive immune system defenses in the bowel and 
helps regulate the commensal population of bacteria normally present in the colon.45 
 
1.2.3 The classification of large bowel tumours 
‘Tumour’ is a Latin word originally used to describe any swelling in the body (similarly the 
term ‘oncology’ is from the Greek ‘oncosis’ meaning swelling). Over time this has evolved 
and its use today usually refers to an abnormal, neoplastic (new growth) expansion of cells 
forming a tissue mass. Such tumours that remain localised to the tissue of origin are 
generally regarded as benign. Tumours comprising cells that develop the ability to infiltrate 
and invade surrounding tissues, as well as travel to distant parts of the body, are usually 
referred to as malignant. Although benign tumours can result in fatal consequences through 
local compression (such as benign meningiomas of the skull compressing the brain stem), 
in general it is malignant tumours that disseminate, take over the normal structure of the 
body and lead to death. The word ‘cancer’ is a general term used to refer to tumours that 
are malignant. When considering cancers of any site in the body, it is generally helpful to 
consider these in the context of all tumour types found in that tissue.46 
 
Bowel cancer most commonly affects the large intestine; small bowel tumours are rare and 
account for only tiny burden (<3%) of the disease.47 Therefore, the focus of this work is on 
large bowel tumours, referred to in the literature as ‘colorectal’. Most colorectal tumours, 
benign and malignant, arise from and distend the mucosal lining of the bowel.48 This usually 
forms a structure protruding into the luminal space, referred to as a polyp. Polyps in the 
traditional description are pedunculated (connected to the bowel with a stalk) but often they 
appear as a more gradually raised (sessile) area. Flat lesions are relatively uncommon but 
almost any of the tumours described here could theoretically present as flat lesion. 
Polypoidal lesions of the colorectum due to mucosal inflammation (inflammatory polyps, 
lymphoid aggregates) are not usually regarded as tumours and thought to have no 
malignant potential.49 
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In the UK, bowel cancers are reported following guidelines set out by the Royal College of 
Pathologists (RCPath) and the NHS. These guidelines largely follow the classification of 
bowel cancer given by the World Health Organization (WHO), summarised in Table 1. The 
WHO classification includes benign and malignant tumours.13,48,50 Primary epithelial 
tumours of the colorectum are subdivided into non-invasive and invasive lesions. Non-
invasive epithelial lesions include ‘conventional’ adenomas, serrated (saw-toothed 
appearance of the mucosa) lesions and hamartomas (non-neoplastic, benign masses of 
abnormally arranged tissue). Each is further sub-classified based on the histological 
architecture. Non-invasive lesions are benign and their prognosis is excellent if completed 
removed. However these lesions may or may not contain dysplasia.48 Dysplasia is a form 
of neoplasia and is said to be a ‘pre-malignant’ feature because there is an increased risk 
of malignant progression (invasion) of the tumour. Dysplastic tumours share morphological 
features with malignant tumours (atypical morphology such as a disordered proliferation of 
glands and cells showing nuclear enlargement, irregularity and hyperchromasia) but lack 
invasion of surrounding tissues (malignancy is by strict definition invasion through a 
basement membrane).46 The degree of dysplasia, where present, is graded as low or 
high.48 
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Epithelial Tumours 
Non-invasive 
Adenoma (with low or high-grade dysplasia) 
Tubular 
Villous 
Tubulovillous 
Serrated lesions 
Hyperplastic polyp 
Sessile serrated adenoma/polyp (sessile serrated lesion) 
Traditional serrated adenoma 
Hamartomas 
Cowden-associated polyp 
Peutz-Jeghers polyp 
Carcinomas (invasive) 
Adenocarcinoma  
Cribriform comedo-type adenocarcinoma 
Medullary carcinoma 
Mucinous adenocarcinoma 
Micropapillary carcinoma 
Serrated adenocarcinoma 
Signet-ring cell carcinoma 
Adenosquamous carcinoma 
Spindle cell carcinoma 
Squamous cell carcinoma 
Undifferentiated carcinoma 
Neuroendocrine neoplasms 
Neuroendocrine tumour (NET): grade1/2 (carcinoid) 
Neuroendocrine carcinoma (NET grade 3): large/small cell 
Mixed adenoneuroendocrine carcinoma 
Enterochromaffin cell, serotonin-producing NET 
L cell, glucagon-like peptide-producing & other peptide-producing NETs 
Mesenchymal tumours 
Leiomyoma 
Lipoma 
Angiosarcoma 
Gastrointestinal stromal tumour 
Kaposi sarcoma 
Leiomyosarcoma 
Lymphoma 
Secondary/metastasis 
 
Table 1. The WHO histological classification of tumours of the colorectum.48 
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Conventional adenomas are very common, most showing a tubular architecture that 
appears to recapitulate the normal tube like structure of the bowel mucosa. Villous 
adenomas form finger-like projections and are slightly less common. All conventional 
adenomas have at least low-grade dysplasia by definition and have the potential to develop 
high-grade dysplasia or invasive carcinoma. Serrated lesions include hyperplastic polyps 
(HP), which are probably by far the most common tumour of the colorectum.48 Hyperplasia 
refers to a non-neoplastic, overgrowth of normal tissue.51 The malignant potential of HPs 
(and hamartomas) has been debated for some time, but in the non-syndromic setting this 
is likely to be very low.46,52,53 Sessile serrated adenomas/polyps lesions (SSL) are a less 
common type of serrated lesion and these have similar appearances to HPs. In the United 
States (US), SSLs are known as sessile serrated adenoma/polyps (SSA/P). Unlike 
conventional adenomas, SSLs are not dysplastic by definition but may harbor foci of low or 
high-grade dysplasia and as such do have malignant potential.34,49,54 The final type of 
serrated lesion is the traditional serrated adenomas (TSA). TSAs are relatively uncommon 
but were described before SSLs and hence were designated ‘traditional’ in recognition of 
more recently described SSLs. TSAs look somewhat different in appearance to SSLs or 
HPs and they are considered to have at least low-grade dysplasia by definition.34,48 Polyps 
with overlapping appearances of many of the various categories are also recognised. 
Occasionally, small areas of early invasion (by adenocarcinoma) are seen in polyps and 
these cases are termed ‘polyp cancers’.48,55,56  
 
There are several subtypes of invasive tumour (cancer) of the colorectum in the WHO 
classification. The most common are those of epithelial origin (carcinomas). Carcinomas 
include adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, spindle 
cell carcinoma. This study will focus on the most common (90%) subtype of carcinoma, 
adenocarcinoma, and therefore from herein ‘colorectal cancer’ (or ‘CRC’) will be taken to 
mean this subtype. Most conventional adenocarcinomas display no specific features, 
however around 5% of tumours display a discrete morphological subtype. The subtypes 
include mucinous (rich in mucin and mucin producing cells), signet-ring cell, medullary 
(very hyperchromatic cells) and serrated (saw-tooth) carcinomas.10,48,57,58 An example of 
the typical morphology of a conventional colorectal adenocarcinoma is shown in Figure 2. 
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Figure 2. Photomicrograph of colorectal adenocarcinoma histology. A. The typical low 
power morphological appearances of a moderately differentiated adenocarcinoma of 
the colorectum (red arrow) with background normal epithelium present either side 
(black arrows). The dark pink band of muscularis propria can be seen here (running 
from top right to bottom left) lying deep to the mucosa and overlying serosal blood 
vessels and fat. B. A high power view of a malignant tumour nest within the 
submucosa (area from square in A), showing an attempt at glandular formation (as 
seen in moderately differentiated tumours), crowded and disorganised cells, nuclear 
enlargement and hyperchromasia, mitoses and central/luminal necrosis. Compare 
with the normal glandular structure demonstrated in the Figure 1 insert. H&E staining 
scanned at x400. H&E = haematoxlyin and eosin 
 
A 
B 
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Neuroendocrine tumours and non-epithelial tumours (including lymphomas and 
mesenchymal tumours) are uncommon and are not considered further in this thesis. 
Tumours arising in the appendix and the squamous lined portions of the anal canal and 
anus are usually considered separately from colorectal tumours and will also not be 
considered further in this work. Although metastasis to the colorectum is rare, extension of 
local tumours (e.g. of the bladder) is relativity common – this study however focuses on 
tumours arising from the colorectum and therefore secondary tumours will not be 
considered further in this thesis.10,48,57 
 
1.2.4 The pathogenesis of colorectal cancer 
Cancer is a genetic disease. Knudson described cancer development as an accumulation 
of mutations in key regulatory genes.46 Genetic dysregulation results in tumour cells that 
are phenotypically characterised by several key hallmarks including the, propensity to 
proliferate, resistance to cell death, evasion of growth suppression, evasion of the immune 
system, an alteration of cell metabolism, the induction of blood vessel formation 
(angiogenesis) and the ability to invade and migrate.59 The pathogenesis of CRC is one of 
the well-established models of cancer development and demonstrates many of these 
hallmarks.10,48 Table 2 shows an overview of the major genetic abnormalities present in 
sporadic CRCs60 that are discussed throughout this Subsection. 
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Gene Lesion Consequence Clinical Significance 
APC Deleted or 
mutated in 90% 
of CRCs 
Wnt signaling 
dysregulation and 
β-catenin 
accumulation 
Little prognostic significance, 
not routinely tested (germline 
mutations in FAP) 
KRAS Point mutation in 
30-40% of CRC 
Over-activation of 
EGF/MAPK 
signaling and 
proliferation 
Predicts prognosis and 
response to some 
treatments, routinely tested 
in clinical practice 
NRAS Point mutation in 
5% of CRC 
Over-activation of 
EGF/MAPK 
signaling and 
proliferation 
Predicts prognosis and 
response to some 
treatments, often tested in 
clinical practice 
18q LOH in 70% of 
CRCs, results in 
SMAD4 deletion 
Increased 
proliferation and 
progression to 
cancer, common in 
CIN 
Little prognostic significance, 
not routinely tested 
TP53 Mutation or 
deletion due to 
LOH 17p in 50% 
of CRCs 
Increased 
proliferation and 
progression to 
cancer 
Little prognostic significance, 
not routinely tested 
BRAF Point mutation in 
10% of CRC 
Over-activation of 
EGF/MAPK 
signaling and 
proliferation 
Predicts prognosis and 
response to some 
treatments, used in Lynch 
syndrome screening 
routinely tested in clinical 
practice 
MLH1 Hypermethylation 
(80%) or point 
mutation in 10% 
to 15% of CRC 
MMR deficiency 
and MSI 
Predicts prognosis and 
response to some 
treatments, used in Lynch 
syndrome screening 
routinely assessed by IHC in 
clinical practice 
 
Table 2. An overview of the common major genetic abnormalities present in sporadic 
colorectal cancer.48,60 Underlined are the clinically significant genes that are recommended 
for testing in routine practice. These include KRAS, NRAS, BRAF and MLH1.11-14,61 CRC = 
colorectal cancer, LOH = loss of heterozygosity, EGF = epidermal growth factor, MAPK = 
mitogen-activated protein kinase, CIN = chromosomal instability, MMR = mismatch repair, 
MSI = microsatellite instability, FAP = familial adenomatous polyposis, IHC = 
immunohistochemistry. 
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The first model of CRC was described by Vogelstein and presents carcinoma as occurring 
in a step-wise sequence from normal tissue.60,62,63 This sequence is demonstrated Figure 
3. The first step in the adenoma-carcinoma sequence is the development of a conventional 
adenoma with low-grade dysplasia, arising from normal tissue due to mutations in various 
genes. A key gene identified early on was APC (adenomatous polyposis coli).60,62 APC is 
involved in the Wnt signaling pathway that regulates β-catenin concentrations in the 
cytosol. β-catenin is a protein which, when translocated to the nucleus, results in the 
activation of a wide range of proliferation and anti-apoptotic pathways. β-catenin in turn is 
regulated by APC, the latter forming a destruction complex with other mediators to target 
β-catenin for ubiquitiniation. Wnt signaling inactivates the destruction complex, resulting in 
accumulation of β-catenin and increased cell survival.64,65 Loss-of-function mutations in the 
APC gene are found in over 90% of CRCs and are one of the first steps in the adenoma-
carcinoma sequence.60,66 
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Figure 3. The adenoma-carcinoma sequence. In this model, colorectal adenocarcinoma 
develops from normal colonic mucosa (shown in light pink) in a step-wise progression. This 
take place classically via the chromosomal instability pathway (genetic events shown along 
the top). Initially an APC mutation results in an early adenoma harboring low-grade 
dysplasia (light blue). Mutations in KRAS or NRAS result in enlargement of the polyp to an 
‘intermediate’ adenoma. Later events include loss of 18q and p53 (TP53), with the 
adenoma progressing through high-grade dysplasia (dark blue) to invasion into the sub-
epithelial tissue (light yellow). The microsatellite instability pathway demonstrates a similar 
step-wise progression (genetic events shown along the bottom). This is characterised by 
hypermethylation of MLH1. Tumours from either pathway may show a CpG island 
methylation phenotype (CIMP), where by hypermethylation downregulates tumour 
suppressor genes.60,67,68 CIMP = CpG island methylation phenotype (High/Low), LOH = 
loss of heterozygosity, MSI = microsatellite instability. 
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The next step in this sequence is a mutation in one of the Ras (rat sarcoma) genes, 
resulting in enlargement of the adenoma (so called intermediate adenoma).60,67,68 Around 
30–40% of sporadic CRCs have mutations in KRAS69-71 and around 5% have mutations in 
NRAS.71,72 RAS proteins are mediators in the mitogen-activated protein kinase (MAPK) 
pathway, which regulates cell proliferation in response to external growth factors such as 
epidermal growth factor (EGF). Binding of epidermal growth factor (EGF) to its receptor, 
epidermal growth factor receptor (EGFR), results in activation of KRas and subsequent 
activation of a cascade, as shown in Figure 4. This results in the up-regulation of a number 
of transcription factors, such as c-myc, that eventually result in increased cell division and 
survival.69,73 Mutations in KRAS or NRAS can result in constitutive expression and 
activation of KRas, leading to an over-activation of the MAPK pathway and uncontrolled 
cell proliferation and neoplasia. Ras mutations are clinically significant because there are 
therapies targeted at the MAPK pathway.69,70,74 This is discussed in further detail in Chapter 
4. 
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Figure 4. An overview of the MAPK signaling pathway. Growth factors (e.g. EGF) activate 
the EGFR receptor resulting in downstream activation via the receptor’s intrinsic tyrosine 
kinase action. Downstream molecules such as Ras proteins (e.g. Kras, Nras), Raf 
proteins (predominantly Braf) and eventually other MAPKs that up-regulate cell 
proliferation are in turn activated in a casecase. Mutations in Ras or Raf genes result in 
constitutively activated proteins in this pathway, even in the absence of EGFR 
signaling.73,75 MAPK = mitogen-activated protein kinase, EGF = epidermal growth factor, 
EGFR = epidermal growth factor receptor, Raf = rapidly accelerating fibrosarcoma family 
proteins, Ras = rat sarcoma family proteins 
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Loss of heterozygosity (LOH; loss of a gene containing chromosomal region) at 
chromosome 18q is the next major event in the adenoma-carcinoma sequence and is the 
most common large-scale chromosomal event seen in CRC. This is accompanied by a loss 
of expression of genes located in this region, such as SMAD4 a mediator in the TGF-β 
driven proliferation pathway. It is probably around this time that the adenoma develops 
high-grade dysplasia. From this point on, large-scale chromosomal abnormalities begin to 
accumulate.60,67,68 LOH is also seen across a large number of chromosomes,76 commonly 
this results in a loss of the TP53 gene (located in a LOH region of chromosome 17). The 
gene product p53 is a well-known tumour suppressor involved in apoptotic and cell-arrest 
pathways that are initiated by cell stress and deoxyribonucleic acid (DNA) damage. Loss 
of p53 function seems to be a gateway event between dysplasia and invasion.60,77 
 
The marked chromosomal abnormalities in the classical adenoma-carcinoma sequence 
described above has led to the use of the term ‘chromosomal instability’ (or ‘CIN’) pathway. 
‘CIN’ differentiates the sequence from other more recently described pathways (discussed 
below), however CIN probably accounts for around 70% of sporadic CRCs. The pathway 
is shown along the top of Figure 3.60,67,68  
 
The CIN pathway may be more common in patients with a history of inflammatory bowel 
disease (IBD), whose overall risk of CRC is much higher than the background population. 
IBD is a spectrum of chronic inflammatory disorders with an autoimmune basis. 
Predominantly IBD includes Crohn’s disease and ulcerative colitis.26,78 IBD patients that 
develop CRC show somatic mutations in classical CIN genes such as APC, KRAS and 
TP53 as well as a number of inflammation pathways such as COX-2.79,80 In contrast to non-
IBD CRCs, these tumours appear to develop more rapidly (driven by inflammatory 
cytokines) and may have an altered sequence of event; loss of p53 seems to occur much 
earlier and may be present in over 50% of biopsies from patients with inflamed non-
neoplastic epithelium. These changes seem to affect a wide area of colonic mucosa (known 
as a field effect) and dysplasia may be multi-focal and non-polypoid in morphology.81,82  
 
A second major pathway of CRC pathogenesis is associated with mismatch repair (MMR) 
deficiency and BRAF mutations.60,67,68 MMR proteins are involved in the repair of point 
mutations and insertion/deletions (indels) which occur during DNA replication. Each 
dividing cell is estimated to gain 10,000 DNA replication errors per day and therefore the 
MMR pathway is a vital cell survival mechanism.83 The MMR pathway was originally 
described in E.coli.84 During DNA replication, errors are initially recognised (sensed) by the 
Mutator S (MutS) protein which then in-turn recruits the Mutator L (MutL) protein. The 
MutS/MutL complex then forms and this recruits endonucleases to the site to initiate 
excision and repair. The MMR system in eukaryotes is demonstrated in Figure 5. In 
eukaryotes there are two major MutS homologs involved in mitotic MMR. These homologs 
are heterodimers comprised of either MSH2 and MSH6 (MutSα – senses base mispairing) 
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or MSH3 and MSH6 (MutSβ – senses indels). Other homologs containing MSH4 and MSH5 
may exist and are thought to be involved in meiotic MMR. The major MutL machinery 
homologs include an MLH1/PMS2 (MutLα) dimer, an MLH1/PMS1 (MutLβ) dimer and an 
MLH1/MLH3 (MutLγ) dimer. The MLH1/PMS2 dimer is thought to be the complex most 
dominant in mitosis, with the MutLβ complex probably more important in meiosis. The 
function of MutLγ is unknown.85,86  
 
MMR proteins are encoded by corresponding MMR genes. The expression of some MMR 
genes seems to influence the expression of others. In this respect, MLH1 and MSH2 can 
be thought of as dominant proteins in the heterodimer complexes because a lack of either 
protein usually leads to the loss of the respective heterodimer binding partners. For 
example, the loss of MLH1 will almost always lead to the loss of PMS2. This does not 
happen the other way around however, i.e. the loss of PMS2 does not usually result in the 
loss of MLH1. Similarly, the loss of MSH2 leads to the loss of MLH6.87-89 
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Figure 5. DNA mismatch repair (MMR) mechanisms. The process begins with a 
mismatched base (demonstrated as a red dot in the double helix) and this is sensed by 
the MSH2/MSH6 (mispairs) or MSH2/MSH3 (indels) sensing heterodimer complex. 
Sensing is followed by MLH1 recruitment and the formation of a second heterodimer with 
PMS2 (predominantly in mitosis), PM1 (unknown function) or MLH3 (predominantly in 
meiosis). The MMR complex then recruits endonucleases such as EXO1 to excise the 
lesion and DNA polymerase δ or ε (via the linker protein PCNA) to re-replicate the 
segment.84-86 
 
 
PMS2 
MSH2 MSH6 
MLH1 
MSH2 MSH6 
MLH1 
MSH2 MSH6 
Pol δ/ε   
EXOI 
PMS2 
37 
 
Point mutations and indels are common (especially the former) in DNA replication and 
areas of the genome where there are long repeats of a short sequence of bases are 
particularly prone. These areas are known as microsatellites and they comprise short 
tandem repeats (a 2-5 base sequence repeated up to 50 times). Microsatellites are 
scattered throughout the genome, many within gene coding areas, and mutations in these 
areas result in lengthening of the segment – known as microsatellite instability (MSI).90-92 
Around 15% of sporadic CRCs demonstrate MSI and this is now recognised as a second 
major pathway for the development of CRC (demonstrated along the bottom of Figure 
3).93,94 MSI is easily detected by examining the DNA sequence and the degree of MSI can 
be graded as MSI-H (high) or MSI-L (low), depending upon the degree of instability.95 MSI 
is almost always due to MMR deficiency, most commonly MLH1 epigenetic silencing by 
hypermethylation (see later), and various methods of assessing the function of MMR 
proteins is also now available.96  
 
Despite the name, the instability of microsatellites and associated MMR protein dysfunction 
are actually not detected until late in the progression of MSI tumours. Like the CIN pathway, 
initial genetic events in the MSI pathway are probably alterations in Wnt signaling. In 
contrast to CIN cancers however, MSI tumours rarely have mutations in Ras genes or show 
large scale chromosomal abnormalities. Instead, MSI tumours commonly show mutations 
in BRAF (an early event), CDC4 and BAX.60 BRAF mutations are particularly prevalent, 
present in 10–15% of sporadic CRCs. Like Ras proteins (Kras and Nras), Braf is a mediator 
in the MAPK pathway (see Figure 4).60,71,73,97 Interestingly, Ras and BRAF mutations 
however are almost mutually exclusive in colorectal tumours.98,99 Clinically, identifying MSI, 
MMR deficiency or BRAF mutations is useful11,13 and this is discussed further in Section 
1.4 and Chapter 3. 
 
A third major group of tumours now recognised belong to the CpG island methylation 
phenotype (CIMP) category.60,67,68 CpG islands are segments of DNA around 1000 base 
pairs (bp) in length, showing an enrichment of CG repeats (the ‘p’ in CpG represents a 
phosphate bond). These regions are very common in the genome and many are found in 
gene promotor regions.100,101 Methylation of cytosine bases in these areas results in a 
cascade of events that cause histone modification and local chromatin remodeling. 
Ultimately, this leads to reduced transcription at the methylation site.102 It is thought that 
around 60% to 80% of CpG islands are methylated and this allows the genome to be 
modified by a mechanism other than classical transcription regulation, a mechanism known 
as epigenetics. Mutations in genes that regulate methylation pathways are thought to in 
turn lead to changes in the methylation patterns of key cell cycle regulatory genes.101 Many 
CRCs (CIN and MSI tumours) show global, non-specific hypomethylation, which is thought 
to probably lead to an over expression of certain proliferative oncogenes.60,103 In CIMP 
CRC however, there is hypermethylation and reduced expression of tumour suppressor 
genes and these seem to be a distinct subset of tumours. Depending on the degree of 
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hypermethylation, such cancers may be designated as CIMP-H (high) or CIMP-L (low).67 
The relationship of CIMP tumours to the CIN and MSI pathways is demonstrated in Figure 
6. Although CIMP is described as a third pathway for the adenoma-carcinoma sequence, 
as can be seen there is much overlap of CIMP with the CIN and MSI pathways.60,68 Some 
serrated lesions are more associated with CIMP than others however. SSLs and serrated 
cancers arising from SSLs are usually CIMP-H, have MSI and show BRAF mutations. In 
contrast, TSAs and serrated cancers arising from TSAs are usually CIMP-L, microsatellite 
stable (MSS) or MSI-L and have KRAS mutations. Hyperplastic polyps are suspected as a 
precursor lesion in the development of both SSLs and TSAs as these polyps usually have 
either a BRAF or a KRAS mutation.34,60,68,104-106  
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Figure 6. Proposed pathways of serrated carcinoma development. In this model dysplasia 
(shown in light blue) and serrated adenocarcinomata (dark blue) develop from normal 
colonic mucosa (light pink) in a step-wise progression via distinct events. Sessile serrated 
lesions (SSL) show early BRAF mutations and arise from a possible hyperplastic polyp 
(HP) precursor. These tumours are CIMP-H and consequently show MLH1 
hypermethylation and microsatellite instability (MSI). Traditional serrated adenomas (TSA) 
may also develop via a HP precursor but by contrast show early KRAS mutations and are 
CIMP-L.34,60,67,68,105 HP = hyperplastic polyp, CIMP = CpG island methylation phenotype 
(High/Low), SSL = sessile serrated lesion, TSA = traditional serrated adenoma, MSI = 
microsatellite instability. 
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The pathogenesis of CRC after the development of invasion includes mechanisms by 
which the tumour is able to disseminate throughout the body. In order to do this, the tumour 
must traverse the sub-epithelial connective tissue and access the lymphovascular space. 
Epithelial-mesenchymal transition (EMT) describes the process by which carcinoma cells 
take on the phenotype of mobile stromal cells (such as fibroblasts).46,107,108 Many pathways 
are involved in this process, including Wnt.109 Once the tumour has accessed the 
lymphatics or vasculature, cells are able to disseminate to lymph nodes and distant organs 
– the latter causing the most disruption to normal physiology. Metastases in vital organs 
and carcinomatosis (generalised, wide-spread metastases) results in end-organ failure and 
death, commonly due to opportunistic infection.46 
 
Most CRCs are sporadic, however around 3–5% of occur in the setting of a directly 
inheritable cancer syndrome.18 Table 3 gives a summary of the major inherited colorectal 
tumour syndromes. Lynch syndrome (LS) is the most common of these in CRC and is 
caused by germline monoallelic mutations in MMR genes, resulting in MSI tumours. LS is 
discussed in detail in Chapter 3.11 Constitutional mismatch repair-deficiency syndrome is a 
rare and aggressive cancer syndrome that is caused by the biallelic MMR gene mutation 
counterpart to LS.110 Many of the other inherited CRC syndromes present with polyposes 
(numerous benign and malignant polyps).111 The most famous of these is familial 
adenomatous polyposis (FAP), which is characterised by thousands of conventional 
adenomas in the colon and an extremely high risk of malignancy. FAP is due to autosomal 
dominant germline mutations in APC, the function of which was discussed above. Some 
APC mutations are less pathogenic and an attenuated FAP syndrome also exists.112 
MUTYH-associated polyposis is characterised by numerous conventional adenomas and 
is caused by mutations in the MYH base-excision repair gene.113 Polymerase proofreading-
associated polyposis (PPAP) is caused by germline mutations in POLE and POLD, which 
encode DNA polymerases. PPAP patients generally develop numerous conventional 
adenomas. DNA polymerases have a proofreading function alongside their role in DNA 
replication and cancers which arise from this syndrome (or those with somatic POLE/POLD 
mutations) show a very high rate of mutations (the hyper/ultramutator phenotype).114,115 
The hyperplastic or serrated polyposis syndrome presents with numerous serrated lesions 
and these patients have an increased risk of serrated carcinoma; no germline mutation has 
yet been identified.116 Finally, hereditary mixed-polyposis is caused by GREM1 mutations 
and presents with various types of neoplastic polyps.117 There are also syndromes which 
present with numerous hamartomatous polyps, including Cowden’s syndrome (germline 
PTEN mutation),118 juvenile polyposis (germline SMAD4 or BMPR1A mutation)119 and 
Peutz-Jeghers syndrome (STK-11 mutation).120  
41 
 
 
 
 
Syndrome Gene(s) affected Characteristics 
Lynch syndrome11 MLH1, PMS2, MSH2, 
MSH6 
Non-polyposis CRC, MSI, 
cancers at other sites (e.g. 
endometrium) 
Familial adenomatous 
polyposis (FAP)112 
APC Thousands of colonic 
polyps , high risk of CRC 
MUTYH-associated 
polyposis113 
MUTYH Similar to FAP 
Polymerase proofreading-
associated polyposis114,115 
POLE, POLD1 Multiple adenomas with 
hypermutated cancer 
development 
Hyperplastic/serrated 
polyposis116 
Unknown Multiple serrated lesions 
with increased cancer risk 
Hereditary mixed 
polyposis117 
GREM1 Mixed polyp types, 
probably cancer risk 
Cowden syndrome118 PTEN Hamartomas of the colon, 
skin tumours, high risk of 
various cancers 
Juvenile polyposis119 SMAD4, BMPR1A Hamartomas (more 
commonly in stomach), 
high cancer risk 
Peutz-Jeghers syndrome120 STK-11  Hamartomas (more 
commonly small bowel) 
and mucocutaneous 
pigmentation, increased 
cancer risk 
 
Table 3. A summary of the major colorectal tumour syndromes, the genes affected and the 
clinical characteristics. CRC = colorectal cancer, MSI = microsatellite instability, FAP = 
familial adenomatous polyposis. 
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1.2.5 The clinical presentation of colorectal cancer 
Most patients with CRC are initially asymptomatic but symptoms when present are 
generally non-specific, including weight loss, abdominal pain and rectal bleeding. Two 
thirds of CRCs present as left sided (distal) tumours and the remaining third are found in 
the transverse and right colon. 20% of patients present with distant metastases.10 Bowel 
obstruction or perforation at presentation is uncommon but, when this occurs, it imparts a 
poor prognosis.60 
 
1.2.6 The investigation and diagnosis of colorectal cancer 
The investigation and diagnosis of CRC in the UK is carried out following the National 
Institute for Health and Care Excellence (NICE) and the British Society of Gastroenterology 
(BSG) guidelines.12,121,122 Early CRC is often asymptomatic and therefore the UK NHS 
Bowel Cancer Screening Program (BCSP) is now offering both a one-off bowel scope 
(flexible sigmoidoscopy) screening for persons aged 55 and then after biannual faecal 
occult blood testing (FOB) for persons aged 60 to 74. FOB testing is based on the principle 
that CRC undergoes microscopic haemorrhage into the faecal stream.121,123 Patients with 
suspected cancer are referred for urgent investigation within two weeks. Patients with 
symptoms or positive screening results are usually investigated by colonoscopy (whole 
bowel endoscopy). Alternatively, where colonoscopy has failed or is not possible, other 
options include flexible sigmoidoscopy and computerised tomography (CT) colonoscopy. 
Small tumours (polyps) identified by colonoscopy will usually be excised, larger lesions are 
biopsied. Histopathological evaluation (see later in Subsection 1.2.9) of colonoscopy 
acquired tissue samples is the gold standard test for CRC. The diagnosis of colorectal 
lesions is based on the WHO classification given in Table 1 and reported following the 
guidelines for the BCSP.10,12,50,122,123 The reporting process may involve the use of 
immunohistochemistry (IHC; also see later in Subsection 1.2.9) to aid diagnosis or detect 
MMR deficiency (MLH1 IHC for example). Molecular testing is becoming increasingly 
common in CRC as this can help guide management (see later Section 1.4). In particular, 
molecular testing for BRAF, KRAS and NRAS mutations is common.11-14 
 
Patients with a strong family history of colorectal cancer, polyposis syndromes or 
inflammatory bowel disease are offered screening with primary colonoscopy at varying 
internals depending on risk stratification.12,121,123,124 
 
1.2.7 The Staging of colorectal cancer 
Staging is an assessment of how far a cancer has invaded and spread throughout the body. 
This is preliminarily carried out clinically on the patient by using various imaging techniques. 
The final definitive Stage is given later by a pathologist and is derived from examination of 
the surgical resection specimen. In general, Staging involves determining the local spread 
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of the primary tumour, the presence of metastases in regional lymph nodes and the spread 
of metastases to other distant sites in the body.46 
 
There are two Staging systems recommended by the RCPath for CRC reporting in the 
UK.13 The Dukes’ Staging system is the older of the two and still preferred by some 
surgeons and oncologists.125 Dukes’ Staging has undergone a number of modifications 
since the original A to C categories were described. The Dukes and Bussey modification 
first split category C into C1 and C2, and the Turnbull modification added a D category. 
The current system is shown in full in Table 4.13,125,126 The more recent Union for 
International Cancer Control (UICC) Tumour Node Metastasis (TNM) classification (given 
in Table 5) streamlines a system for Staging across sites in the body and is increasingly 
becoming the gold standard.127 Although the TNM system categories emulate the same 
groups as the traditional Dukes’ system (see a comparison in Table 6), it is more detailed 
and therefore offers greater patient sub-classification. Therefore, Dukes’ is being largely 
replaced by the TNM system in clinical practice.128  
 
 
 
Dukes’ Stage Criteria 
A No invasion beyond muscularis propria, no 
metastases  
B Invasion beyond muscularis propria, no 
metastases  
C1 Regional lymph nodes positive, highest 
resected node negative 
C2 Regional lymph nodes positive, highest 
resected node positive  
D Distant metastases  
 
Table 4. The Dukes’ staging system for colorectal cancer. The 
approximate equivalent TNM classification is given in brackets. 
The Stage D group and split of C into C1 and C2 were later 
developments from the original A to C system.13,129 
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TNM Designation Criteria 
T Primary Tumour 
TX Cannot be assessed 
T0 No invasive tumour 
T1  Tumour invades the submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through muscularis propria 
into serosa or pericolic/perirectal tissue 
T4a Tumour directly invades other organs or 
structures 
T4b Tumour perforates the visceral peritoneum 
N Regional Lymph Nodes 
NX Cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases in 1 to 3 regional lymph nodes 
N2 Metastases in 4 or more regional lymph nodes 
M Distant Metastases 
MX Cannot be assessed 
M0 No distant metastases 
M1 Distant metastases identified 
 
Table 5. The Union for International Cancer Control 5th TNM classification of 
colorectal cancer.13,129  
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Groupings UICC Groupings Dukes Stage Equivalent  
T0 N0 M0 0 N/A 
T1 or T2 and N0 M0 I A 
T3 or T4 and N0 M0 II B 
T1, T2, T3 or T4 and 
N1 or N2 and M0 
III C1 or C2 
T1, T2, T3 or T4 and 
N1 or N2 and M1 
IV D 
 
Table 6. A comparison of the Union for International Cancer Control (5th edition) and 
Dukes’ Staging systems.13 
 
 
 
Although TNM is replacing the older Dukes’ system, there are problems with using TNM. 
The system is currently up to its 8th edition,127 however the RCPath guidelines (not updated 
since the 7th edition) mandate the use of the 5th edition, citing a lack of high-level evidence 
for the changes made in the TNM 6th and 7th editions. The RCPath guidelines also reject 
the 5th TNM’s designation of Tis to tumours that have breached the epithelial basement 
membrane (BM) and invaded the lamina propria.13 Although a BM breach would satisfy the 
definition of malignancy, (invasion of the surrounding tissues)46 the RCPath designates 
these as T0 adenomas with high-grade dysplasia and does not recognise the Tis 
designation (therefore Tis is not given in Table 5); only tumours that invade the submucosa 
are designated T1. The reason for this disagreement is because the traditional view is that 
lamina propria invasion has no metastatic potential due to a lack of lymphovascular 
spaces.13 It has been shown however that the lamina propria does contain lymphatics130 
and that intramucosal carcinoma may be clinically important to differentiate from 
adenoma.50,131,132 The issue remains an area of contention in the UK. There are advantages 
and disadvantages to both the UICC and Dukes’ Staging systems then and disagreement 
over which should be used in practice. Therefore, the RCPath guidelines recommend that 
pathologists report the Stage with both systems currently.13 Internal RCPath and NHS 
BCSP discussions (unpublished) suggest the 8th TNM will be recommended from 2018. 
 
Polyp cancers by definition will tend to fall into the T1/Dukes’ A stage, however providing 
additional information on how deep within the polyp the cancer has invaded (Haggitt level 
for pedunculated polyps or Kikuchi level for sessile polyps) may be prognostic and so is 
recommended by the RCPath.13,50,129    
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1.2.8 The management of colorectal tumours 
The management of colorectal tumours in the UK is also based on NICE and BSG 
Guidelines. The discussion below is derived from these guidelines, however local practices 
and individualised treatment plans may vary.12,121,122,133-135  
 
Patients with isolated non-malignant and non-dysplastic polyps (e.g. hyperplastic polyps), 
or negative colonoscopies, in general require no further intervention. Small, non-invasive 
pedunculated or sessile dysplastic lesions are usually treated by simple snare 
polypectomy. Larger polyps can be removed by piecemeal endoscopic mucosal resection 
(EMR). Distal polyps that cannot be easily removed at endoscopy can be removed using a 
more extensive technique known as transanal endoscopic microsurgery (TEM). Polyps are 
categorised into low (one or two small adenomas, both ≤10mm), moderate (three to four 
small adenomas or one adenoma ≥10mm) and high (more than five small adenomas or 
more than three small adenomas, one of which is ≥10mm) risk. Low risk polyps can 
essentially be discharged from screening whereas follow-up colonoscopy is recommended 
for moderate risk (at three years) and high-risk (at one year) polyps up to the age of 75 
years. Large sessile polyps are at risk of incomplete excision at endoscopy and therefore 
resection site tattooing and re-examination after two to three months is advised. Polyp 
cancers are often discovered incidentally within clinically benign appearing polyps and 
these are managed similar to high-risk benign polyps, with follow-up shortly after surgery if 
initial excision margins were clear of tumour. Patients diagnosed with polyposis syndromes 
at this stage are offered more intensive colonoscopy follow-up, depending upon their 
risk.12,121,123,135  
 
Patients with invasive disease will undergo CT scanning as part of a pre-operative 
assessment for tumour Stage (see earlier) and resectability (technical ease of surgery). 
Rectal tumours are further assessed for resectability with magnetic resonance imaging 
(MRI).12,133 Pre-operative blood carcinoembryonic antigen levels are predictive of outcome, 
but likely just reflect tumour burden and are not often used routinely.60  
 
Radiologically resectable Stage I-III colonic tumours are generally amenable to surgical 
resection, either traditional open or preferably where possible laparoscopic surgery. EMR 
is sometimes considered for Stage I colon tumours. Small resectable stage I rectal tumours 
may be treatable by TEM or EMR. Further management is based on histopathology of the 
resection specimen.12,133 
 
Radiologically unresectable Stage I-III colonic tumours may be offered neoadjuvant (prior 
to surgery) chemotherapy to try to optimise the tumour into a resectable state. Treatment 
would otherwise be palliative. Chemotherapy options include capecitabine monotherapy or 
oxaliplatin with 5-flurouracil (5-FU) and folinic acid combinations.12,133  
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Radiologically resectable Stage I-III rectal tumours deemed to be high-risk (tumours with 
venous space invasion or resection specimens likely to result in positive surgical resection 
margin, as predetermined by imaging) may be offered short-course preoperative 
radiotherapy (SCPRT) and/or neoadjuvant chemotherapy to optimise (minimize the risk of) 
the tumour for surgery.12 
 
Patients with Stage IV disease by imaging may be offered surgery if both the primary and 
distant metastases can be resected, otherwise resection may be limited to the primary 
tumour with further chemo-radiotherapy palliative treatment or palliative care alone. 
Monoclonal antibody (mAb) therapy with cetuximab or panitumumab may be indicated in 
some patients with advanced metastatic disease (see Chapter 4).12,133 
 
The type of surgery offered for CRC depends on the location of the tumour. Most are left 
sided cancers and require either a left hemicolectomy (removal of most of the distal large 
bowel), sigmoidectomy, anterior resection (excision of the lower sigmoid and upper rectum) 
or an abdominoperineal resection (excision of the rectum and anal canal). Right-sided 
tumours will usually be excised as a right hemicolectomy and occasional tumours may 
require transverse colectomy. A pancolectomy (excision of the entire colon) is rare for 
cancer management but may be used where synchronous tumours (separate primary CRC 
tumours arising at the same time in different sites) affect distal and proximal parts of the 
bowel. Further management is planned post-operatively, based upon the histopathological 
evaluation of resected tissue and molecular testing (see Subsection 1.2.9 below).136 
 
1.2.9 The histopathological assessment of colorectal cancer   
The histopathological assessment and reporting of CRC in the UK must follow RCPath 
guidelines in order to meet UK Government laboratory accreditation policy, overseen by 
the UK Accreditation Service (UKAS).13,137,138 Traditional histopathology involves both a 
macroscopic (gross) and a microscopic examination of tissues removed from the body. For 
preservation and easy of preparing microscopy slides, tissues are formalin-fixed and 
paraffin-embedded (FFPE). The resulting blocks of tissue are thinly sectioned using a 
microtome, placed on a glass slide and stained for contrast. The routine histological stain 
is the haematoxylin and eosin (H&E) preparation, as demonstrated in Figure 1. Most 
diagnoses are made by a morphological examination of the microscopic tissue with H&E. 
The development of immunostaining has seen histopathology expand into the assessment 
of cell protein expression. In IHC, a specific primary antibody (Ab) is applied to tissue 
sections and this binds to the target protein (if present) of interest. A secondary Ab labeled 
with a chromogen is then applied and this secondary Ab in turn binds to the primary Ab. 
Finally, the chromogen is enzymatically converted into a visible dye that stains the tissue, 
highlighting the presence and location of the target protein by light microscopy 
(immunoperoxidase staining). Alternatively, a fluorescent dye is used 
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(immunofluorescence staining). Now largely automated, both morphological and protein 
expression analysis of tissue sections has remained the focus of diagnostic histopathology 
for some 30 plus years.139-141  
 
The initial histopathological diagnosis of CRC is usually made on a small tissue biopsy 
taken during the screening or diagnostic process. Definitive histological diagnosis of the 
tumour is considered a gold standard test and is necessary to predict outcome and direct 
therapy. This initial diagnosis will be later confirmed on the resection specimen. Once a 
diagnosis of adenocarcinoma is made, a number of other features must also be assessed. 
The grade of the cancer gives an indication of the aggressiveness of the disease. This is 
based upon the morphological appearances (the degree of glandular differentiation) as is 
given as well, moderately or poorly differentiated – the latter carrying the worst prognosis 
if considered independently of other factors.10,48,57 Of less prognostic significance, but still 
helpful and in common use, is noting the presence or absence of lymphovascular space 
invasion or perineural invasion.142  
 
Following the biopsy diagnosis, the pathologist will receive the surgically resected 
specimen. The specimen should be fixed, examined macroscopically, dissected and 
examined microscopically to confirm the biopsy findings. Confirmation of the diagnosis and 
other features on the resection specimen is considered definitive and therefore should 
always be carried out. The specimen will generally include a long segment of bowel that 
contains the tumour and a safe distance of normal bowel to either side, to ensure complete 
removal of the cancer. Attached to the bowel will be a portion of mesentery, blood vessels, 
lymphatics and draining lymph nodes. Usually the mesentery is resected as a triangular 
wedge-shaped segment along with its corresponding vascular branch from the superior or 
inferior mesenteric artery, the apex of which is tied off at the vessel ligation site. Also at the 
apex is the highest (most proximal) draining lymph node. The pathologist will assess how 
cleanly the specimen has been dissected from the body by the surgeon, as the plain of 
excision can in some circumstances influence outcome. The pathologist will then ink the 
specimen (see later) and open the bowel to examine the tumour. It is important to note the 
relationship between rectal tumours and the peritoneal reflection.13 Rectal tumours above 
the peritoneal reflection actually behave like colon tumours and have a better prognosis, 
so this is important information to relay to the surgeon and oncologist.33 The pathologist 
will then make cuts through the tumour to see the extent of its spread. Samples of the 
invasive area will be taken for microscopic confirmation. The extent that the tumour has 
spread locally is important as this gives an indication of how advanced the disease is and 
predicts outcome for the patient. This is referred to as Staging and was discussed earlier 
in Subsection 1.2.7. As part of the Staging process, assessment of tumour spread to lymph 
nodes is required and so these nodes will be dissected out from the mesentery and 
examined microscopically.13 
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The completeness of excision is obviously very important, as residual tumour in the patient 
must be followed up with further treatment. Therefore, the tissue margins must be assessed 
microscopically and the status reported to the surgeon (‘involved by’ or ‘clear of’ tumour). 
As part of this process the pathologist will ink the margin surfaces during dissection, to aid 
with identification during microscopy. The highest draining node and the root of the apical 
blood vessels also give an indication of possible residual tumour left in the body and so 
these structures are always examined microscopically.13 
 
Distant metastases are also very important as these indicate a very poor prognosis (Stage 
IV disease). In general, metastases are easily detected on imaging and biopsy confirmation 
is not usually necessary. The treatment at that point is likely to be palliative and as such, 
resection of metastatic tissue is also uncommon. It is unusual then for the pathologist to 
examine metastatic tissue and so the M category of Staging is usually assessed by a 
radiologist.10,13,57 
 
The findings of the pathologist are reported to the surgical and oncological teams and this 
is used to determine the prognosis and any follow-up therapy needed. Follow-up 
management is based on NICE and BSG guidance. Pathologically (histologically) Stage III 
and high-risk (tumours with venous space invasion or resection specimens with positive 
surgical resection margins) pathologically Stage II rectal tumours are followed up with post-
operative adjuvant chemotherapy. Pathologically Stage II colonic tumours deemed high-
risk (poorly differentiated, obstructed, with perineural invasion or low surgical lymph node 
yield, as determined by histological assessment) and pathological stage III tumours are 
also offered post-operative adjuvant chemotherapy.10,12,57 
 
1.2.10 The prognosis of colorectal cancer 
The prognosis of CRC is largely based upon Staging, which is carried out as described 
above (Subsection 1.2.7) by combining pathology and radiology findings. In developed 
regions, the overall 5-year survival for CRC is around 65% and has remained static for 
some years. Just over half of patients present with low-staged (Stage I/II, limited to the 
bowel wall) tumours and have relatively good prognoses when treated by surgical 
resection, with a 5-year survival of around 90%. Tumours that have spread to local lymph 
nodes (Stage III) have a poorer prognosis and this group makes up the majority of patients 
with higher-staged disease. The 5-year survival in this group is around 70% and these 
patients usually require adjuvant chemotherapy. The survival figures fall sharply to around 
10% for patients who present with, or later develop, distant (e.g. liver/lung) metastases 
(Stage IV). In some instances, these patients are fit and tumour metastases are amenable 
to resection. However, for those with inoperable metastases the management is 
palliative.10  
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1.3 Diagnostic molecular pathology  
1.3.1 Overview of molecular diagnostics 
So far, this thesis has discussed the traditional approach to cancer management based 
upon histopathological and radiological tumour assessment. However, there is now an 
understanding that the genetic make-up of a tumour can significantly inform and guide 
clinical management. Testing normal tissues (such as blood) for germline mutations and 
inherited syndromes is not new and is a well-established practice that takes place in Clinical 
Genetics laboratories in most hospitals. It is becoming increasingly recognised however 
that testing abnormal tissues and tumours is also clinically useful. This recognition has led 
to a new branch of pathology known as ‘molecular diagnostics’, or ‘diagnostic molecular 
pathology’. The two main types of lesion encountered in this practice are translocations 
and point mutations. Testing for these lesions may aid the diagnostic process, guide 
treatment and influence prognosis.18,112,143 
 
Translocations and other chromosome level abnormalities have been detected using 
cytogenetic approaches for many decades but these are now becoming increasingly 
viewed as a part of diagnostic molecular pathology testing in cancer management. 
Traditionally karyotyping, a technique whereby the chromosomes were stained and viewed 
directly, was used. The most common method of detecting translocations in the diagnostic 
setting today is by in situ hybridisation (ISH) techniques. ISH uses a labeled nucleic acid 
probe to bind to denatured DNA within cells to allow visual recognition. Similarly to IHC, 
probes may be labeled with a chromogen (CISH) visible by light microscopy or a 
fluorophore (FISH) visible with fluorescent microscopy. Probes are designed to bind to 
specific regions of the chromosome which will allow the microscopist to determine the 
status of chromosomes. Probes are usually designed for two different locations on a 
chromosome with two different colours, allowing the spatial analysis of chromosomal 
components. Classically, two ‘break-apart’ probes target DNA regions close together on 
the genome and in the non-translocated setting the two colours blend (for example green 
and red become yellow). In the translocated scenario, the colours are seen as separate 
and distinct (red and green), indicating a separation of the chromosomal regions. So-called 
‘fusion’ probes are designed in the opposite manner, to bind to areas of DNA at loci of 
chromosome fusion (thus translocated is yellow and non-translocated is red and green). 
FISH can also be used to assess gene copy number variation relative to ploidy within cells, 
in a technique known as comparative genomic hybridisation.143  
 
Mutation analysis is really the main area of emerging genetic testing in diagnostic molecular 
pathology. Mutation testing relies upon two main techniques – polymerase chain reaction 
(PCR) and gene sequencing, both of which will be discussed in turn in the Subsections 
below.143  
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1.3.2 Sample preparation  
Before any mutational analysis can be carried out, nucleic acid (most commonly DNA) 
needs to be extracted from the tissue. DNA extraction requires physical disruption of the 
cell and nuclear membranes, and digestion of DNA-binding proteins. Extraction can be 
carried out on fresh tissue, frozen tissue (fresh tissue which was frozen and processed at 
a later time after thawing), FFPE tissue and blood. Blood is generally only used for germline 
sequencing or for testing haematological disorders. Sequencing germline DNA is useful for 
molecular tumour testing because the germline is subtracted from the tumour DNA 
sequence and this leaves only somatic changes. PCR or sequencing for solid tumour 
molecular diagnostics is usually carried out on either fresh frozen (FF) or FFPE tissue. The 
general pathway for tissue handling in molecular diagnostics is shown in Figure 7.144 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. An overview of the tissue handling workflow in diagnostic molecular pathology. Small biopsies taken from the patient for molecular testing are generally 
processed in the Fresh Frozen (FF) pathway (along the top). After freezing in liquid nitrogen, a small sample is taken for frozen section histology to confirm the 
presence of tumour. For large resection specimens FF tissue may be taken before fixation, however the need for molecular testing is often only realised at a later 
stage and so must be carried out on the fixed tissue. In this circumstance the Formalin Fixed, Paraffin Embedded (FFPE) pathway (along the bottom) is needed. 
In the FFPE pathway, the tumour is identified by routine histology and thin sections from that tissue block are matched against the slides. The DNA content is 
optimised by using macro-dissection to discard non-tumour tissue. In either pathway, DNA (or RNA) is extracted from the sample following histology and this is 
stored for molecular testing.144 DNA = deoxyribonucleic acid, RNA = ribonucleic acid  
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The first step in molecular testing is to confirm that the tissue sample contains viable (non-
necrotic) tumour cells and if so to make an estimate of the number of nuclei (i.e. the amount 
of DNA) present that are of tumour (somatic) or background normal (germline) cells. Each 
molecular test has its own limit of detection (LOD; also called analytical sensitivity) of 
mutation frequencies within the extracted DNA pool. It is therefore best practice to check 
the tissue sample meets the minimum tumour DNA content (usually given as a percentage 
tumour nuclei content) required in order to avoid diluting the sample with the germline and 
masking somatic mutations (causing false negative results). Checking the sample tumour 
content can easily be carried out using H&E histology. To do this, a piece of the fresh tissue 
biopsy is frozen and a frozen microtomy section is taken for histology. If suitable for testing 
the remaining tissue is processed for DNA extraction. For cases being tested from FFPE 
tissue (tissue samples not taken specifically for molecular testing, e.g. resection 
specimens), histology sections will already have been prepared for diagnostic examination. 
From the H&E slides, a suitable area of the tumour (area high in tumour cell content, non-
necrotic and with little DNA contamination by lymphocytes) will be selected and marked 
with ink. The corresponding paraffin-embedded tissue block will then be used for molecular 
testing. From that tissue block, either microtomy sections will be cut or a small tissue punch 
will be taken for DNA extraction144 
 
DNA extraction is a time-consuming process requiring specialist skill and equipment. To 
ensure the DNA is of high quality, the cold ischaemia time (time from when biopsy was 
taken to fresh extraction or fixation) should be kept to under 24 hours. Data on warm 
ischaemia time (while blood flow to sampled area is disrupted but tissue is still in the body) 
are lacking. Fresh or fresh-frozen samples are the ideal for molecular testing as the 
extracted DNA is usually of high quality and is not altered by fixation.145 It is technically 
difficult to acquire samples from soft, unpreserved material (i.e. from the patient or fresh 
resection specimen), so these tend to be large pieces of tissue. In comparison, FFPE 
samples are easy to take from the tissue block and are usually small. In order to extract 
the DNA, the sample for testing first requires disruption (dividing into smaller pieces, cells 
separated from each other and the connective tissue matrix, cell and nuclear membranes 
lysed) and homogenisation (cells and cellular components evenly distributed in the 
suspension). These are achieved using a combination of physical (rotator-blade) and 
chemical (denaturing enzyme buffer) methods; disruption and homogenisation usually 
occur simultaneously.144,146-148 
 
Tissue fixation results in DNA fragmentation, DNA base changes (C>T and G>A) and DNA-
DNA or DNA-protein cross-linking, all of which can introduce artifacts when sequencing or 
amplifying.145 This makes molecular testing less reliable when carried out on FFPE tissue 
and so these samples are discouraged where possible. However, routine diagnostic 
molecular pathology tests are carried out on only a small proportion of cases and this it is 
usually only realised that molecular testing is needed after a histological diagnosis is made. 
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Therefore, testing FFPE tissue is difficult to avoid in practice. The method of formalin 
preparation and fixation may however influence the extent of DNA damage and so fixation 
protocols can be optimised for molecular testing.144,149 There are a large number of 
available tissue fixatives, each with specific advantages and disadvantages. The most 
widely used in the clinical setting for histology are based on formaldehyde. Traditionally, 
formaldehyde fixatives were prepared as either 10% formalin (40% formaldehyde aqueous 
stock solution diluted to 4% formaldehyde with distilled water) or 10% formal saline (10% 
formalin buffered with sodium chloride and sodium phosphate).150 Modern formalin 
protocols buffer 10% formalin (40% formaldehyde aqueous stock solution that may contain 
up to 12% methanol, diluted with distilled water) to a neutral pH with sodium dihydrogen 
phosphate, monophosphate (4g per 100ml formalin) and disodium hydrogen phosphate, 
anhydrous (6.5g per 100ml formalin).151 Neutral-buffered formalin appears to be superior 
for preservation of DNA than older buffered or unbuffered formalin fixatives, and therefore 
it is now the recommended fixative for all clinical histology laboratories. Data on non-
formaldehyde fixatives is beginning to surface and may show future promise.152 Fixation 
should be for no longer than 72 hours and carried out at 4°C. Fixed tissue should then be 
embedded in plain paraffin wax. As mentioned above, FFPE specimens are generally small 
because they are easier to acquire from relatively solid preserved material.144,149 The 
samples are often already partially disrupted (small punches or thin microtomy sections) 
and therefore require little physical disruption. However, FFPE tissue requires 
deparaffinisation, re-hydration, cell separation and homogenisation; this is often achieved 
using ultrasonication. The cells can then be disrupted (lysed) using an enzyme buffer and 
homogenised with a vortex mixer.146,148 Once extracted, DNA is purified using a number of 
filtration methods. Extracted nucleic acids are generally of variable quality and quantity and 
therefore a quality control step using fragment size analysis and/or total nucleic acid 
quantitation (UV-absorbance or fluorescence) is usually reccomended.146,148,153,154 
 
1.3.3 Conventional PCR-based tests 
The PCR reaction is a simple process of amplifying fragments of DNA, as demonstrated in 
Figure 8. Double stranded DNA (dsDNA) is heated until the strands denature and separate 
(melt). Specific DNA sequences known as primers are then added. The sample 
temperature is next lowered, allowing the primers to anneal (by hybridisation) to the target 
DNA. DNA polymerase and G, T, A and C nucleotide bases are then added and the 
temperature is raised slightly to allow the polymerases to extend the primers across each 
DNA strand until the whole region of interest is replicated. The result is two new molecules 
of dsDNA. The reaction can be cycled over and over again, each time doubling the DNA 
content.155  
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Figure 8. The basic principle of the polymerase chain reaction (PCR). First, the DNA is 
denaturised by heating to around 95°C for up to 30 seconds. This causes hydrogen bonds 
to break between the strands, allowing separation. The temperature is then lowered to 
around 50°C for 30 seconds, primers are added and these anneal through hybridisation to 
specific DNA sequences of interest. Next, nucleotide bases are added along with DNA 
polymerase (only added once in the first cycle) and the sample is heated to around 80°C. 
The heating time is dependent on the number of bases being amplified (around 1000 bases 
per minute). The process is cycled over and over until detectable levels of DNA have been 
amplified.155 DNA = deoxyribonucleic acid 
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Traditionally, PCR products were run out on gel electrophoresis in order to identify whether 
a specific product was present. The advent of real-time quantitative PCR (qPCR) saw a 
move to semi-automated analysis of the DNA product. In qPCR a fluorescent signal is 
produced in the presence of the DNA product in solution. This originally was carried out by 
the reporter-dye method, whereby a dye that produced luminescence upon binding to 
double-stranded DNA, would accumulate during the reaction. This was later replaced by 
florescent reporting probes (e.g. TaqMan), which contain a luminescent reporter molecule 
and an anti-luminescence quencher probe in close proximity. In the resting state no signal 
is produced and during the hybridisation stage the probe will anneal to single stranded DNA 
(ssDNA) fragments of specific sequences. Upon extension by DNA polymerase, the 
quencher is released allowing the reporter to fluoresce and be detected by the PCR 
machine.155,156 
 
The detection of fluorescent a signal enables the quantification of the amplified DNA with 
reasonable accuracy. The point at which the fluorescent signal intensity reaches above the 
background noise threshold (known as the cycle quantification or Cq value) can be used 
to calculate (known as a ΔΔCq calculation) the end product concentration. The 
quantification process involves calibrating the system against a known concentration of 
DNA beforehand. The PCR test is considered positive once the product exceeds the Cq 
value. The ΔΔCq method of identifying a DNA sequence is diagnostically useful when 
detecting for example vial DNA, however this method has less utility in gene mutation 
detection because designing primers which specifically target mutated DNA (such as point 
mutations) is challenging and thus specifically amplifying only mutated DNA above the Cq 
value is difficult. Many conventional PCR-based mutations tests instead use a melting point 
analyses. In melting point analyses, the rate at which the amplified dsDNA product melts 
over a range of temperatures is compared a known reference standard for the target 
sequence in question. Once again a florescent probe (various types available) is used to 
detect the amount of DNA product which has melted. Subtle changes in the nucleotide 
base sequence can significantly alter the melting curve profile of a DNA product (G-C bonds 
are more thermostable than A-T bonds) and therefore reporting a mutation with this method 
becomes highly specific.155,156  
 
An advancement of traditional PCR, known as droplet digital PCR (ddPCR), is becoming 
popular for validation work. This technique uses extracted DNA dispersed into oil 
nandroplets, each droplet containing one molecule of DNA. The PCR reaction then takes 
place within the droplet, which is then either positive or negative by fluorescent signaling. 
This is a very sensitive method of detecting tiny quantities of a DNA segment of interest 
and using Poisson statistics, exact quantification is possible. The downside of this 
technology however is the high cost and need for highly skilled staff, meaning it is yet to be 
used in routine clinical practice.157 
57 
 
1.3.4 Sequencing-based tests 
Sequencing refers to a technique whereby the actual sequence of bases is determined in 
a molecule of RNA or DNA. The traditional chain-termination technique was developed by 
Frederick Sanger in the late 1970’s.158 In so-called ‘Sanger sequencing’ the DNA is 
extracted and amplified using PCR. The DNA samples are then split into four aliquots. All 
four DNA bases are added to the aliquots along with DNA polymerase and a primer to start 
the reaction. In addition, a dideoxynucleotide form of one of the bases is added; a 
dideoxynucleotide of a different base to each of the four aliquots. The dideoxynucleotide 
when randomly incorporated to the extending DNA molecule (instead of a regular 
deoxynucleotide) halts the chain reaction at that base. This results in a sample comprising 
DNA molecules terminated at different lengths, each one representing a position where 
that base is present in the sequence. When all four aliquots are run out next to each other 
on an electrophoresis gel, the radiolabeled dideoxynucleotide bases will be seen at each 
position in the DNA fragmentation ladders, allowing the sequence to be determined. Later 
the technique evolved into what is known as capillary sequencing, where by different 
fluorescent tags in the sequence are read by a laser and the sequence is determined by 
an automated process.159   
 
Sanger sequencing was a revolution in molecular biology and much of the human genome 
project was carried out using this technology. There are practical limitations to Sanger 
sequencing however, the method is slow, expensive and sometimes of poor quality, which 
means the diagnostic utility of this technology has remained limited. Despite these issues, 
Sanger sequencing is still considered a gold standard by many, however next-generation 
sequencing (NGS) attempts to overcome the issues with Sanger’s methodology.159 NGS is 
a high-throughput method of sequencing with a fast turnaround time and low cost. Many 
different platforms and versions of the principle are available, however the underlying 
principle is massive sequencing of small DNA fragments in parallel. DNA is first extracted 
and then fragmented randomly. The fragments are ligated at each end with adaptors. The 
adaptors allow the DNA fragments to bind to a matrix for sequencing and can incorporate 
a unique base sequence barcode so that multiple patient samples can be processed 
together. The two main platforms available for clinical diagnostic use are the Illumina 
(Illumina, Inc.)160 and Ion Torrent systems (Thermo Fisher Scientific Inc.).161 The Illumina 
platform uses a glass slide ‘flow cell’ matrix that is covered by a ‘lawn’ of complimentary 
adaptors. The complimentary adaptors allow sample DNA fragment adaptor binding. The 
sample is washed over the slide and the DNA fragments bind, becoming spatially fixed at 
one co-ordinate on the slide. In contrast, Ion Torrent uses a solution of microbeads, each 
with a similar complimentary adaptor. Once the DNA fragment attaches to the microbead, 
each microbead is centrifuged into a single microwell. In both Illumina and Ion Torrent 
systems, DNA fragments are amplified in situ using conventional PCR methods, during 
which each of the four bases is washed over the samples in turn in a continuous cycle. The 
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incorporation of a base into the extending fragment is detected – ‘sequencing by synthesis’. 
In the Illunima platform, a fluorescent signal is produced as a base is incorporated and a 
high-resolution digital image capture and analysis system acquires the signal at each co-
ordinate on the glass slide lawn after each base addition. In the Ion Torrent platform an ion 
sensitive field-effect transistor semiconductor chip detects changes in the pH in the 
overlying microwell as hydrogen ions are released during base incorporation. In both 
systems, the DNA fragment is read as it is replicated and because many copies of the 
same genome are present in the sample, there are multiple random DNA fragments 
covering and overlapping any one area of the genome. Furthermore, each DNA fragment 
is replicated (read) numerous times in the sequencing process. Reads (the sequence from 
each replication) are combined, and overlapped using bioinformatic software, by comparing 
with a reference genome, so the entire sequence can be presented. The reference genome 
may either be the same person’s germline from their blood or an internationally 
standardised reference genome (currently GRCh38). As mentioned, any one area of the 
genome is present in multiple DNA fragments that are read numerous times, therefore 
every base of DNA will have been sequenced many times. The number of times each base 
has been read is known as the depth of coverage and this gives an indication of how 
accurate the sequencing is likely to have been. There are many applications of NGS, 
targeted genes or gene segments can be sequenced or the entire genome can be read 
(whole genome sequencing; WGS). Software can be used to annotate regions where base 
changes (compared to reference sequence or germline) are present. Any base change 
identified can be crosschecked with reference databases and the wider literature, to 
determine if the base change has a known pathological or clinical consequence.159-161  
 
Traditional Sanger sequencing showed initial success in the research, forensic and some 
clinical settings, but the application to diagnostic pathology has been limited. NGS is now 
emerging as a technology that offers fast and cheap detection of gene mutations and can 
compete with conventional PCR in molecular diagnostics. Most prominently, the use of 
WGS is being promoted with the 100,000 genomes project, however understanding this 
data and integrating it into clinical care is some way off. Targeted gene panels though, 
which use NGS to sequence specific known sites of deleterious gene mutations, has the 
most clinical potential at present and is becoming popular. Gene panels offer mutation 
analyses at speeds and costs comparable to conventional PCR, while offering a much 
wider range of mutation detection in one assay than a PCR-based test can.159,162  
 
In this Subsection, the two main types of NGS methodologies in widespread use have been 
discussed. There are other types of NGS systems available however and all have quite 
different properties and test limitations. It is important to note which type of NGS 
methodology is being discussed when evaluating any system because each is quite 
different. In this thesis, the Ion Torrent system has been focused upon and therefore the 
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term ‘NGS’ from herein, unless otherwise stated, will be used to mean sequencing 
specifically on this platform.  
 
1.3.5 RNA and protein expression profiling 
Finally, a remaining major area of molecular diagnostics, which is worth noting, are 
molecular technologies that investigate RNA and protein expression. Detecting and 
profiling the RNA content of cells (transcriptomics) allows for a direct measurement of cell 
gene expression. The main techniques have involved extracting RNA, converting this to 
complimentary DNA (cDNA) and using a number of hybridisation techniques for detecting 
the levels of expression. Although these techniques proved promising initially, there seems 
to have been little translation into routine diagnostics as of yet. This could change in the 
future as these techniques become more streamlined.163 Protein expression using IHC may 
be surpassed in the future by emerging proteomics techniques – the examination of the 
whole protein content of the cell using mass spectrometry. Once again, this has yet to make 
it into routine diagnostic practice but once the cost and time restraints are resolved this 
could be a powerful clinical tool.164  
 
1.4 The molecular diagnostics of colorectal cancer 
Routine diagnostic molecular pathology tests for patients with CRC generally include 
targeted identification of specific gene mutations and determining the MSI status. The most 
common tests in routine practice are for mutations in BRAF, KRAS and NRAS. Whilst most 
centers use PCR-based tests for targeted mutation identification, a few centers use 
targeted NGS panels. Whole genome sequencing (WGS) is generally not used in routine 
practice yet.165  
 
Microsatellite status is prognostic (MSI indicates a better survival), may indicate poor 
response (if MSI present) to 5-FU therapy and most importantly is useful for LS screening 
(MSI is present in LS-associated tumours; see Chapter 3).60,93,166 MSI status can be 
determined with PCR-based assaying using multiple markers of microsatellite length. 
Depending on the degree of microsatellite expansion, tumours are designated as 
microsatellite stable (MSS), MSI low (MSI-L) or MSI high (MSI-H) – as mentioned earlier in 
Subsection 1.2.4. Alternatively, many centers use MMR protein IHC in conjunction with 
BRAF targeted mutation testing (see below). Loss of expression in one or more of the four 
MMR proteins (MMR deficiency), MLH1, PMS2, MSH2 or MSH6, is associated with 
MSI.11,167 The method of determining MSS vs. MSI/MMR deficiency is probably not 
important167 and IHC evaluation of MMR protein expression in conjunction with BRAF PCR 
is the most commonly used approach to LS screening in the UK and US. MMR gene 
methylation is also used in some institutions.11,13,167,168  
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Targeted mutation detection in current routine practice focuses on the BRAF, KRAS and 
NRAS genes. A detailed discussion of each of these will follow in Chapters (3 & 4), but a 
brief overview will be considered here. BRAF mutation status is prognostic for patients with 
Stage II or above CRC and is also useful in screening for LS in conjunction with MMR IHC 
(as mentioned above). BRAF testing in this context is carried out on those tumours with a 
loss of MLH1 IHC expression. This is a common event in sporadic as well as hereditary 
tumours and causes many false positives in LS screening. BRAF mutations are almost 
never present in LS (see Chapter 3) and so the detection of such a mutation helps rule out 
LS. BRAF testing has therefore been a routine PCR-based test for some time in many 
pathology laboratories.11,13,167,168 Recently, an IHC method of detecting BRAF mutations 
has gained popularity and is used in a number of institutions, although accuracy data have 
been conflicting.169,170  
 
KRAS (and probably NRAS) mutation status is useful in directing anti-EGFR monoclonal 
antibody (mAb) therapy in Stage IV CRC and may be prognostic. Therefore KRAS (and 
increasingly NRAS) testing has now become routine in many pathology laboratories. 
Commercial PCR-based tests are available for KRAS, however there are few widely used, 
commercially available and approved NRAS tests. Generally, NRAS testing is carried out 
with NGS.69,70,133,134,171,172 Routine EGFR testing for CRC is not common, however recent 
data suggest that the S492R codon change may predict response to therapy in Stage IV 
disease. EGFR S492R testing in CRC may become increasingly used in the future, 
however no commercial test is available yet.173,174 
 
Although this thesis focuses on current clinically routine testing, it is worth mentioning other 
areas of molecular testing that have been, or are currently under investigation. 
Unsurprisingly, somatic APC testing has been evaluated over the years. An APC mutation 
appears to impart a poor prognosis, however this mutation is found in over 90% of sporadic 
tumours and so the clinical utility of testing for these mutations has not be easy to prove. A 
similar story exists for TP53 mutations and the loss of 18q, although some specific losses 
in the latter (i.e. ‘deleted in colorectal carcinoma’ and SMAD4 gene mutations) are 
predictive of poor outcome and reduced response to 5-FU therapy. Despite this, 18q testing 
has yet to make it into clinical practice due to some conflicting data on the issue.60  
 
The effectiveness of 5-FU is also predicted by a number of polymorphisms in several 
enzyme pathways, including thymidylate synthetase, dehydropyrimidine dehydrogenase 
and methylenetetrahydrofolate reductase. Similarly, oxaliplatin therapy may be predicted 
by polymorphisms in glutathione-S-transferases. These have yet to make it into clinical 
practice, but this may be a significant area of personalised medicine in the future, once 
WGS is more widely available.60 
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HER-2 amplification (common in breast cancer) is seen in around 13% of rectal cancers 
and may be associated with poor outcome in those treated with 5-FU. HER-2 amplification 
is also thought to impart anti-EGFR mAb therapy resistance in a small number of KRAS 
wild type cases.175,176 The data is early on these findings, however testing may be important 
in the future. Likewise, some early data suggest PIK3CA mutations may predict anti-EGFR 
mAB and aspirin therapy, and direct inhibitors of the gene product (PI3K) look to become 
important in the future of CRC therapy.177 
 
Finally, an emerging area of cancer treatment is immunotherapy. Strictly, immunotherapy 
could be said to include any of the above Ab-based therapies, but the term is more 
commonly used to mean vaccine or checkpoint inhibitor drugs178. Vaccine therapy in CRC 
has been focused around anti-carcinoembryonic antigen (CEA) immunisation strategies179 
and this could be an indication for routine CEA testing (on tumours or blood) in the future. 
Checkpoint inhibitors aim to alter the T-cell immune response to tumours. The alteration 
can be by enhancing the immune surveillance of T-cells or can be by overcoming the 
mechanisms by which tumours avoid cell-mediated death. The most intensively 
investigated drug targets involved in immune surveillance are PD-1/PDL-1 and CTLA-4. It 
is likely that testing of these or other related targets (such as markers of microsatellite or 
MMR status), to stratify patients for checkpoint therapies, will be a significant part of future 
routine molecular diagnostics for CRC.178 
 
1.5 Developments in colorectal molecular diagnostics 
The current (and probably the future) focus of research in CRC surrounds the molecular 
(genetic) basis of the disease and how this can inform the diagnostic and management 
pathways. This will likely include molecular screening tests, non-invasive (blood-based) 
diagnostics and monitoring, as well as personalised medicine. For histopathology, the 
implications are likely to be further molecular scrutiny of tumours and the role of molecular 
diagnostics in CRC will become increasingly important.180 Aside from this, the main 
movement of molecular diagnostics now is driven towards building and integrating PCR 
and NGS-based tests into routine practice to allow wider access to targeted testing across 
the NHS. The main issue is related to service provision. PCR and NGS-based technologies 
require expensive specialist laboratories and skilled staff, and so availability is fragmented 
across the UK. Therefore, testing is not universal and is lacking in many NHS hospitals.15 
There is a continual drive to streamline testing and reduce costs in order to address these 
problems. At the same time, new technologies are evolving at a fast pace. One such new 
technology is fully automated PCR. This approach is promoted as cheap, fast and requiring 
no specialist facilities or staff. In this sense, automated PCR may address some of the 
current issues with diagnostic molecular pathology and help widen testing availability. The 
technology however has not been rigorously validated or studied to date. The focus of this 
thesis in the following Chapters is to address this lack of validation data. The work will be 
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carried out within the context of CRC, because this comprises a significant proportion of 
the histopathology and molecular testing workload in most clinical departments. The 
investigation will focus on the use of automated PCR for routine molecular testing in CRC. 
This includes BRAF, KRAS and NRAS mutation testing.155,165,167,180,181  
 
1.6 Automated PCR 
1.6.1 The Idylla System 
Many of the commercially available PCR and NGS systems offer partial or semi-automated 
processing. Fully automated PCR however (referred to from hereon as ‘automated PCR’) 
is novel and as yet there is only one platform commercially available that offers end-to-end 
automation in one setup: the Idylla System (Biocartis). Idylla is a fully automated real-time 
PCR system that can detect mutations in BRAF, KRAS, NRAS and EGFR, as well as the 
presence of some respiratory viruses, in a variety of tissue sample types. The system has 
an on-demand (i.e. non-batched) turn-around time of between 90 and 150 minutes 
(depending on the test), including pre-test preparation and post-test analysis. It is suitable 
for use by staff not trained in molecular biological techniques and can be carried out in any 
setting (including the potential for point-of-care testing with blood in the future). The system 
is a small, stand-alone platform which can be placed in any histopathology (i.e. non-
specialist/non-molecular) laboratory (see Figure 9) and comprises a computer console and 
up to four processing units. Each processing unit can test one patient sample per run and 
each unit can run different tests with different samples, at the same time and on-demand, 
independent of the other units. The system provides end-to-end processing without the 
need for additional molecular equipment. The cost per test is variable and based on the 
caseload, but is competitive at around £100 per test (based on the manufacture quotation). 
Tissue preparation (section cutting) adds no additional burden beyond that of conventional 
PCR.161,182,183 
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Figure 9. The Idylla computer console 
(above) with a single processing unit 
(below). 
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The Idylla technology is cartridge-based (see Figure 10) and uses microfluidic (capillary 
action-based pumping) processing with all the reagents on-board. This allows almost all of 
the pre-test sample preparation to be automated. The cartridges require a user only to input 
a small volume of FFPE tissue and the remaining processes, including nucleic acid 
extraction, are fully automated – carried out onboard the processing unit (Figure 9). The 
system does this using high-frequency ultrasound focused at the sample (dissolved in a 
buffer and enzyme solution) to disrupt the cell membranes.182  
 
 
 
 
 
 
Figure 10. An Idylla test cartridge (an NRAS-BRAF-EGFRS492R Mutation 
Assay cartridge shown here). 
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At the time of planning this thesis, the Idylla System had two test cartridges for commercial 
use in diagnostic settings. The Idylla BRAF Mutation Test184 and the KRAS Mutation Test185 
are both Conformité Européene in vitro diagnostics (CE-IVD marked) approved (legally 
required and marks completion of a quality control process before sale as a diagnostic 
medical device in the European Economic Area)186,187 and were the first Idylla assays on 
sale for diagnostic use.182,184,185,188 Further prototype tests were also available at the time. 
The Idylla NRAS-BRAF-EGFRS492R Mutation Assay189 and the Idylla ctBRAF Mutation 
Assay190 were available for Research Use Only (RUO; not CE-IVD marked). The Idylla 
Respiratory (IFV-RSV) Panel (for infectious disease) was also available but this test was 
not clinically relevant for this study.191 
 
The Idylla PCR amplification takes place onboard the console and the system uses real-
time fluorophore-based detection with a highly specific system of novel primers, probes 
and signaling molecules – conventional TaqMan-based methodology (discussed earlier in 
Subsection 1.3.3) for the Idylla BRAF Mutation Test and a novel PlexPCR-based (SpeeDx 
Pty Ltd) methodology for the Idylla KRAS and NRAS-BRAF-EGFR assays.185,189,192 
PlexPCR uses a system of primers (PlexPrime) that create amplicons containing a small 
region with a sequence different from that of the target DNA. This works together with a 
specific amplicon sequence-matched reporter probe (PlexZyme). This detection method 
significantly increases the overall target specificity and allows multiplexing of numerous 
gene mutations in one assay.193,194 
 
A Cq value is calculated onboard the Idylla computer console for each mutation target and 
this is automatically compared against a wild type standard curve to give a ΔCq value. If 
this ΔCq value falls within a validated range, a positive (mutant) result is given; if the value 
falls outside of the validated range, a negative (wild type) result is given. Because the Idylla 
assay probes have highly specific binding properties (unlike those used by conventional 
PCR systems), the signal curve produced during the PCR reaction can itself be used for 
detection of the mutation with the Cq method, unlike most conventional platforms which 
use the melting technique as discussed in Subsection 1.3.3. This means that the Idylla 
results are ready at the end of the PCR amplification process, making the whole process 
quicker and able to detect low levels of tumour mutation burden with high specificity. The 
curve analysis is automated on-board the console and the results are presented on screen 
as either ‘No mutation detected’ or ‘X mutation detected’.182 
 
1.6.2 Potential benefits of Idylla 
There are essentially two basic methodologies for detecting gene mutations in clinical 
practice, those based on PCR and those based on gene sequencing. A comparison of the 
tests available for BRAF, KRAS and NRAS testing on the Idylla with the most commonly 
used PCR system (Cobas) and NGS (Ion Torrent) assays for these targets are given in 
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Table 7. Tests that are based on PCR are by far the most commonly used in practice as 
this is a fast, robust (low test failure rate) and cost effective technique. Sequencing 
technologies, at present, are only available to a small number of UK NHS clinical 
laboratories in specialist centres. Sequencing technology is much slower and it is far more 
expensive than PCR. PCR is therefore preferential. There are several potential benefits of 
the Idylla System over conventional PCR approaches or NGS technology. First, the Idylla 
System is fully automated, meaning that no specialist training is needed and no specialist 
setting is needed to house the system. The typical NHS histopathology laboratory does not 
have the specialist training or facilities needed in order to run molecular tests such as PCR 
or NGS gene panels. The Idylla System is unique in that all the processes are automated 
and carried out on-board the system. This means that it can be placed in any histopathology 
laboratory and tissue does not have to be sent elsewhere for testing. This eliminates a 
whole range of practical, legal and administrative issues around sending tissue out of the 
department. The Idylla tests are also much faster than most molecular tests, providing 
same day results when current tests can take on average a week or longer. Finally, the 
Idylla claims to need far less tissue than most PCR or NGS platforms, with adequate DNA 
obtained from a single tissue section (cf. up to eight tissue sections often needed for PCR 
or NGS). Therefore, the Idylla System could prove to be superior to many other 
technologies available for BRAF, KRAS and NRAS testing in CRC. The potential 
advantages could remove the barriers to testing in some centers and help to provide the 
wider availability of these tests that is needed.182 
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 Gene     Idylla182 Cobas z 480 (PCR)183 Ion PGM (NGS)161 
  BRAF 1) NRAS-BRAF-
EGFRS492R Mutation 
Assay189 
Coverage: 
V600D/E/E2/K/R 
PCR method: 
PlexPrime/PlexZyme Cq 
curve 
Detection limit: ≤5% 
Turn-around time: 2 
hours (approx.) 
 
 
2) BRAF Mutation Test184 
Coverage: 
V600D/E/E2/K/M/R 
PCR method: TaqMan 
Detection limit: 1%  
Turn-around time: 1.5 
hours 
 
1) BRAF V600 
Mutation Test195 
Coverage: V600E 
PCR method: TaqMan 
Cq curve 
Detection limit: >5% 
Turn-around time: <8 
hours 
 
 
AmpliSeq Cancer Hotspot 
Panel version 2196 
Coverage†: R444W, P453T, 
R462I, G464E/V/R, 
G466R/V/A/E, 
G469R/S/V/A/E, V471F, 
N581S, I582M, F583F, 
L584L/F, E586E/K, D587E/A, 
I592M/V, D594E/N/V/G, 
F595S/L, G596D/R, 
L597L/Q/S/V/R, A598V, 
A598_T599insV, T599I, 
T599_V600insTT, 
T599_V600insT, 
V600D/E/G/A/K/R/M/L/Q, 
K601N/E, V600_K601>E, 
K601del, R603*, W604G, 
W604del S605F/N/G, G606E, 
H608R,  
Detection limit: 98% 
detection rate for 5% variant 
frequency at positions with 
average sequencing coverage 
from 1,000X to 4,000X  
Turn-around time: Single day 
  KRAS KRAS Mutations Test185 
Coverage: 
G12C/R/S/A/D/V, G13D, 
A59E(G&T), 
Q61H(H2)/K(K2)/L(R), 
K117N1(N2), A146P(T&V) 
PCR method: 
PlexPrime/PlexZyme Cq 
curve 
Detection limit: ≤5%  
Turn-around time: 2 
hours (approx.) 
KRAS Mutation Test197 
Coverage: 
G12C/R/S/A/D/V, 
G13C/S/R/D/V/A, 
Q61K/E/P/R/L/H/H2 
PCR method: TaqMelt¶ 
melting curve  
Detection limit:  <5% 
Turn-around time: <8 
hours 
 
AmpliSeq Cancer Hotspot 
Panel version 2196 
Coverage†: V8V, 
G10_A11insG, G12_G13insG, 
A11P/V,  
A11_G12insGA, 
G12F/C/L/V/S/R/E/V/D/A/G/Y/I
/W, G13R/C/S/R/V/D/A/V/G/E, 
G13_V14insG, V14I , G15S, 
A18D, L19F, Q22K, T58I 
,A59G/T/E, Q61K/E/P/R/L/H/K, 
K117N, A146T/V/P 
Detection limit: see above 
Turn-around time: Single day 
  NRAS NRAS-BRAF-EGFRS492R 
Mutation Assay189 
Coverage: 
G12C/S/D/A(V), 
G13D/V(R), A59T, 
Q61K/L/R/H(H2), 
K117N(N2), A146T(V) 
PCR method: 
PlexPrime/PlexZyme Cq 
curve 
Detection limit: 1-5% 
Turn-around time: 2 
hours (approx.) 
No relevant test 
available on this 
platform 
AmpliSeq Cancer Hotspot 
Panel version 2196 
Coverage†: A11T, 
G12N/R/C/S/D/A/V/G, 
G13R/C/S/V/D/A/G, A18T, 
G60E, Q61L/K/R/E/P/L/R/H/Q, 
S65C, A146T 
Detection limit: see above  
Turn-around time: Single day 
*Terminating codon notation. †Coverage given is for the codon changes that are likely to be relevant in CRC. 
¶TaqMelt probes are proprietary detection probes used by Roche in melting point assays. () indicate codon 
changes covered by Idylla but not distinguishable by the system from the preceding codon 
 
Table 7. BRAF, NRAS and KRAS assays on the Idylla System compared with common 
PCR (Cobas) and NGS (Ion Torrent) platforms. Turn-around times and detection limits are 
quoted from manufacturers. Permission to reproduce this table from a similar published 
table has been granted by the British Medical Journal Publishing Group Ltd.4 PGM = 
personal genome machine, PCR = polymerase chain reaction, NGS = next generation 
sequencing, X = average number of times base/DNA segment has been sequenced 
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1.6.3 Literature review for the Idylla System 
The published literature on the Idylla System and its technology is extremely limited. When 
this thesis was conceived and planned there were no studies with Idylla System published. 
Biocartis did provid access to a number of posters and a conference abstracts on their 
website.198 These appeared to be internal to or sponsored by Biocartis and contain data 
from small validation style studies mostly using the Idylla BRAF Mutation Test. These 
posters quote the concordance of Idylla with PCR and various sequencing methodologies 
as between 97% and 100%. The cases analysed in these studies appear to be highly 
selected and the results probably only serve as a proof-of-principle. It is extremely unlikely 
this data had been peer-reviewed and is therefore of uncertain reliability. However, if taken 
on face value, the data did suggest a high level of concordance with conventional testing 
methods and so the diagnostic accuracy was expected to be high.199-207 No attempt to 
formally investigate the diagnostic accuracy of the Idylla System had been made before 
this thesis work was started though. Some of the data from the initial posters and abstracts 
appears to have been included in later publications by the same authors. These papers 
and other literature published since this thesis work was carried out, is discussed in Section 
5.5. 
 
1.6.4 Research questions unanswered by the literature  
The evidence for the Idylla System was extremely scanty and so there remained a number 
of unanswered research questions. There was a need to carry out full, unbiased and 
unselected diagnostic test accuracy studies for the Idylla System in detecting BRAF, KRAS 
and NRAS mutations with comparisons against routine standard tests currently used 
(conventional PCR and NGS). There was also a need to compare the BRAF Mutation 
Assay with IHC methods that are becoming popular in many laboratories.  
The aim of the study described in the following Chapter was to address these unanswered 
research questions as far as possible within the limits of time and funding.  
 
1.7 Chapter summary  
CRC is a significant health problem in the UK and results in a large number of deaths each 
year. The aetiology of CRC is not well established but the pathogenesis is thought to occur 
via an intermediate adenoma stage and progress along a number of well-defined molecular 
pathways. The traditional approach to managing patients with CRC is largely based on the 
prognosis, determined by Staging. Staging involves initial clinical Staging using radiological 
findings and final definitive Staging based on a histopathological assessment of the 
resected tumour. The mainstay of treatment for CRC is surgery, but histological features 
may predict the likelihood of disease progression and death. Based on the 
histolopathological findings, further chemo-radiotherapy may be offered. In recent years, a 
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number of therapies have been developed that are aimed at altering the significant 
molecular pathways in CRC pathogenesis. Mutations in the MAPK pathway are major 
drivers of CRC pathogenesis and as such detecting these mutations has prognostic 
significance for patients. Mutations in these pathways also render anti-EGFR mAb 
therapies ineffective and are therefore very clinically relevant. The most clinically 
informative mutations in the MAPK pathway are found in BRAF, KRAS and NRAS and so 
these are the most commonly tested genes in routine clinical practice. Despite testing 
recommendations by many prominent organisations, there is a shortfall in availability of 
testing in many centers, probably in large part due to funding limitations. Newer testing 
technologies to the market however could address these issues. One such technology that 
could overcome this problem is an automated PCR platform called the Idylla System. This 
thesis aims to assess the potential of the Idylla tests for use in clinical practice by evaluating 
the accuracy and cost-effectiveness of the system.  
 
1.8 Hypothesis 
The hypothesis for this thesis is that the Idylla System is highly accurate in detecting BRAF, 
KRAS and NRAS mutations in CRC FFPE tissue and that the system is superior to other 
technologies currently available.  
 
1.9 Aims and objectives of the thesis 
This study aimed to test the hypothesis, set out above, that the Idylla System is accurate 
and superior to other technologies available for BRAF, KRAS and NRAS testing in CRC. 
Such a study would address the lack of evidence for the Idylla System in the literature, 
validate the various assays where possible and conduct clinical assessments of test 
diagnostic accuracy. The study also aimed to evaluate the system in terms of placement in 
the diagnostic pathway, financial implications and practicalities of use.  
 
The objectives were: 
 
 An audit of the potential workload and financial burden of the Idylla System  
 A validation and diagnostic test accuracy study of the Idylla BRAF Mutation Test 
 A validation and diagnostic test accuracy study of the Idylla KRAS Mutation Test 
 A validation of the Idylla NRAS-BRAF-EGFRS492R Mutation Assay 
 
 
 
 
 
 
Some of the ideas and information presented in this Chapter are also presented in 
publications and posters arising from this work.1-8
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Chapter 2: Materials and Methods 
2.1 Introduction  
To test the hypothesis and address the aims of this thesis, a number of experiments were 
conducted as part of a wider study. The study design and experiments are described in this 
Chapter. A description of the specific materials and protocols are given first followed by a 
discussion of the overall design and conduct of the study. 
 
2.2 Materials  
2.2.1 Tissue  
 Diagnostic FFPE tissue blocks  
 Corresponding H&E histology slide 
 
2.2.2 Reagents 
 4% hydrogen peroxide (Sigma-Aldrich, Inc.) 
 Absolute ethanol (Sigma-Aldrich, Inc.) 
 10M Molecular biology grade NaOH (Sigma-Aldrich, Inc.) 
 Haematoxylin II (Ventana Medical Systems, Inc.) 
 Nuclease free water (QIAGEN) 
 Molecular biology grade water (Sigma-Aldrich, Inc.) 
 Distilled water (Thermo Fisher Scientific Inc.) 
 Tap water 
 DPX mountant (Sigma-Aldrich, Inc.) 
 Laboratory grade mineral oil (Sigma-Aldrich, Inc.) 
 Deparaffinization Solution (QIAGEN)208 
 EZ Preparation Solution (Ventana Medical Systems, Inc.)209 
 Cell Conditioning 1 (high pH Tris-Borate-EDTA; Ventana Medical Systems, Inc.) 
Buffer210 
 
2.2.3 Consumables 
 Microtomy blades (Leica Biosystems) 
 Electrostatically charged glass microscopy slides 25 x 75mm, for IHC cases only 
(Thermo Fisher Scientific Inc.) 
 Uncharged glass slides 25 x 75mm (Thermo Fisher Scientific Inc.) 
 Cover slips 25 x 50 mm (Thermo Fisher Scientific Inc.) 
 Razor blades (Agar Scientific Ltd) 
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 Scalpels (Sigma-Aldrich, Inc.) 
 1.5ml microcentrifuge (eppendorf) tubes (Sigma-Aldrich, Inc.) 
 0.2ml PCR tubes (Sigma-Aldrich, Inc.) 
 96 well optical plates (Thermo Fisher Scientific Inc.) 
 Clear adhesive plate film (Thermo Fisher Scientific Inc.) 
 5mm blotting paper discs (supplied with Idylla by Biocartis) 
 Filtered universal pipette tips, range of volumes (Thermo Fisher Scientific Inc.) 
 QIAamp MinElute Columns (QIAGEN)211 
 
2.2.4 Assay kits  
 dsDNA HS Assay Kit (Thermo Fisher Scientific Inc.)212 
 Cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems Inc.)195 
 Cobas KRAS Mutation Test (Roche Molecular Systems Inc.)197 
 Ion AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific Inc.)213 
 Ion Xpress Barcode Adapters (Thermo Fisher Scientific Inc.)214 
 Ion AmpliSeq Cancer Hotspot Panel version 2 kit (Thermo Fisher Scientific Inc.)196 
 Axygen Axyprep Mag PCR Clean-up Kit magnetic beads (Thermo Fisher Scientific 
Inc.)215 
 Ion Library TaqMan Quantitation Assay (Thermo Fisher Scientific Inc.)216 
 Rox Reference Dye (Thermo Fisher Scientific Inc.)217 
 Custom TaqMan Probes with FAM/MGB reporter molecules (Thermo Fisher Scientific 
Inc.)218 
 Ion One Touch 2 200 Template Kit (Thermo Fisher Scientific Inc.)219 
 Ion 318 Chip Kit version 2 (Thermo Fisher Scientific Inc.)220 
 QIAamp FFPE Tissue Kit (QIAGEN)221 
 Anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody (Ventana Medical 
Systems, Inc.)222 
 OptiView Amplification Kit (Ventana Medical Systems, Inc.)223 
 OptiView DAB IHC Detection Kit (Ventana Medical Systems, Inc.)224 
 Idylla BRAF Mutation Test (Biocartis)184 
 Idylla KRAS Mutation Test (Biocartis)185 
 Idylla NRAS-BRAF-EGFRS492R Mutation Assay (Biocartis)189 
 Dynabeads MyOne Streptavidin C1 Beads (Thermo Fisher Scientific Inc.)225   
 
2.2.5 Equipment 
 Rotary microtone (Leica Biosystems) 
 Microtomy water bath (Leica Biosystems) 
 Microcentrifuge (Thermo Fisher Scientific Inc.) 
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 Plate centrifuge (Thermo Fisher Scientific Inc.) 
 Vortex mixer (Thermo Fisher Scientific Inc.) 
 Ultraviolet steralisation cabinet (Thermo Fisher Scientific Inc.) 
 Thermal cycler (Biometra) 
 Compound light microscope (Olympus)  
 Slide etching marker (Leica Biosystems) 
 Slide marker pen (Leica Biosystems) 
 Magnetic tube rack (Thermo Fisher Scientific Inc.) 
 P10, P20, P200 & P1000 micropipettors (Sigma-Aldrich, Inc.) 
 Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc.)226 
 Qubit 2.0 Fluorometer (Thermo Fisher Scientific Inc.)227 
 Heating incubation block (Thermo Fisher Scientific Inc.) 
 Cobas z 480 Analyzer (Roche Molecular Systems Inc.)183 
 Applied BioSystems 7500 Real Time PCR System (Thermo Fisher Scientific Inc.)228 
 Ion OneTouch 2 Instrument and Enrichment System (Thermo Fisher Scientific Inc.)229 
 Ion Chip Minifuge (Thermo Fisher Scientific Inc.)230 
 Ion Torrent PGM System (Thermo Fisher Scientific Inc.)231 
 Idylla System (Biocartis) 182 
 QX100 Droplet Digital PCR System (Bio-Rad Laboratories, Inc.)232 
 Benchmark ULTRA (Ventana Medical Systems, Inc.)233 
 
 
Some suppliers varied depending on laboratory stock ordering and availability; where no 
specific citation is given, example suppliers that are used locally are quoted 
 
2.3 Methods  
2.3.1 Overview   
In order to test the hypothesis, a series of experiments were carried out on retrospective 
diagnostic tissue from patients with CRC. The overall study design is explained below in 
Section 2.4, but first the methods of individual experiments are given. Firstly, tissue on 
glass slides was acquired from the existing archival bank. This was used directly for IHC 
but was removed (by macro-dissection) from the slide for molecular testing. Macro-
dissected tissue was used for a range of PCR techniques and for NGS. DNA was extracted 
prior to conventional PCR and NGS. For NGS a sample library was prepared and amplified 
before being sequenced. Each of these steps are discussed in detail in the following 
Subsections.  
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2.3.2 Slide preparation  
Tissue tested in the study was taken from the same tissue blocks that were used in the 
comparison tests originally carried out for molecular diagnostics. Tissue sections were cut 
from FFPE blocks using a microtome and floated on warm water in a water bath containing 
tap water at 30°C. Sections were collected on glass slides and left to dry. Molecular testing 
was carried out on 5µm sections placed on uncharged slides. H&E sections were prepared 
with 4µm sections placed on uncharged slides. IHC testing was carried out on 4µm tissue 
sections place on charged slides. Water baths and microtome blades were changed 
between cases for molecular testing to avoid contamination. FFPE slides were stored at 
room temperature until ready for use.  
 
2.3.3 Immunohistochemistry   
VE1 IHC was performed on unstained 4µm FFPE tissue whole sections that were placed 
on positively electrostatically charged glass slides and baked in a 60°C oven for two hours. 
Sections were then loaded onto the Benchmark ULTRA (Ventana Medical Systems, Inc.)233 
for automated IHC processing using the pre-installed protocol for VE1 (Protocol 7). 
Sections were dewaxed in EZ Preparation Solution (Ventana Medical Systems, Inc.)209 at 
72°C for 20 minutes. Antigen retrieval was carried out by incubating the sections in Cell 
Conditioning 1 (high pH Tris-Borate-EDTA; Ventana Medical Systems, Inc.) Buffer210 at 
95°C for 64 minutes. Slides were then washed with 4% hydrogen peroxide for pre-primary 
Ab peroxidase inhibition. Sections were incubated with anti-BRAF V600E (VE1) Mouse 
Monoclonal Primary Antibody222 for 16 minutes at 36°C. Amplification was carried out with 
the OptiView Amplification Kit223 by incubating with kit reagent for 8 minutes. Detection was 
carried out with the OptiView DAB IHC Detection Kit224 reagent. Tissue was counterstained 
with Haematoxylin II for four minutes and blued for a further four minutes in tap water. 
Slides were mounted in DPX and a glass cover slip was applied. The slides were left 
overnight to dry.  
 
2.3.4 Tissue macro-dissection  
In general, tissue blocks contain tumour with adjacent non-neoplastic tissue which can 
potentially dilute the tumour nucleic acid content if processed together in the same sample. 
Tissue used in molecular tests is ideally acquired from sections placed on slides rather 
than used directly from the cut microtome sections. Placing tissue on slides allows 
comparison of the unstained section with the stained histology slide and then non-tumour 
tissue can be selectively removed (scraped away) and discarded prior to the assay. This is 
a technique known as macro-dissection.144  
 
To carry out macro-dissection, the unstained slide was compared and matched against the 
corresponding H&E stained sections using light microscopy. The tumour was marked on 
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the H&E slides with a pen by the reporting pathologist at the time of diagnosis. Tissue was 
then approximated on the unstained sections. Where possible the same area of tissue that 
had undergone PCR or NGS originally was selected for Idylla testing and IHC.144 Tumour 
identified on the unstained section was marked using an etching slide marker. Macro-
dissection was carried out using a razor blade or scalpel. Tissue to be discarded was first 
scraped from the glass slide and disposed of. The tissue of interest was then scraped from 
the slide and set aside ready for testing. Macro-dissected tissue was stored at room 
temperature in 1.5ml Eppendorf tubes if not tested immediately.  
 
Each assay had minimum tissue requirements to be met by macro-dissection. For 
conventional PCR testing, a tissue area of up to 250mm2 on up to eight sections at a 
maximum thickness of 10um was used with a minimum of 50% tumour nuclei content 
(BRAF Mutation Test)195 or 10% (KRAS Mutation Test)197 in line with Cobas manufacturer 
(Roche Molecular Systems Inc.) directions and internally validated quality assurance (QA) 
protocols. For NGS, a tissue area of up to 250mm2 on up to eight sections at a maximum 
thickness of 10um was used at a minimum of 40% tumour nuclei content, in line with Ion 
Torrent manufacturer (Thermo Fisher Scientific Inc.) directions196 and internally validated 
QA protocols. For Idylla testing a tissue area of 50-600mm2 from a single 5µm section 
containing ≥10% (KRAS Mutation Test), 25% (NRAS-BRAF-EGFRS492R Mutation Assay) 
or 50% (BRAF Mutation Test) tumour nuclei content was used as directed by 
Biocartis.184,185,189  
 
All Idylla testing was carried out using the same FFPE tissue block that underwent original 
molecular testing (PCR or NGS). In a small minority of cases, 1mm punch tissue was taken 
from FFPE blocks for original molecular testing. Where this occurred, tissue for macro-
dissection was selected surrounding the punched area.  
 
2.3.5 Nucleic acid extraction  
Nucleic acid extraction was carried out for conventional PCR and NGS by the Oxford 
Molecular Diagnostics Centre (OMDC). Manual extraction was not carried out for Idylla 
testing as this was automated internally within the cartridge. Nucleic acid was extracted 
from macro-dissected FFPE tissue. The QIAamp FFPE Tissue Kit (QIAGEN) was used for 
extraction.221 FFPE was incubated in Deparaffinization Solution (QIAGEN)208 on a heat 
block at 56°C for three minutes. Lysis buffer and proteinase K were added and the solution 
was incubated at 56°C for 16 hours and then 90°C for one hour. An ethanol-based buffer 
was then added and the sample transferred to a QIAamp MinElute Column (QIAGEN)211 
for centrifuge filtration, followed by elution with the elution buffer.  
 
QA was carried out in line with manufacture instructions for Cobas (Roche Molecular 
Systems Inc.) PCR and Ion Torrent (Thermo Fisher Scientific Inc.) NGS. For all samples, 
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the extracted nucleic acid content was quantified to calculate volumes required in PCR and 
sequencing. For PCR testing, samples were quantified using the Nanodrop 2000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific Inc.).226 A minimum of 125ng of DNA at a 
minimum concentration of 5ng/µl (BRAF Mutation Test)195 and a minimum of 50ng of DNA 
at a concentration of 4ng/µl (KRAS Mutation Test)197 were required as per Cobas (Roche 
Molecular Systems Inc.) manufacturer instructions. For NGS-based tests, samples were 
quantified using the Qubit 2.0 Fluorometer (Thermo Fisher Scientific Inc.)227 with the 
dsDNA HS Assay Kit (Thermo Fisher Scientific Inc.)212 and a minimum of 10ng of DNA at 
a concentration of 3ng/µl was required for the Ion AmpliSeq Cancer Hotspot Panel version 
2 (v2) kit (Thermo Fisher Scientific Inc.) in line with manufacturer requirements.196 If the 
concentration of DNA was lower than the minimum required, where possible further FFPE 
tissue underwent extraction to enhance the concentration. An estimate of purity 
(DNA:protein ratio; the acceptable range was 1.8-2.0) was acquired for both PCR and NGS, 
carried out using the Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific 
Inc.).226  
 
Extracted nucleic acid was stored at room temperature for up to 24 hours, at 4°C for up to 
14 days and up to 60 days at -20°C. A maximum of three freeze-thaw cycles were 
permitted. Samples not adherent to QA protocols were discarded.  
 
2.3.6 Conventional PCR  
Conventional PCR testing was carried out on extracted DNA, prepared at a concentration 
of 2ng/µl. The Cobas BRAF V600 Mutation Test and Cobas KRAS Mutation Test (Roche 
Molecular Systems Inc.) were used for conventional PCR.195,197 A master mix containing 
primers, probes, DNA polymerase and nucleotides was prepared from the kit reagents. 
Samples were added to a 96-well plate along with the master mix, wild type and mutant 
gene controls. The plates were covered by an adhesive film and centrifuged. Plates were 
run on the Cobas z 480 Analyzer (Roche Molecular Systems Inc.).183  
 
2.3.7 Droplet digital PCR  
Droplet digital PCR (ddPCR) was performed on discordant cases, for confirmation of 
results by Biocartis. Full details of this protocol were not disclosed. DNA was extracted from 
unstained tissue section slides provided to Biocartis. Tests were run on a QX100 Droplet 
Digital PCR System (Bio-Rad Laboratories, Inc.).232  
 
2.3.8 Automated PCR  
Automated PCR was carried out on the Idylla System182 directly on macro-dissected FFPE 
tissue. DNA extraction was carried out automatically by the Idylla System during the assay. 
FFPE tissue was placed between two 5mm discs of blotting paper, wetted with nuclease 
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free water, and placed inside an Idylla test cartridge (Biocartis). The cartridge was loaded 
onto the Idylla System (Biocartis) for processing. The Idylla BRAF Mutation Test, the Idylla 
KRAS Mutation Test and the Idylla NRAS-BRAF-EGFRS492R Mutation Assay (Biocartis) 
cartridges were used.184,185,189 All results from comparison tests were blinded at the time of 
Idylla testing. 
 
2.3.9 Sequencing library preparation  
The library was prepared from extracted DNA under an ultraviolet lit hood using the Ion 
AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific Inc.).213 and the Ion AmpliSeq Cancer 
Hotspot Panel v2 primers (Thermo Fisher Scientific Inc.).196 The concentration was 
standardised to 10ng/µl. Following this, unique specimen barcodes were added (Ion Xpress 
Barcode Adapters; Thermo Fisher Scientific Inc.),214 along with DNA ligase and adaptors 
and the samples were again loaded in a thermal cycler for the ligation reaction. Purification 
and clean up was carried out using Axygen Axyprep Mag PCR Clean-up Kit magnetic 
beads (Thermo Fisher Scientific Inc.).215 Ligated samples were incubated with Axyprep 
beads then washed three times in ethanol on a magnetic block. Purified DNA was then 
eluted from the Axyprep beads, the beads separated on the magnetic block and then 
removed.   
 
The library was quantified using the Ion Library TaqMan Quantitation Assay (Thermo Fisher 
Scientific Inc.)216 on a 96-well plate. Each specimen was tested in duplicate. Master mix, 
primers and probes were added to each well. Standardisation was carried out against the 
E. coli DH10B reference samples included in the kit. Rox Reference Dye (Thermo Fisher 
Scientific Inc.)217 was used as the passive reference and Custom TaqMan Probes with 
FAM/MGB reporter molecules (Thermo Fisher Scientific Inc.)218 were used. The qPCR 
reaction was run on the Applied BioSystems 7500 Real Time PCR System (Thermo Fisher 
Scientific Inc.).228 Quantification was calculated for each sample based on the qPCR curves 
and the samples were diluted to 100 pM for NGS.  
 
2.3.10 Library amplification and enrichment  
Library samples were amplified and enriched using the Ion OneTouch 2 200 Template Kit 
(Thermo Fisher Scientific Inc.)219 and run on the Ion OneTouch 2 System, which comprises 
the OneTouch Instrument and Enrichment System (ES).229 Samples were combined and 
the kit Reagent Mix, PCR Reagent, Enzyme Mix and Ion Sphere Particles were added. The 
samples were then loaded on to the Ion OneTouch Plus Reaction Filter Assembly (included 
in Template kit; Thermo Fisher Scientific Inc.), sealed with oil and run on the Ion OneTouch 
2 Instrument (Thermo Fisher Scientific Inc.) for templating and amplification. Following this, 
the filtration tubes were emptied and the pellets re-suspended in recovery solution and 
combined. Enrichment was carried out using Dynabeads MyOne Streptavidin C1 Beads225 
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on the Ion OneTouch ES (Thermo Fisher Scientific Inc.). Control sphere particles were 
added to the samples following enrichment and thermal cycling was carried out.  
 
2.3.11 Sequencing  
PGM 200 Sequencing Polymerase (from the OneTouch 2 200 kit; Thermo Fisher Scientific 
Inc.) was added to the amplified and enriched DNA library samples. The libraries were then 
loaded on to an Ion Torrent Chip (Ion 318 Chip Kit v2; Thermo Fisher Scientific Inc.).220 
The chip was spun on an Ion Chip Minifuge (Thermo Fisher Scientific Inc.)230 and then 
loaded and run on an Ion Torrent PGM System (Thermo Fisher Scientific Inc.).231 Analysis 
was carried out using the web-based Ion Reporter Software (Thermo Fisher Scientific 
Inc.),234 using the most recent international reference genome.   
 
 
2.4 Study design  
2.4.1 Overview 
The experiments described above were brought together in an overall study design to test 
the hypothesis. Initially, an audit of the case workload was carried out to identify relevant 
archival cases and to also assess the financial impact of introducing the Idylla System into 
routine practice. Next a series of comparison tests were carried out to assess the accuracy 
of the Idylla System. It is important at the outset to highlight the difference between a test’s 
performance under controlled laboratory conditions using preselected positive and 
negative cases, and a test’s diagnostic accuracy in the clinical setting for detecting a 
disease state (here a BRAF, KRAS or NRAS mutant tumour). The former is a technical 
validation and often serves as a proof-of-concept for a new test or to verify the successful 
implementation of an established test. These validation studies are designed to determine 
the new (index) test’s concordance with existing standard (reference) tests. A validation 
study in some settings can also be used to determine the LOD (or analytical sensitivity). 
These measures should not be confused with the sensitivity and specificity of test derived 
from a diagnostic trial in clinical settings. Diagnostic studies are far more informative for 
using a test in clinical practice and therefore a preferable study design.235-237 
 
The main study in this thesis comprised two arms. The first arm followed a diagnostic test 
accuracy study design with the aim of estimating the accuracy of the Idylla BRAF and KRAS 
Mutation Tests on the Idylla System under clinical conditions. There was already some 
limited validation data from Biocartis for these tests and a diagnostic trial would be the best 
model for testing the hypothesis.184,185 The comparisons were made with the Cobas KRAS 
and BRAF Mutation Tests run on the Cobas 4800 System z 480 analyzer (Roche Molecular 
Systems Inc.).183 
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In order to fully investigate diagnostic accuracy (sensitivity, specificity etc.) an unbiased, 
unselected population of cases that reflect genuine practice is required.237,238 This was not 
always possible for all Idylla tests due to funding, tissue or cartridge availability limitations. 
For these reasons, the second arm of the study then was limited to a series of more 
technical validations. Although this is less informative, it still allows some assessment of 
the test’s performance to be made. Also, in some circumstances where an Idylla test had 
been assessed in the first arm of the study by comparing with PCR, it was probably enough 
to just make a more technical validation with NGS and a full study was unnecessary. For 
other Idylla tests not assessed in the first arm, a technical validation would serve as a proof-
of-principle for a future diagnostic accuracy study. In this second arm, validation studies 
aimed to investigate concordance. The LOD was not assessed as accuracy was the 
primary focus of this thesis. The BRAF Mutation Test was validated against the anti-BRAF 
V600E (VE1) Mouse Monoclonal Primary Antibody IHC assay (Ventana Medical Systems, 
Inc.) as this is now a commonly used test169,222. The KRAS Mutation Test was validated 
against NGS Ion Torrent methodology (Thermo Fisher Scientific Inc.)161 using the Ion 
AmpliSeq Cancer Hotspot Panel v2 (Thermo Fisher Scientific Inc.)196 gene panel assay 
(which includes BRAF, KRAS and NRAS coverage) on the Ion Torrent PGM System 
(Thermo Fisher Scientific Inc.).231 Finally, the NRAS-BRAF-EGFRS492R Mutation Assay 
(Biocartis)189 was validated against the same NGS panel.  
 
As well as test accuracy, an important indicator of the value of a test is reproducibility. This 
is a third type of study design for evaluating tests. As accuracy was the focus of this thesis, 
reproducibility was not specifically measured in this work. Automated molecular test 
reproducibility is expected to be very high anyway and resources were limited in this thesis 
to investigate this matter specifically. However, the reproducibility (agreement) of the IHC 
scoring was assessed using Cohen’s kappa, because IHC agreement is a known problem 
in diagnostic histopathology. This problem is discussed further in Section 5.4. 
 
Full validation of the NRAS-BRAF-EGFRS492R Mutation Assay was not possible as no 
comparison tests are commercially available for the S492 codon change in EGFR.  
 
2.4.2 Timeline  
The data collection began in spring 2015 with the audit. Cases from the year 2013 were 
selected to ensure a full calendar year could be audited and that a long enough time period 
had passed before auditing to avoid missing molecular and supplementary results (which 
could take several months to be transcribed to the system). Data for the BRAF Mutation 
Assay clinical study were also collected in the spring of 2015 and cases with full molecular 
reports were selected from 2013-2014 in the diagnostic archival database. KRAS data were 
collected in part over the summer of 2015 and in part during late 2015/early 2016 when 
funding was available. Cases were selected from 2014-2015. Later cases (than those used 
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for BRAF testing)  were selected because during 2015 there was a transition to NGS and 
data from both PCR and NGS were required for the thesis. NRAS-BRAF-EGFRS492R 
Mutation Assay validation took place in early 2016 following delays with cartridge 
availability. Cases from a long period between 2013 and 2016 were needed to maximise 
number of NRAS mutant tumours to be included (see Subsection 4.1.3). Results are 
presented in a logical order for convenience in the following Chapters, however this 
obviously may not always reflect the true timeline of the study.  
 
2.4.3 Study setting  
The study was based in the Department of Cellular Pathology at the John Radcliffe (JR) 
Hospital, part of the Oxford University Hospitals NHS Foundation Trust (OUH).239 Where 
applicable, work was carried out within Clinical Pathology Accreditation (CPA) / UKAS 
accredited laboratories to the International Organization for Standardization (ISO) 
15189:2012 specifications and in accordance with the Care Quality Commission (CQC) 
regulations.137,240,241  
 
2.4.4 Ethics approval and local regulations 
Ethical approval for the study was granted by the National Research and Ethics Service 
(Oxfordshire Research and Ethics Committee A; reference 04/Q1604/21), see Appendix 
1.242 The Oxford Centre for Histopathology Research (OCHRe) approved the thesis work 
to be carried out under local regulations (Application number 14/A209 and amendment 
numbers 15/A041 and 16/A002), see Appendix 2.243 
 
2.4.5 Funding 
Consumables, some Idylla tests and costs from OCHRe were funded from a grant provided 
by the Oxfordshire Health Services Research Committee (Fund 8262).244 Salary was 
provided by the Department of Oncology, University of Oxford via the National Institute for 
Health Research Biomedical Research Centre, Oxford.245 The Idylla System was made 
available for the project by Biocartis free of charge and on loan for a trial period. Biocartis 
provided a proportion of the Idylla tests for free. Biocartis did not directly fund any of the 
work, provide any salary or provide any financial incentive. Biocartis has no involvement in 
the production of this thesis. There were no competing interests of any of the parties 
involved in the study. 
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2.4.6 Risk assessment 
A Control of Substances Hazardous to Health (COSHH) risk assessment was carried out 
prior to Idylla data collection, see Appendix 3. 
 
2.4.7 Contributions 
The author devised and designed the work in this thesis, secured the funding, selected and 
prepared tissue, carried out all Idylla testing and carried out all statistical analyses. Original 
diagnostic specimen preparation – including dissection, processing, slide preparation and 
tissue preparation for molecular testing – was carried out by members of the Department 
of Cellular Pathology, John Radcliffe Hospital. Tissue for the study was provided 
anonymised by OCHRe. Original diagnostic molecular testing used for comparisons was 
carried out by OMDC.246 IHC testing was carried out with assistance from members of the 
Department of Cellular Pathology, John Radcliffe Hospital. IHC scoring was carried out by 
consultants in the department.  
 
2.4.8 Participants and inclusion criteria  
Cases were selected from the departmental database at OUH. Inclusion criteria used for 
the database search were: reported cases from any patient with microscopic findings of a 
primary adenocarcinoma in a colorectal specimen. Such specimens included endoscopic 
biopsies, colectomy, hemicolectomy, anterior resection, abdominoperineal (including low) 
resections, transanal endoscopic mucosal resections (TEMs) and metastasis excisions. 
For technical validations only primary tumour tissue from resections were tested; all 
specimen types were included in clinical studies.  
 
Participants from whom cases were selected were all NHS patients undergoing treatment 
for colorectal adenocarcinoma within OUH. All diagnoses were authorised by a qualified 
consultant histopathologist. The majority of these patients had undergone their surgery at 
the JR or the neighbouring Churchill Hospital (also OUH). NHS patients were asked to 
provide or withhold consent for their tissue to be used in teaching and research as standard 
practice before any type of biopsy/surgery.247 
 
For the audit part of the thesis, all cases of CRC reported through the OUH department 
over a 12-month period were identified and the number of molecular tests ordered were 
recorded. A consecutive series of cases meeting the inclusion criteria over a three-month 
period were selected out from the search results for the clinical diagnostic accuracy study 
of BRAF and KRAS testing. For BRAF, KRAS and NRAS validation studies, a sample was 
selected out from these search results to include positives and negatives, in line with 
recommendations.248 There was some overlap in the patients participating in some parts 
of the study. 
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2.4.9 Exclusion criteria  
Referred cases and cases from patients lacking documented consent were excluded. 
Referred cases were included for the audit however as this provided relevant information 
about genuine workloads. Internal cases (not referred) where the tissue blocks were not 
available or lost (i.e. cannot therefore be tested) were excluded. Cases from other tumour 
sites (non-colorectal) or tumour types (non-adenocarcinomas or metastases) were also 
excluded. Cases where using tissue for research would have left no diagnostic tissue 
remaining or would otherwise encroach on the usual, safe diagnostic pathway were 
excluded in line with OCHRe policy.243  
 
2.4.10 Sample size estimations 
For the technical validation studies, 20 cases were selected in line recommendations.248 
Sample size estimations and calculations were carried out for the BRAF and KRAS clinical 
studies prior to data collection, in line with guidelines on clinical diagnostic test accuracy 
study design.249 These are described in relevant sections. General advice about sample 
size calculations was given by a medical statistician. The sample size calculations 
presented in this thesis were carried out manually by the author.  
 
2.4.11 Interpretation 
Determining IHC results is discussed later in Chapter 3. Any mutation detected by Idylla, 
Cobas or NGS was considered to be a positive result. Wild type genes were considered 
negative results.  
 
2.5 Statistical Analysis 
Statistical analysis was carried out using standard formulae. Diagnostic accuracy (test 
accuracy) was analysed using sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and likelihood ratios. Diagnostics accuracy was only 
assessed for comparisons with unselected cohorts of patients with minimal bias. The 
technical validations (selected positive/negative cases) were analysed using concordance 
(agreement) only. Inter-observer agreement (test reproducibility) was analysed with 
Cohen’s kappa. Where appropriate, values were calculated with confidence intervals (CI) 
of 95%. The calculations presented in this thesis were carried out manually by the author 
with the aid of Microsoft Excel. See Appendix 4 for details and formulae.235,250,251 
 
 
 
 
 
Some of the methods and information presented in this Chapter are also presented in 
publications and posters arising from this work.1-8 
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Chapter 3: BRAF Testing with Automated PCR 
 
3.1 Introduction 
3.1.1 Chapter overview 
BRAF is a key marker in CRC and mutations in the gene are commonly tested for in routine 
clinical practice. This is predominantly because detecting BRAF mutations aids in the 
screening for Lynch Syndrome.97 However, testing is lacking in many centers due to poor 
access to molecular laboratories or a lack of resources.15 This Chapter aims to test the 
hypothesis that the Idylla System is highly accurate for BRAF testing in CRC and is superior 
to other systems available. This could then potentially allow the Idyla system to be used to 
overcome the under-testing seen in many areas of the NHS. BRAF was the first gene target 
for which testing was offered on the Idylla System and as such this part of the study took 
place first, influencing how the Ras testing part of the study was later designed. Therefore, 
the BRAF results will be discussed first. This will begin with consideration of the gene and 
its diagnostic utility. This is followed with an audit of the clinical service locally in order to 
evaluate the financial impact of BRAF testing with the Idylla System. Next, a full clinical 
study of the BRAF Mutation Test compared with conventional PCR is presented in order to 
establish the diagnostic accuracy of Idylla to detect BRAF mutations. Funding did not cover 
a full clinical study for the system compared with NGS or IHC, however basic technical 
validations of these are presented to give some indication accuracy in this context. This 
Chapter will specifically evaluate the Idylla BRAF Mutation Test and the BRAF component 
of the Idylla NRAS-BRAF-EGFRS492R Mutation Assay. 
 
3.1.2 The BRAF gene 
Rapidly accelerated fibrosarcoma (Raf) kinases are downstream mediators of EGFR 
signaling in the MAPK pathway (see Figure 4). Three members of the Raf kinase family 
have been identified: ARAF, BRAF and CRAF. As already discussed in Chapter 1, the 
primary function of Raf kinases is the regulation of cell proliferation in response to external 
growth factors such as epidermal growth factor (EGF). Each Raf kinase probably has 
different targets within the cell and Braf (Raf b homolog encoded by BRAF) and Craf (Raf 
c homolog encoded by CRAF) appear to be more significant in EGF signaling than Araf 
(Raf a homolog encoded by ARAF). In addition, Braf is known to directly activate 
Craf.75,252,253 Mutations in Raf kinases result in constituent activation of the MAPK 
proliferation pathway in the absence of EGF. These mutations have been identified in 
numerous cancers, such as melanoma, papillary thyroid carcinoma, and some 
lymphomas.254 BRAF mutations are the most widely implicated in carcinogenesis; this may 
explain why BRAF is prognostic and the gene target of most clinical utility. ARAF and CRAF 
mutations are less common and appear to have less pathogenic or clinical relevance.75 
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However, given the action of Braf, mutant BRAF may also increase the activity of Craf and 
this could be one mechanism for resistance to anti-BRAF therapy (see below).255  
 
BRAF mutations are detected in around 10% of CRC resection specimens. Clinically, 
BRAF status is useful for prognosis and screening for Lynch syndrome (LS).97 Although 
targeted cancer therapies against BRAF mutations, such as vemurafenib, have been 
successful in improving patient outcomes in metastatic malignant melanoma,256 results 
have been disappointing in colorectal cancer.257-260 On the other hand, anti-EGFR mAb 
therapies in metastatic colorectal cancer have proven to be of significant benefit to patients 
and therefore testing for mutations which may render the MAPK pathway constituently 
active (in Ras or Raf proteins) has been explored. Whilst the benefit of identifying Ras 
mutations has been demonstrated, stratifying treatment based on Raf (i.e. BRAF) 
mutations is less clear. Some data suggest BRAF mutations may be of use in directing 
treatment,60,261,262 but testing is not currently recommended.260,263,264 BRAF mutations are 
used as a marker or poor prognosis however. ARAF and CRAF testing are not thought to 
be clinically useful and are not carried out in routine practice.  
 
3.1.3 Lynch syndrome and BRAF testing 
The main clinical indication for BRAF testing in CRC patients currently is for LS screening. 
Most cases of CRC are sporadic, but around 3-5% of cases occur in patients with LS. LS 
is an inherited, autosomal dominant cancer syndrome caused by mutations in MMR genes. 
A number of genes have been implemented in LS over the years but many have 
subsequently been shown not to be associated with increased cancer risk. The genes now 
thought to cause LS are MLH1, PMS2, MSH2, MSH6 (discussed in Chapter 1) and, rarely, 
epithelial cell adhesion molecule (EPCAM).265-267 EPCAM encodes EpCAM is a 
transmembrane cell-cell adhesion molecule. The gene directly precedes MSH2 on 
chromosome 2 and mutant EPCAM expression results in transcriptional read-through 
silencing of MSH2 expression. In colorectal epithelium, where there is generally high 
EPCAM expression, this can lead to a loss of MSH2 function and CRC.268 LS can also lead 
to, endometrial, ovarian, stomach and other cancers. Identifying cancer patients who may 
have LS is important for preventing future tumours.11 Therefore, screening of CRC tumour 
resection tissue for LS is now endorsed by the Royal College of Pathologists, NICE and 
others.11,167,168,266,267,269  
 
The terminology and diagnostic criteria surrounding LS are complex and so the history of 
this syndrome warrants some brief discussion. LS was possibly first described by Warthin 
in 1913 in a group of families with a predisposition to develop gastrointestinal and 
gynaecological cancers. Henry T. Lynch later described similar features in other families in 
the 1960’s. Following this, the term ‘Lynch syndrome’ became popular to refer to these 
patients.270 The syndrome presents as a non-polyposis (although there is an increased 
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tendency for patients to develop polyps) associated cancer, hence the term ‘hereditary non-
polyposis colorectal cancer’ (HNPCC), proposed by Lynch, later became the agreed name. 
The clinical criteria for diagnosing HNPCC, known as the Amsterdam criteria (see Table 8) 
were agreed upon in the in 1980s. The original Amsterdam criteria (Amsterdam I) were 
later felt to be too stringent and so were refined (Amsterdam II) to encompass more patients 
at-risk.271,272 As the genetic basis of the disease was uncovered however, some began to 
again use the term ‘Lynch Syndrome’ (or ‘LS’) to refer to a subset of HNPCC patients with 
proven MMR gene mutations. With this new molecular understanding, criteria for genetic 
testing, known as the Bethesda criteria, were introduced. These criteria have also been 
revised several times and currently the Revised Bethesda criteria are in use (see Table 9). 
Today, all HNPCC cases are thought to be caused by MMR gene mutations, making LS 
and HNPCC synonymous and the clinical diagnostic Amsterdam criteria largely 
redundant.168,265-267,271,273-277  
 
 
 
Amsterdam I 
At least three family members with histologically confirmed colorectal cancer 
One of which must be a first degree relative of the other two 
At least two consecutive generations must be affected 
At least one of the cancer cases must have diagnosed before age 50 
Familial adenomatous polyposis must be excluded 
Amsterdam II 
At least three family members must have a cancer associated with HNPCC 
(colorectal, endometrial, urothelial, small bowel etc.)  
One of which must be a first degree relative of the other two 
At least two consecutive generations must be affected 
At least one of the HNPCC related cancers must have been diagnosed before 
age 50 
Familial adenomatous polyposis must be excluded 
 
Table 8. The Amsterdam criteria for HNPCC. Patients meeting the criteria for either 
Amsterdam I278 or the revised (the original criteria were deemed to be too narrow) 
Amsterdam II271,272 are designated as HNPCC. When a patient had a proven genetic 
aetiology, in around 60% of HNPCC cases, they were said to have LS.265,271 HNPCC = 
hereditary non-polyposis colorectal cancer, LS = Lynch syndrome. 
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Table 9. The revised Bethesda guidelines for LS screening. Patients meeting one 
or more criteria should be screened. LS-associated tumours include colon, 
rectum, stomach, ovary, endometrium, pancreas, uterus, kidney, biliary tract, 
brain, small bowel and some skin tumours. These supersede the Amsterdam 
criteria (I and II) for genetic screening purposes, as all HNPCC patients would be 
included by default within these Bethesda criteria.11,74,168,266,267,271,274 Permission 
to reproduce this table from a similar published table has been granted by the 
British Medical Journal Publishing Group Ltd.1,2 LS = Lynch syndrome, CRC = 
colorectal carcinoma, MSI = microsatellite instability 
 
 
 
There continues to be disagreement and conflicting use of the terms ‘hereditary non-
polyposis colorectal cancer’ (or ‘HNPCC’) and ‘Lynch syndrome’ (or ‘LS’) but, as 
mentioned, most now agree that LS and HNPCC should be considered the same entity. 
There are a number of alternative terms for patients fulfilling the Amsterdam criteria without 
proven genetic abnormalities, such as ‘Lynch-like’ tumours (somatic MSI and MMR 
deficiency but no germline mutation) and familial cancer syndrome X (patients fulfilling the 
Amsterdam criteria but have no germline mutation) and these probably should be used 
instead of ‘HNPCC’. The distinction still made by some between HNPCC and LS becomes 
a moot point anyway because the Revised Bethesda criteria de facto indicate genetic 
testing for all traditional HNPCC patients and as such, supersede the Amsterdam criteria 
for identifying at-risk patients. Therefore, ‘HNPCC’ is probably best regarded as an 
outdated term. It is for these reasons that ‘Lynch syndrome’ (or ‘LS’) shall be preferred and 
used in this thesis as a synonym for ‘hereditary non-polyposis colorectal cancer’ (or 
Revised Bethesda Criteria 
1. CRC diagnosed at younger than 50 years 
2. Presence of synchronous or metachronous CRC or other LS-associated 
tumours 
3. CRC with MSI-high pathological-associated features (Crohn’s-like 
lymphocytic reaction, mucinous/signet cell differentiation, or medullary 
growth pattern) diagnosed in an individual younger than 60 years old 
4. Patient with CRC and CRC or LS-associated tumour diagnosed in at 
least 1 first-degree relative younger than 50 years old 
5. Patient with CRC and CRC or LS-associated tumour at any age in 2 first-
degree or second-degree relatives 
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‘HNPCC’) and will mean any patient with a germline mutation in MLH1, PMS2, MSH2, 
MSH6 or EPCAM.168,265-267,271,273,274  
 
Most guidelines (including the RCPath) recommend all patients meeting the Revised 
Bethesda criteria (Table 9) should be screened for LS (i.e. germline mutations in MMR 
genes), however recent NICE guidelines suggest screening all patients with CRC. The 
most common screening approach uses IHC evaluation of MMR protein expression and 
this is supported by NICE guidance. Alternatively direct is MSI testing may be used (also 
supported by NICE). Following MMR or MSI testing the screening pathway also 
incorporates BRAF mutation testing (see Figure 11) and MLH1 promoter region 
hypermethylation testing. The loss of MLH1 expression alone has low specificity for 
detecting LS (in part due to MLH1 hypermethylation and somatic mutation in sporadic 
tumours), but this is improved by incorporating tests to rule out MLH1 hypermethylation 
and by including BRAF mutation analysis in to the algorithm. BRAF mutations are rare in 
non-sporadic tumours and thus identifying a mutation virtually excludes LS.11,13,167,168,265-
267,269,274,279 The BRAF 1799 nucleotide point mutation substitution of thymine to adenine 
(c.1799T>A) which results in an amino acid change from valine to glutamate at the codon 
position 600 (V600E, first incorrectly designated at V599E) is the most common lesion 
found and so many tests target this base change, however mutations in the E2, D, K, M 
and R codons have all been shown to be clinically relevant, including in LS screening.74,279-
282 
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Figure 11. A flow diagram of the NICE recommended LS screening algorithm in CRC. 
Older guidelines indicate LS screening for patients meeting Bethesda criteria, new NICE 
guidelines call for all CRC patients to be screened. This figure is adapted from similar 
images presented in publications arising from this work and others and is based on LS 
screening guidelines.11,266,267,269 Permission to reproduce this figure from a similar 
published figure has been granted by the British Medical Journal Publishing Group Ltd.1,2 
NICE = National Institute for Health and Care Excellence, CRC = colorectal cancer, LS = 
Lynch syndrome  
 
MLH1 promoter 
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BRAF mutation analysis 
BRAF mutation 
Stain tissue with IHC for MLH1, PMS2, MSH2, MSH6 
MLH1 +/-PMS2 expression 
loss AND 
 MSH2/MSH6 normal 
MSH2, MSH6 or 
isolated PMS2 
expression loss 
OR isolated PMS2 
expression loss 
Normal expression 
of all four antigens 
BRAF wild type 
MLH1 promoter 
hypermethylation negative 
MLH1 promoter 
hypermethylation positive 
Recommend referral to 
clinical genetics 
Referral for germ-line testing 
not needed 
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There are alternative methods for LS screening. LS patients have MSI CRC and as 
mentioned above (and supported by NICE) MSI can be detected directly by using PCR.269 
In this method, specific tandem repeat sequences are amplified and the fragment lengths 
are visually compared to a control reference curve of the distributions of fragment lengths. 
MSI tumours contain expanded microsatellites due to mutations and thus amplicons of the 
tandem repeats in these microsatellite will have fragment lengths that are different than 
expected. When compared with the reference curve, these fragments will be observed as 
additional peaks in the graph. The US National Cancer Institute (NCI) standardised the 
reference panel of markers used for MSI testing to include two mononucleotide repeats 
(BAT25 and BAT26) and three dinucleotide repeats (D5S346, D2S123 and D17S250). 
MSI-H tumours demonstrate expansion in two or more markers, MSI-L in only one. MSI 
testing by PCR correlates well with IHC, but is more expensive and technically challenging 
than IHC screening.283,284 Some have suggested another alternative is testing for BRAF 
mutations alone in LS screening in those patients meeting the revised Bethesda criteria, 
however this approach is much less common.285 In reality, most of the testing options offer 
similar accuracy and overall similar costs and because this is a screening process and not 
a definitive test for LS, it probably doesn’t really matter which method is being used. 
Recommendations based on health economics assessments back this up and state that 
as long as some form of screening is used, the method is not important.167  
 
There are other reasons why BRAF testing is common in practice, other than directly for 
LS screening. Many centers are beginning to carry out MMR IHC testing as routine to 
establish MSI status because MSI-H carries a poorer prognosis. Consequently BRAF 
testing is needed on a greater number of cases because more MLH-1 loss is being detected 
and LS needs to be excluded as a duty of care.93,166 BRAF testing is also recommended by 
some in stage II or greater CRC as a prognostic marker.74,279-282 
 
There are conflicting data over whether BRAF mutations are predictive of resistance to 
anti-EGFR mAb therapy (see Chapter 4). This is not a current indication for testing 
therefore. There are also some early data which indicate that non-V600 mutations may 
impart a good prognosis, again this is not a routine indication for testing yet 
however.262,286,287 
 
3.1.4 Rationale for BRAF testing with automated PCR 
Most BRAF testing is currently carried out using conventional PCR-based tests, the most 
common being the Cobas platform.183,281 Unlike Cobas, which only detects the V600E 
amino acid change,195 the Idylla BRAF Mutation Test cartridge covers the full range (D, E, 
E2, K, M and R)184 of clinically relevant and actionable V600 mutations in CRC and has a 
turn-around time of 90 minutes. The test cannot however distinguish between E, E2 and D 
or between K, R or M substitutions.279 The NRAS-BRAF-EGFRS493R Mutation Assay also 
90 
 
covers a larger range of BRAF mutations than most conventional PCR tests (E, D, K and 
R), but similarly cannot distinguish between E and D or K and R substitutions. This assay 
has a turn-around time of two hours. The Ion AmpliSeq Cancer Hotspot Panel v2 covers 
all of the BRAF codon changes covered by Idylla and Cobas, however the test turn-around 
time is at least 24 hours.196 The review of the literature identified some deficiencies in the 
evidence and the aim of this part of the study was to technically validate the Idylla System 
for the detection of BRAF mutations in CRC and to clinically assess the diagnostic accuracy 
in patients for whom BRAF testing is carried out as standard care. This includes LS 
screening for patients meeting the revised Bethesda criteria and for prognostication in 
stage II (pT3N0 & pT4N0) or above CRC patients.  
 
3.2 Experimental design 
3.2.1 BRAF workload and costings audit 
All cases of CRC from a 12-month period were assessed for the number of tumours 
undergoing MMR IHC. This method was chosen to capture all patients who may need 
BRAF testing; testing is only indicated in CRC for patients with MLH1 loss by IHC. BRAF 
testing is not routine locally however due to funding shortages, but this method identified 
all patients who should be eligible for BRAF testing, see Figure 11. Note however, the audit 
preceded NICE guidance for testing all patients and here was based on Bethesda criteria 
only, in line with RCPath guidance at the time.13,269  
 
3.2.2 BRAF automated PCR diagnostic test accuracy study  
The Idylla BRAF Mutation Test was compared against the standard-care test, the Cobas 
BRAF V600 Mutation Test performed on the Cobas 4800 System. A consecutive series of 
cases was selected from the departmental database search results (see Chapter 2). 
Selection criteria in addition to those set out in Chapter 2 were used to limit cases selected 
from patients for whom BRAF was to be carried out on clinical grounds (LS screening, 
Stage III or above, at the request of clinicians for prognostication).  
 
At this stage no reliable data existed on how well the Idylla was likely to perform under 
clinical conditions for a formal sample size calculation. Therefore, a basic nomogram 
method of estimating the same size was carried out in line with recommendations (see 
Appendix 4).288 This method is semi-formal and allows an easy visual representation of the 
various likely sample sizes needed for a range of test sensitivities or specificities, as well 
as varying prevalence and confidence intervals. For BRAF testing, the aim is to screen out 
and reduce the number of patients for Clinical Genetics testing by obtaining a positive 
result. Therefore, high specificity is probably more important in this setting and so the 
specificity nomogram was used. The specificity was estimated to be high based on the 
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poster abstracts discussed in Subsection 1.6.3. This was expected to be around 90 to 
100% and using the nomogram method, a range of possible sample sizes were estimated. 
The results of this suggested that a sample size of 100 cases was probably a reasonable 
and achievable estimate. 
 
3.2.3 Validating BRAF automated PCR with IHC  
The Idylla BRAF Mutation Test was validated against IHC with the VE1 Ab on the Ventana 
Benchmark ULTRA autostainer platform.233 18 cases were selected out from the clinical 
study cohort results (Subsection 3.3.2) and two new cases selected required additional 
Idylla testing: 10 positive and 10 negative by conventional PCR (Cobas BRAF V600 
Mutation Test). Only cases with V600E mutations were selected as the VE1 Ab does not 
bind with other amino acid changes. The cases were processed in line with the methods 
outlined in Chapter 2.  
 
IHC staining was not scored by the author due to a possible risk of bias (lack of blinding), 
but instead was independently assessed by two consultant (fully qualified) 
histopathologists who were blinded to any molecular test results. Recommendations 
suggest only one pathologist is needed for scoring, however the study here aimed to 
investigate agreement (reproducibility) for VE1, so two pathologists were used. No 
consensus on how to score the VE1 Ab exists so a sensible scoring system was devised 
based on that used by others (including the original laboratory which produced the Ab) and 
based on recommended H-scoring methodologies.169,170,289,290 Only cytoplasmic staining 
was considered positive as non-cytoplasmic staining is reported to be non-specific.169 
Cases were scored for intensity (1 to 3, 0 = no staining) and percentage of cells stained (0 
= <20%, 1 = 20-50%, 2 = >50%). For each case, the pathologists’ scores were multiplied 
together (intensity x %) and the mean of the two assessors’ scores was taken. A final score 
of >1 was considered positive. Agreement between pathologists was assessed using 
Cohen’s kappa as described in Section 2.5.  
 
3.2.4 Validating BRAF automated PCR with NGS 
The Idylla NRAS-BRAF-EGFRS492R Mutation Assay was validated for BRAF mutation 
detection against NGS with the Ion AmpliSeq Cancer Hotspot Panel v2. 18 cases separate 
from the clinical cohort (Subsection 3.3.2) were selected (this cohort did not have NGS 
testing at the time so different cases needed selecting): 9 positive and 9 negative by NGS. 
Only 18 cases were selected due to the limited supply of prototype assays available and 
limited funding. Cases were processed in line with the methods outlines in Chapter 2.   
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3.3 Results  
3.3.1 BRAF workload and costings 
In a 12-month period, 284 CRC resections were reported in the department. 209 cases 
(74%) were screened for LS. Cases were tested for BRAF mutations in line with the LS 
pathway as set out in Figure 11. Around half of those cases undergoing IHC were because 
they met the Revised Bethesda criteria and BRAF was only carried out on those with loss 
of MLH1 expression. The other half of cases were evaluated with IHC for prognostication 
in Stage II and above cancer. Consequently, MLH1 loss in this cohort raised the question 
of LS and so cases were also tested for BRAF as part of the full LS screening. In total 44 
cases were eligible for BRAF testing, however NHS funding was in place for only 28. The 
cost of the Cobas BRAF V600 Mutation Test is around £180 per case and therefore the 
total annual cost was estimated at £7,920. The list price of the Idylla BRAF Mutation Test 
given by Biocartis is £110 per case, or £4,840 per year. The potential saving of introducing 
the Idylla System for BRAF testing therefore was estimated to be £3,080. Had all 284 CRC 
cases been screened for LS in line with new NICE guidelines,269 the number of BRAF tests 
would probably have been much higher and the saving greater. Further discussion of these 
findings is presented later in Subsection 4.3.1.  
 
3.3.2 BRAF automated PCR diagnostic accuracy  
100 consecutive CRC cases from 97 patients were retrieved, representing around 30% of 
CRC resection workload. A summary of the patient characteristics is given in Table 10. 96 
cases were resection specimens and four cases were biopsies. All cases were invasive 
adenocarcinoma covering the clinical spectrum from well to poorly differentiated tumours 
and ranging from Stage I to IV tumours. All cases met the minimum tissue requirements for 
testing. The four biopsy cases and two of the resection cases required multiple sections to 
meet the tissue area requirements; the maximum number of sections used in any case was 
six. Of the 98 cases with results (i.e. excluding failed tests), 30 (31%) cases were MLH1 
negative on IHC and therefore tested for BRAF mutations within the context of LS 
screening. The remaining 68 cases had been tested for BRAF mutations for 
prognostication. 
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Characteristic Values n=97 
Age* 72 (12) years 
Male 43% 
Adenocarcinoma 100% 
Site  
Right colon 52% 
Transverse colon 7% 
Left/sigmoid colon 14% 
Rectum 27% 
Specimen type  
Biopsy 4% 
Polypectomy 1% 
Right hemicolectomy 53% 
Transverse colectomy 1% 
Left Hemi/sigmoidcolectomy 9% 
Anterior resection 26% 
Abdominoperineal resections 3% 
Pancolectomy 1% 
TEM 2% 
Metastatic resections 0% 
Grade  
Well differentiated 4% 
Moderately differentiated 76% 
Poorly differentiated 20% 
Stage at surgery  
Stage I 20% 
Stage II 44% 
Stage III 31% 
Stage IV 1% 
 Unknown (biopsy only) 4% 
Neo-adjuvant chemotherapy given 8% 
*  = variables expressed as a Mean (Standard Deviation) 
 
Table 10. Summary of the patient characteristics for the patients 
tested with the Idylla BRAF Mutation Test in the diagnostic accuracy 
study. TEM = transanal endoscopic mucosal resection. 
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All cases had both the Idylla test and the Cobas PCR. Two cases (both resections) 
contained insufficient DNA in the tissue available to the study to produce a result, thus 
these were excluded from the statistical analysis. Three initial tests failed due to an Idylla 
machine fault and the processing unit was replaced (tests were repeated). Two tests failed 
due to initial user error (these were repeated). One test failed under normal conditions (also 
repeated).  
 
BRAF mutations were found in 29 cases by Cobas making the reference test prevalence 
29.5% (95% CI: 21.5% to 39.3%) and in 30 cases by Idylla making this prevalence 30.6% 
(95% CI: 22.4% to 40.3%). This is a little higher than predicted by the literature, although 
was representative of the detection levels usually seen in local practice. All mutations 
detected by both tests were V600E. In total 30 cases had tested positive for BRAF 
mutations on the Idylla System. All but one case showed agreement between the Idylla 
System and Cobas, making the concordance 98.98% (95% CI: 94.4% to 99.8%). All 29 
Cobas positive cases tested positive with Idylla and 68 of the 69 Cobas negative cases 
tested negative with Idylla. Therefore, the one discordant case was Idylla positive and 
Cobas negative. A summary of the results is given in Table 11.  
 
 
 
 
 Cobas Positive Cobas Negative Totals 
Idylla Positive 
 
29 1 30 
Idylla Negative 
 
0 68 68 
Totals  29 69 98 
 
Table 11. Summary of the diagnostic accuracy study comparing Idylla (index test) with 
Cobas (reference test) PCR for BRAF mutations Permission to reproduce this table 
from a similar published table has been granted by the British Medical Journal 
Publishing Group Ltd.2  
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The sensitivity of the Idylla System therefore was 100.0% (95% CI: 88.3% to 100.0%) and 
the specificity was 98.6% (95% CI: 92.2% to 99.7%). The positive predictive value was 
96.7% (95% CI: 83.3% to 99.4%) and the negative predictive value was 100% (95% CI: 
94.7% to 100.0%). The positive likelihood ratio was 69 and the negative likelihood ratio 
was zero.  
 
The case was adjudicator tested by ddPCR for BRAF which found the case to be positive 
for the V600E mutation, making the Idylla result a true positive and the original Cobas result 
a false negative. Including these findings in the statistical analysis improves the results: the 
concordance then was 100.0% (95% CI: 96.2% to 100.0%), the specificity 100.0% (95% 
CI: 94.7% to 100.0%) and the PPV 100.0% (95% CI: 88.7% to 100.0%). A summary of the 
statistical analysis is given in Table 12.  
 
 
 
Statistic  Value 
Prevalence (defined by Idylla) 30.6% (95% CI: 22.4% to 40.3%) 
Prevalence (defined by Cobas) 29.5% (95% CI: 21.5% to 39.3%) 
Concordance  98.98% (95% CI: 96.8% to 97.5%) 
Concordance including ddPCR 
results 
100.0% (95% CI: 96.2% to 100.0%) 
Sensitivity 100.0% (95% CI: 88.3% to 100.0%) 
Specificity 98.6% (95% CI: 92.2% to 99.7%) 
Specificity including ddPCR results 100.0% (95% CI: 94.7% to 100.0%) 
PPV 96.7% (95% CI: 83.3% to 99.4%) 
PPV including ddPCR results 100.0% (95% CI: 88.7% to 100.0%) 
NPV 100% (95% CI: 94.7% to 100.0%) 
LH+  69 
LH+ including ddPCR results Undefined (a/0)* 
LH- 0 
* = division by zero is mathematically undefined 
 
Table 12. Summary of the calculated statistics from the Idylla data for the BRAF 
diagnostic test accuracy study. PPV = positive predictive value, NPV = negative 
predictive value, LH+ = likelihood ratio positive, LH- = likelihood ratio negative, 
ddPCR = droplet digital PCR 
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3.3.3 BRAF automated PCR validation with IHC  
There were 12 cases which were scored overall >1 and called positive with IHC. An 
example of VE1 staining is shown in Figure 12 and the raw data of the BRAF IHC scoring 
are shown in Table 13.  
 
 
Figure 12. Photomicrograph of a poorly differentiated colorectal adenocarcinoma stained 
with the VE1 antibody by IHC. This is case 1 from Table 13 and shows predominantly 
strong brown IHC cytoplasmic staining (intensity scored 3 by both histopathologists) in all 
tumour cells (% tumour scored 2 by both histopathologists). The background stroma is 
negative for IHC staining and seen as light blue haematoxylin-stained cells. DAB 
chromogen staining and counterstained with haematoxylin, scanned at x400. Permission 
to reproduce this figure from the same published image has been granted by the British 
Medical Journal Publishing Group Ltd.4 DAB = 3,3'-Diaminobenzidine, IHC = 
immunohistochemistry  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = discordant case with molecular result (Idylla/Cobas) 
 
 Table 13. Results of the VE1 immunohistochemistry scoring. 
Case Pathologist 
1: cell 
percentage 
Pathologist 
1: intensity 
Pathologist 1: 
combined 
score 
Pathologist 2: 
cell 
percentage 
Pathologist 2: 
intensity 
Pathologist 2: 
combined 
score 
Average 
score 
IHC Result 
1 2 3 6 2 3 6 6 + 
2 2 2 4 2 2 4 4 + 
3 0 0 0 0 0 0 0 - 
4 0 0 0 0 2 0 0 - 
5 0 0 0 0 0 0 0 - 
6 2 2 4 2 2 4 4 + 
7 0 0 0 0 0 0 0 - 
8 1 1 1 2 1 2 1.5 +* 
9 2 3 6 2 3 6 6 + 
10 2 3 6 2 3 6 6 + 
11 2 2 4 2 2 4 4 + 
12 0 0 0 0 1 0 0 - 
13 2 3 6 2 3 6 6 + 
14 2 3 6 2 3 6 6 + 
15 0 0 0 0 1 0 0 - 
16 0 0 0 1 1 1 0.5 - 
17 1 1 1 2 1 2 1.5 + 
18 0 0 0 0 0 0 0 - 
19 1 2 2 2 1 2 2 +* 
20 0 0 0 2 2 4 2 + 
9
7
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In this part of the study, accuracy of Idylla and reproducibility of VE1 were assessed. For 
assessing accuracy, there was agreement between IHC and Idylla in 18 cases making the 
concordance 90% (95% CI: 69.9% to 97.2%). There was however 100.0% (95% CI: 83.9% 
to 100.0%) concordance between Idylla and Cobas in these cases and all mutations 
detected were V600E (VE1 is V600E specific). In both discordant cases (case 8 and case 
19 in Table 13) there were minor disagreement between the two pathologists scoring the 
slides and both felt the staining was ambiguous. A summary of these results is given in 
Table 14.  
 
 
 
 IHC Positive IHC Negative Totals 
Idylla Positive 
 
10 0 10 
Idylla Negative 
 
2 8 10 
Totals 
 
12 8 20 
 
Table 14. Summary of the BRAF validation study comparing Idylla with IHC. 
Permission to reproduce this table from a similar published table has been granted 
by the British Medical Journal Publishing Group Ltd.4  
 
 
 
For assessing reproducibility, there was agreement between the two pathologists in 17 of 
the 20 cases. There were three cases was called positive by Pathologist 2 but negative by 
Pathologist 1 (cases 8, 17 and 20 in Table 13). This gave a kappa value of 0.71 (95% CI: 
0.41 to 0.99). The results are summarised in Table 15.  
 
 
 Pathologist 2  
positive 
Pathologist 2 
negative 
Totals 
Pathologist 1 
positive 
9 0 9 
Pathologist 2 
negative 
3 8 11 
Totals 12 8 20 
 
Table 15. Agreement between pathologists scoring the VE1 IHC. 
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3.3.4 BRAF automated PCR validation with NGS 
The results of the BRAF NGS validation study are shown in Table 16. These results are 
derived from the same Idylla run (NRAS-BRAF-EGFRS492R Mutation Assay) carried out 
from which the NRAS results in Subsection 4.3.4 were derived. There was one failed test 
due to a technical error with the Idylla software. As this was the same cartridge testing for 
NRAS, as such it represents one failed assay but two failed tests. A replacement assay to 
repeat the sample could not be obtained. 12 of these same cases were also tested with a 
different assay run (the Idylla KRAS Mutation Test), the results of which are presented in 
Subsection 4.3.3.  
 
There was 100.0% (95% CI: 81.6% to 100.0%) concordance between Idylla and Ion 
Torrent. All mutations detected were V600E.  
 
 
 
 NGS Positive NGS Negative Totals 
Idylla Positive 
 
8 0 8 
Idylla Negative 
 
0 9 9 
Totals 8 9 17 
 
Table 16. Summary of the BRAF validation study comparing Idylla with NGS. 
Permission to reproduce this table from a similar published table has been 
granted by the British Medical Journal Publishing Group Ltd 4 
 
 
 
3.4 Conclusion 
The results from the diagnostic study show that the Idylla BRAF Mutation Test has a very 
high level of diagnostic accuracy. The Idylla NRAS-BRAF-EGFRS492R Mutation Assay 
showed high accuracy by complete concordance with the reference test for detecting BRAF 
mutations. This was the first study to demonstrate the accuracy of these tests in CRC and 
these findings support the hypothesis. 
 
The BRAF Mutation Test showed only moderate concordance with IHC. However, Idylla 
showed 100% concordance with Cobas in these cases, highlighting the problem being with 
the VE1 Ab and not a weakness of Idylla. IHC is therefore not a suitable test for routine 
clinical practice.   
 
In the current clinical context, there is a need for faster, more cost effective BRAF testing. 
Screening for LS is now increasingly recommended by many professional bodies11,13 and 
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the most recent guidance suggests LS screening for all patients with CRC.269 Furthermore, 
emerging treatment options are providing more indications for establishing MMR status. 
Thus requests for BRAF testing are only going to increase.291 The need for a rapid test 
which is far more widely available to smaller centers, at lower cost, can be fulfilled by the 
Idylla System. 
 
3.5 Discussion 
There was only one discrepant case in the BRAF Mutation Test diagnostic study. This was 
shown by ddPCR to be a true positive result by Idylla and a false negative by Cobas. 
Initially, this was suspected to be due to lack of D, E2, K or R codon coverage by Cobas, 
however ddPCR confirmed the mutation was the V600E change and was therefore a lack 
of sensitivity of Cobas. In this case, conventional PCR would have led to an unnecessary 
referral to clinical genetics for LS assessment with significant patient anxiety and significant 
financial cost. In this regards, Idylla was demonstrated to be a superior test and again this 
supports the hypothesis. There were six failed Idylla BRAF Mutation Tests. All but one of 
these were actual failures under normal working conditions and therefore the failure rate 
was acceptably low (~1%).  
 
The Idylla NRAS-BRAF-EGFRS492R Mutation Assay was shown to be accurate in a 
concordance validation but the test would ideally need further evaluation in a diagnostic 
accuracy study before routine use could be recommended with high confidence. Only one 
test failed, but this was due to a cartridge software error rather than an intrinsic issue with 
the test. 
 
IHC with VE1 failed to produce satisfactory results. IHC is a cheaper test (Around £30) by 
comparison to either Idylla (£110) or Cobas (£180), however given the fact that significant 
management decisions could be made upon this result (such as referral for genetic 
screening), these results would not give enough confidence in VE1 for it to be used in 
routine practice.170 Ab-based tests are generally very cheap and very fast ways of detecting 
the presence of a protein of interest, commonly in tissue sections (IHC) or on the 
electrophoresis gels of cell lysis products (Western blot). The idea that some cells 
preferentially express certain proteins or combinations of proteins is the basis for using 
these tests in clinical practice.292 There are some drawbacks to this approach however. 
Firstly, the validation of Abs produced commercially or in private laboratories is not always 
robust and there is often no guarantee that a particular Ab purchased will specifically target 
the protein in question. Furthermore, the protocol for using Abs is rarely fully optimized or 
validated. When validation data are available, it is often difficult to obtain and commonly 
not checked by the user (who may not even know how to check).293,294 Beyond this, there 
is often a lack of unbiased clinical data on the diagnostic accuracy of many of the antibodies 
used in clinical practice. Indeed, many IHC tests are used in combinations and there is 
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rarely any validation of such ‘panels’.292 This problem can only be tackled by enforcing strict 
guidelines for Ab validation.294 
 
A second major issue is how such tests are interpreted. Interpretation to date is 
predominantly performed visually.292 IHC tests rely on staining with chromogen dyes and 
this is a continuous variable, not a discrete positive negative result. For most IHC stains, 
the protocol can be changed to allow for greater or lesser staining depending on the user 
preference. What’s more, false positive staining due to endogenous peroxidase or other 
artefacts is a very common pitfall for the observer. Therefore, there is potentially a great 
deal of inter-observer variation and subjectivity introduced into these tests, and any scorer 
agreement is not often assess empirically.294,295 The potential for digital image analysis to 
overcome the subjectivity of IHC is starting to emerge as more reliable however and this 
could be a potential solution to reproducibility in the future.296 
 
Despite these limitations, IHC is very widely used in histopathology practice and viewed by 
many as robust.292,295 The potential to use IHC for molecular targets is obviously therefore 
very attractive to many histopathologists and oncologists. An example of probably the most 
commonly used IHC marker of a molecular target is the Ab for p53, marking the expression 
of the TP53 gene. In this example, a mutation in TP53 either renders the protein stable or 
results in truncation, and consequently is detected as an over expression (strong staining 
in all cells) or a total absence of staining.297,298 In the context of CRC, like most targeted 
molecular testing, genetic lesions are generally focused on small point mutations or indels 
and engineering an Ab for a subtle base change is challenging. The VE1 Ab was one of 
the first developed against a single amino acid change (BRAF V600E),290 although similar 
Abs for IHC detection of KRAS mutations have also been developed.299,300 The limitation 
of these Ab tests however is that they are only targeted for one mutation at a time as the 
Ab structure is specific and there is a very limited range of chromogen colours (and 
secondary Ab combinations) which can be applied to a single tissue section for marking 
multiple antigens. For this reason, it would be necessary to use a great number of tissue 
sections to get the full coverage of clinically relevant mutations in several gene targets, 
such as is required in KRAS for example.14,260,292 For routine clinical use this is not practical 
and for basic science work the information about the underlying biology available from IHC 
staining is rather limited when compared with other available technologies, such as NGS 
or other sequencing methods.301,302   
 
In this study VE1 showed only moderate concordance with molecular testing and this is not 
surprising given the mixed findings of recent reviews of the Ab. These have mentioned 
difficulties with stain interpretation, false positive pitfalls, wide ranging diagnostic accuracy 
rates and variable inter-observer agreement, but have come to somewhat differing 
conclusions.169,170,290,303 In this study the inter-observer agreement was good with a kappa 
value of 0.7, demonstrating that the rather simplistic scoring system used was quite useful. 
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However, despite good scoring agreement, the Ab still performed too weakly for confident 
routine clinical use and in line with some of the mentioned recent literature, it is not 
recommended for use based on the findings in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The methods, data, statistical analysis and some points of discussion presented in this 
Chapter are also presented in publications and posters arising from this work.1-8 Non-
integer values are rounded to one decimal point. For all statistical analysis formulae, see 
Appendix 4.  
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Chapter 4: Ras Testing with Automated PCR 
4.1 Introduction 
4.1.1 Chapter overview  
KRAS and NRAS genes are key molecular targets in CRC and mutations in these are 
commonly tested for in clinical practice. This is predominantly because mutations in these 
genes can predict response to targeted therapies. This Chapter aims to test the hypothesis 
that the Idylla System is accurate for detecting KRAS and NRAS mutations in CRC. The 
Chapter will begin with an overall discussion of Raf signaling and its diagnostic utility. This 
is followed with an audit of the clinical service locally to establish the financial impact of 
using the Idylla System for Ras testing. Next, a full clinical study of the Idylla KRAS Mutation 
Test compared with conventional PCR is presented to evaluate the diagnostic accuracy of 
the test. Funding did not cover a full clinical study for the test compared with NGS, however 
a technical validation is presented to give some indication of this. This Chapter also 
includes a validation of the NRAS component of the Idylla NRAS-BRAF-EGFRS492R 
Mutation Assay in order to give an indication of the accuracy of the system for detecting 
NRAS mutations. 
 
4.1.2 Ras genes 
The Rat sarcoma (Ras) subfamily of GTPase proteins are downstream mediators EGF 
signaling in the MAPK pathway and belong to the larger Ras superfamily of related proteins. 
These proteins act upstream of Raf kinases, such as BRAF. As discussed, binding of EGF 
to its receptor EGFR results in activation of Ras proteins and subsequent activation of a 
cascade which results in the up-regulation of a number of transcription factors, such as c-
myc (Figure 4). This eventually results in increased cell division. Mutations in Ras proteins 
can result in constitutive activation of KRas, leading to an over-activation of the MAPK 
pathway, uncontrolled cell proliferation and neoplasia. There are three members of the Ras 
subfamily: KRAS, NRAS and HRAS. Each Ras member has similar actions within the cell, 
but may be expressed at different levels in different tissues and may have different 
downstream targets. 69,70,74,304  
 
The Kirsten Ras viral oncogene homologue (KRas) is encoded by the proto-oncogene 
KRAS and appears to be the dominant member of the Ras group most widely expressed. 
KRAS has been implicated in the development of numerous malignant and pre-malignant 
(dysplastic) tumour types, including those of the lung, pancreas, breast and, as mentioned, 
are driver mutations in the adenoma-carcinoma sequence in CRC. Around 30-40% of 
CRCs harbor KRAS mutations, most importantly in exons 2, 3 and 4.10,14,69,70 KRAS 
mutations in CRC may impart a poorer prognosis, especially those in exon 2 (which are the 
most common), and in those patients with wild type BRAF.305,306 
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The Neuroblastoma Ras viral oncogene homolog (Nras) is encoded by the proto-oncogene 
NRAS. Mutations in NRAS can also result in constitutive activation of Nras, similarly leading 
to an over-activation of the MAPK pathway and uncontrolled cell proliferation and 
neoplasia.72,307 NRAS mutations are uncommon though and only detected in around 5% of 
CRCs. HRAS appears to be of less clinical significance in CRC.72,308 
 
4.1.3 Ras testing in CRC 
Ras testing is important clinically as it is used to guide anti-EGFR therapy. Two types of 
anti-EGFR therapy exist: tyrosine kinase inhibitors (TKi), small molecule drugs that inhibit 
the tyrosine kinase activity of EGFR, and monoclonal antibodies (mAb) that specifically 
bind to and block EGFR receptor activity (receptor antagnostism). Anti-EGFR mAb 
therapies such as cetuximab and panitumumab have proven effective in colorectal 
adenocarcinoma; TKis are not thought to be useful. Patients with non-adenocarcinoma 
subtypes of CRC or metastases to the colorectum have not been shown to respond to 
therapy. These anti-EGFR mAb drugs are not curative but can extend remission times. 
Given this, along with their cost and side-effect profiles, these therapies are generally 
reserved for Stage IV CRC for patients with unresectable metastases. Around 20% of 
patients who have metastases with wild type somatic KRAS show a good response to anti-
EGFR mAb therapy. However, CRC patients with somatic mutations in almost any KRAS 
codon show autonomous stimulation of the MAPK pathway and do not respond to 
treatment.10,14,69,70,133,134,171,260,261 Interestingly, one mutation, the G13D codon change, 
seems to impart a better response to anti-EGFR mAb therapy. The mechanism behind this 
is uncertain.309 It is clinically prudent to identify individuals with any of these mutations in 
order to avoid exposing non-responding patients to potentially harmful side effects and 
wasting financial resources. Therefore, testing CRC tissue for mutations in KRAS is 
becoming routine with UK, European and US guidelines recommending KRAS testing in 
all primary CRC tumours following surgical excision.14,70,260,261,310,311  
 
Initially, only mutations in KRAS were thought to predict response to anti-EGFR mAb 
therapy, however it is becoming increasingly recognised that NRAS mutations are 
predictive and hence it is becoming increasingly common to test for both. Patients with 
NRAS mutations, via a similar mechanism to that proposed with KRAS mutations, are 
probably resistant to anti-EGFR mAb therapies. The role of HRAS in CRC is unclear and 
this is rarely tested in clinical practice.14,70,260,261,264,310,311 
 
There is no high-profile guidance for Ras testing in the NHS and what is available focuses 
on KRAS testing. NICE guidelines state that anti-EGFR mAb therapy is effective in patients 
with wild type KRAS metastases but do not explicitly recommend Ras testing or comment 
on proposed diagnostic algorithms or methods.133 The development of further NICE 
guidance on testing has been discontinued312 and an update to anti-EGFR mAb therapy in 
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metastatic CRC has been pending publication for some time.134 Some pathologists suggest 
that testing all primary CRC resection specimens at initial reporting would avoid treatment 
initiation delays should they be found to develop metastases at a later date. This so-called 
‘reflexive testing’ is controversial and often funding will only cover testing patients with 
proven metastases, however in some centers reflexive testing is a popular approach. 
Therefore, because no consensus on which CRC patients should have Ras testing exists, 
testing is fragmented across the UK and often performed ad hoc at the request of 
oncologists. It is extremely likely that some patients are started on therapy without testing 
and many others are tested unnecessarily.10,14,133,260,310  
 
There is also no consensus on which tissue the Ras testing should be carried out, but this 
is often the primary tumour. The reasons for this may be historical, with unwarranted 
worries about low concentrations of DNA in biopsy material (metastases are not usually 
resected) being prevalent for some time.313 There is also now a general feeling that there 
is good concordance between primary and secondary tumour genotypes and that testing 
metastatic tissue is not needed.145,314 The phenomenon of tumour heterogeneity between 
populations of cells in a tumour (intra-tumoral) and between metastatic and primary 
tumours (inter-tumoral) is well documented however315-320 and it is uncertain how genotype 
of the metastatic tumour affects anti-EGFR mAb therapy; most of the clinical drug trials 
were probably carried out with primary tumour KRAS testing.321 Given this confusing 
situation, there is no consensus on which tissue should be tested and pathology guidance 
suggests primary or secondary tumour tissue can be tested, with only a ‘preference’ for 
metastatic tissue where available. Extracting DNA from resected metastases is easy but 
these patients are not considered palliative, are not offered anti-EGFR mAb therapy and 
so these specimens should probably not be tested.14,314  
 
4.1.4 Rationale for Ras testing with automated PCR 
One of the most widely used KRAS tests is run on the Cobas platform. The test is now 
quite old and can only detect changes in exon 2 (codons 12 & 13) and exon 3 (codon 
61).183,197 However, recent evidence suggests testing for targets in exon 4 (codons 117 and 
46), therefore so-called ‘extended Ras testing’ now being called for in routine practice.322 
The Idylla KRAS Mutation Test has recently been launched for use in CRC in Europe. The 
assay has a turn-around time of two hours and covers the detection of a similar range (to 
Cobas) of clinically relevant KRAS mutations that can be used in the clinical setting for 
guiding anti-EGFR mAb therapy, see Table 7. The substitutions which can be detected by 
the test are G12C/R/S/A/D/V, G13D, A59E/G/T (exon 3; the test cannot distinguish 
between different mutations in codon 59), Q61H/H2/K/K2/L/R (the test cannot distinguish 
between H and H2, between K and K2 or between L and R changes), K117N1/N2 (the test 
cannot distinguish between N1 and N2 changes) and A146P/T/V (the test cannot 
distinguish between mutations in codon 146). Despite the limitations of differentiating 
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codon changes, determining the mutation type is not currently necessary for directing 
therapy. Testing for KRAS mutations with the Idylla System may also offer faster results 
than Cobas and may do so at a lower cost. The Ion AmpliSeq Cancer Hotspot Panel v2 
covers all of the KRAS codon changes covered by Idylla and Cobas, however the test turn-
around time is at least 24 hours.196 There are no published data on the Idylla KRAS 
Mutation Test as discussed, therefore this part of the study aimed to address this lack of 
evidence.  
 
There are few widely available and approved commercial PCR-based tests for detecting 
NRAS mutations. Most centers use NGS gene panel approaches for detecting these 
mutations. This approach is slow and costly as discussed.264,323 The Idylla NRAS-BRAF-
EGFRS492R Mutation Assay is currently available for research only and exists in a 
prototype format for testing. The Idylla assay has a similar mutation coverage to NGS, see 
Table 7. The assay has a turn-around time of two hours and detects the G12C/S/D/A/V 
(the test does not distinguish between A and V), G13D/V/R (the test does not distinguish 
between V and R), A59T, Q61K/L/R/H/H2 (the test does not distinguish between H and 
H2), K117N/N2 (the test does not distinguish between N and N2) and A146T/V (the test 
does not distinguish between T and V) substitutions. Although there is little data available 
for NRAS testing, as with KRAS mutations, the type of NRAS mutation is probably not 
important and so these limitations are unlikely to be inhibitory to clinical use.189 The Ion 
AmpliSeq Cancer Hotspot Panel v2 covers most of the NRAS codon changes covered by 
Idylla (it does not include coverage of A59T or A146V), however the test turn-around time 
is at least 24 hours.196 The Idylla assay then potentially offers a cheaper and much faster 
testing method over NGS approaches, but requires validation and clinical evaluation. There 
was only a limited supply of prototype assays available for testing and therefore a full 
clinical study was not possible at this time. The test however requires a basic validation 
and this was possible within these limitations. 
 
4.2 Experimental design 
4.2.1 Ras workload and costings audit  
In line with local and national/international guidelines already mentioned, KRAS testing is 
carried out on all CRC excisions.14,70,260,261,310,311 Therefore the total number of annual CRC 
cases was used in the costing audit for KRAS testing. These methods are similar to those 
described in Chapters 2 and 3. The number of cases requiring NRAS testing would 
essential be the same (284 patients) as those requiring KRAS testing as the indication is 
the same in both therapies.14,70,260,261,264,310,311 
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4.2.2 KRAS automated PCR diagnostic accuracy study  
The Idylla KRAS Mutation Test was compared against the standard-care Cobas KRAS 
Mutation test. All cases were tested for KRAS mutations at the time of original reporting. A 
consecutive series of cases was selected from the diagnostic archival database search 
results (see Chapter 2). Selection criteria in addition to those set out in Chapter 2 were 
used to limit cases selected from patients for whom KRAS testing was performed.  
 
At this point in the study there was more information available to make a sample size 
calculation possible. The results of the BRAF diagnostic study carried out in Chapter 3 
suggested the sensitivity and specificity of Idylla is 100%. In the intervening time a number 
studies were published and further poster abstracts were presented that also suggested 
the Idylla System had high diagnostic accuracy (see Chapter 5).324-328 For KRAS mutations 
the sensitivity of a test is probably more important as it is used to rule out patients from 
targeted therapy. A conservative estimate of 99% was taken based on the findings in 
Chapter 3 and other published data. Furthermore, the standard formulae do not function 
well at values of 100% (numerator of zero) so a lower value had to be used. This is in line 
with standard practice. The sample size was estimated for a confidence interval of 95% 
and was carried out using standard formulae (see Appendix 4).235,329 
 
The estimated sample size was calculated as 30 cases for a prevalence of KRAS mutations 
at 50% (based on local rates): 
 
 
 
DP = 1.962
0.99 (1 −  0.99)
0.052
= 15 
𝑛 (𝑆𝑛) =
15
0.5
= 𝟑𝟎 
 
 
 
4.2.3 Validating KRAS automated PCR with NGS  
The Idylla KRAS Mutation Test was validated against NGS with the Ion Torrent Gene 
Panel. Test. 18 cases were selected rather than 20 as funds were limited and prioritised 
for the clinical study. Nine positive and nine negative cases by NGS were selected. Cases 
were processed in line with the methods outlined in Chapter 2.  
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4.2.4 Validating NRAS automated PCR with NGS  
The Idylla NRAS-BRAF-EGFRS492R Mutation Assay was validated for NRAS mutations 
against NGS with the Ion Torrent gene panel. 18 cases were selected for the validation as 
only a limited number of prototype testing cartridges were available and these were 
supplied in packs of six per unit. Five positive and 13 negative cases by conventional NGS 
were selected. Only five positive cases had been identified from the entire hospital 
database of NRAS testing (not unexpected as these mutations are uncommon). The cases 
were processed in line with the methods outlines in Chapter 2. 
 
4.3 Results 
4.3.1 Ras testing workload and costings 
As presented in Subsection 3.3.1, 284 CRC cases were reported in the department over a 
12-month period; all would have been eligible for KRAS testing. Only around half had 
actually undergone testing due to funding shortfalls. The Cobas KRAS Mutation Test costs 
around £180 and therefore the total cost would be estimated at £51,120. The list price of 
the Idylla KRAS Mutation Test given by Biocartis is £149 per test, or £42,316 per year. 
Therefore, the potential saving by introducing the Idylla System for KRAS testing is £8,804. 
There was obviously some overlap of the actual cases audited here with those for BRAF.  
 
NRAS testing has only just been introduced in Oxford, however all 284 KRAS eligible cases 
would also have been eligible for NRAS testing within the same time period. No 
conventional PCR test is available therefore NGS testing on the gene panel, which is 
around £300 per case, would be needed. For NRAS alone this would cost an estimated 
£85,200. The list price of the Idylla NRAS/BRAF/EGFRS492R Mutation Assay given by 
Biocartis is £212, or £60,208 per year. This would give a potential saving of £22,992 if the 
Idylla System was introduced into routine practice for NRAS testing alone.  
 
4.3.2 KRAS automated PCR diagnostic accuracy  
30 CRC samples from 30 patients were processed with the Idylla System. A summary of 
the patient characteristics is given in Table 17. All cases were invasive adenocarcinoma 
covering the clinical spectrum from well to poorly differentiated tumours and ranging from 
Stage I to III tumours. There were no biopsy specimens in this cohort. All cases met the 
minimum tissue requirements for testing and no case required more than one tissue section 
for Idylla testing.  
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Characteristic Values n=30 
Age* 71 (9) years 
Male 57.0% 
Adenocarcinoma 100.0% 
Site  
Right colon 30.0% 
Transverse colon 3.3% 
Left/sigmoid colon 30.0% 
Rectum 36.6% 
Specimen type  
Right hemicolectomy 33.3% 
Transverse colectomy 3.3% 
Left Hemi/sigmoidcolectomy 13.3% 
Anterior resection 36.6% 
Abdominoperineal resections 6.6% 
TEM 6.6% 
Grade  
Well differentiated 3.3% 
Moderately differentiated 83.3% 
Poorly differentiated 13.3% 
Stage at surgery  
Stage I 16.6% 
Stage II 40.0% 
Stage III 43.3% 
Stage IV 0.0% 
Neo-adjuvant chemotherapy given 2 cases (6.6%) 
* Variables expressed as a Mean (Standard Deviation) 
   
Table 17. Summary of the patient characteristics for cases 
tested with the Idylla KRAS Mutation Test. TEM = transanal 
endoscopic mucosal resection. 
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All cases had the Idylla test and conventional PCR. No cases failed testing by Idylla. In 
keeping with the expected findings from the literature, KRAS mutations were found in 15 
cases by Cobas making the reference test prevalence 50.0% (95% CI: 33.2% to 66.9%) 
and in 17 cases by Idylla making this a prevalence of 56.7% (95%CI: 39.2% to 72.6%). 
There were no failed tests.  
 
Of the mutations found by Idylla, 88.2% (15/17 mutations) were in codons 12 and 13 (see 
Table 18) and over a range of specific amino acid changes. None of the additional mutation 
types covered by the Idylla test (mutations in codons 59, 117 and 146) were detected in 
this study. 
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*The Idylla System cannot distinguish between these 
codon changes185 
 
 
Table 18. Summary of the KRAS mutation types detected in the clinical study. The table 
includes the full list of detectable mutations by the Idylla KRAS Mutation Test. Mutation 
types here are given by Idylla; Cobas reports only the exon of the mutation. Codon 
changes not detected by Idylla are not shown; no such codon changes happened to be 
present in the cohort tested here. One of the five G12V mutations was not concordant 
with Cobas and this was later shown to be mutant by ddPCR. The one Q61L/R 
mutations was Cobas negative and later confirmed to be wild type with ddPCR. 
Frequencies are given in absolute numbers. Mutations are given at the protein level with 
amino acid change notation. Numbers represent codon/amino acid position. G =glycine, 
C = cysteine, R = arginine, A = alanine, S = serine, V = valine, D = aspartate, E = 
glutamate, T = threonine, K = lysine, L = leucine, H = histidine, N = asparagine, P = 
proline, ddPCR = droplet digital polymerase chain reaction 
  
Mutation type Frequency  
G12C 1 
G12R 1 
G12A 1 
G12S 0 
G12V 3 (incl. 1 discordant) 
G12D 9 
G13D 0 
A59E/G/T* 0 
Q61K/K2* 0 
Q61L/R* 2 (incl. 1 discordant) 
Q61H/H2* 0 
K117N1/N2* 0 
A146P/T/V* 0 
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There was agreement between the Idylla System and Cobas in 28 of the 30 cases, making 
the concordance 93.3% (95% CI: 78.7% to 98.2%). Both discordant cases were Idylla 
positive but Cobas negative. A summary of the results is given in Table 19. 
 
 
 
 
 Cobas Positive Cobas Negative Totals 
Idylla Positive 
 
15 2 17 
Idylla Negative 
 
0 13 13 
Totals 15 15 30 
 
Table 19. Summary of the diagnostic accuracy study test results comparing Idylla 
(index test) with Cobas (reference test) PCR for KRAS mutations.   
 
 
 
The sensitivity of the Idylla System was 100.0% (95% CI: 79.6% to 100.0%) and the 
specificity was 86.7% (95% CI: 62.1% to 96.3%). The positive predictive value was 88.2% 
(95% CI: 65.7% to 96.7%) and the negative predictive value was 100.0% (95% CI: 77.2% 
to 100.0%). The positive likelihood ratio was 7.5 and the negative likelihood ratio was zero. 
A summary of the statistical analysis is given in Table 20. 
 
  
113 
 
 
 
 
 
 
 
 
Statistic  Value 
Prevalence (by Idylla) 56.7% (95%CI: 39.2% to 72.6%) 
Prevalence (by Cobas) 50.0% (95% CI: 33.2% to 66.9%) 
Concordance  93.3% (95% CI: 78.7% to 98.2%) 
Concordance including ddPCR results 96.7% (95% CI: 83.3% to 99.4%) 
Sensitivity   100.0% (95% CI: 79.6% to 100.0%) 
Specificity  86.7% (95% CI: 62.1% to 96.3%) 
Specificity including ddPCR results 92.9% (95% CI: 68.5% to 98.7%) 
PPV  88.2% (95% CI: 65.7% to 96.7%) 
PPV including ddPCR results 94.1% (95% CI: 73.0% to 99.0%) 
NPV   100.0% (95% CI: 77.2% to 100.0%) 
LH+  7.5 
LH+ including ddPCR results 14.0 
LH-   0.0 
 
Table 20. Summary of the calculated statistics from Idylla data for the KRAS 
diagnostic test accuracy study. PPV = positive predictive value, NPV = negative 
predictive value, LH+ = likelihood ratio positive, LH- = likelihood ratio negative, 
ddPCR = droplet digital PCR 
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The discordant cases tested both met the minimum tissue requirements for Idylla and 
therefore were adequate samples. Both discordant cases were disagreements between 
Idylla and Cobas. One discordant case was a G12V codon change and one was a Q61L/R 
codon change. The two cases were adjudicator tested by ddPCR for KRAS. The G12V 
codon change was confirmed by ddPCR making the Idylla results a true positive. The 
Q61L/R case however was confirmed to be wild type by ddPCR making the Idylla result a 
false positive. Including these findings in the statistical analysis improves the results: the 
concordance then was 96.7% (95% CI: 83.3% to 99.4%), the specificity 92.9% (95% CI: 
68.5% to 98.7%), the PPV 94.1% (95% CI: 73.0% to 99.0%) and the positive likelihood 
ratio 14.0.  
 
4.3.3 KRAS automated PCR validation with NGS  
The results of the KRAS PCR validation study are shown in Table 21. 13 of these cases 
were from the same cohort of patients tested for BRAF and NRAS mutations in Subsections 
3.3.4 and 4.3.4 but represent unique assay runs. Five cases were a unique set of patients 
not tested elsewhere.  
 
 
 
 
 
 
 NGS Positive NGS Negative Totals 
Idylla Positive 
 
9 0 9 
Idylla Negative 
 
0 9 9 
Totals 9 9 18 
 
Table 21. Summary of the KRAS validation study comparing Idylla with NGS. 
Permission to reproduce this table from a similar published table has been 
granted by the British Medical Journal Publishing Group Ltd.4 
 
 
There was 100.0% (95% CI: 82.4 to 100.0%) concordance between Idylla and Cobas. The 
mutation types detected are given in Table 22.  
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Mutation type Frequency  
G12C 1 
G12R 0 
G12A 0 
G12S 0 
G12V 2 
G12D 5 
G13D 0 
A59E/G/T* 0 
Q61K/K2* 1 
Q61L/R* 0 
Q61H/H2* 0 
K117N1/N2* 0 
A146P/T/V* 0 
*The Idylla System cannot distinguish between these codon 
changes185 
 
 
Table 22. Summary of the KRAS mutation types detected in the validation study with NGS. 
The table includes the full list of detectable mutations by the Idylla KRAS Mutation Test. 
Codon changes not detected by Idylla are not shown; no such codon changes happened 
to be present in the unselected cohort tested here. Frequencies are given in absolute 
numbers. Mutations are given at the protein level with amino acid change notation. 
Numbers represent codon/amino acid position. G =glycine, C = cysteine, R = arginine, A = 
alanine, S = serine, V = valine, D = aspartate, E = glutamate, T = threonine, K = lysine, L 
= leucine, H = histidine, N = asparagine, P = proline. 
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4.3.4 NRAS automated PCR validation with NGS  
The results of the NRAS validation study are shown in Table 23. The mutations detected 
are given in Table 24. These results are derived from the same Idylla run (NRAS-BRAF-
EGFRS492R Mutation Assay) carried out from which the BRAF results in Subsection 3.3.4 
were derived. 12 patients from this cohort were also tested with a separate assay for KRAS 
mutations (see result of this in Subsection 4.3.3).  
 
 
 
 
 
 NGS Positive NGS Negative Totals 
Idylla Positive 
 
5 1 6 
Idylla Negative 
 
0 11 11 
Totals 5 12 17 
 
Table 23. Summary of the NRAS validation study comparing Idylla with NGS. 
Permission to reproduce this table from a similar published table has been 
granted by the British Medical Journal Publishing Group Ltd. 4  
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*The Idylla System cannot distinguish between these codon 
changes189 
 
 
Table 24. Summary of the NRAS mutation types detected in the validation study with NGS. 
Codon changes not detected by Idylla are not shown; no such codon changes happened 
to be present in the unselected cohort tested here. Frequencies are given in absolute 
numbers. Mutations are given at the protein level with amino acid change notation. 
Numbers represent codon/amino acid position. G =glycine, C = cysteine, R = arginine, A = 
alanine, S = serine, V = valine, D = aspartate, E = glutamate, T = threonine, K = lysine, L 
= leucine, H = histidine, N = asparagine, P = proline, NGS = next generation sequencing. 
 
 
 
Mutation type Frequency  
G12C 1 
G12S 0 
G12D 3 
G12A/V* 0 
G13D 0 
G13V/R* 0 
A59T 0 
Q61K 0 
Q61L 1 (discordant, NGS wild type) 
Q61R 1 
Q61H/H2* 0 
K117N/N2* 0 
A146T/V* 0 
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The concordance between Idylla and Ion Torrent was 94.1% (95% CI: 73.0% to 99.0%). 
There was one discordant case that was Idylla positive (Q61L) but wild type by Ion Torrent 
(Q61L is covered by the Ion Torrent panel). The case met the minimum tissue requirements 
for the Idylla processing. ddPCR confirmed the presence of the Q61L mutation making the 
concordance 100%. There was one failed test due to an Idylla software error; this was the 
same assay failure as in Subsection 3.3.4 and thus represents overall one failed cartridge 
but two failed tests. A replacement assay to repeat the sample could not be obtained.  
 
4.4 Conclusion 
The results of the diagnostic study show the Idylla System has a high level of accuracy for 
detecting KRAS mutations. The results also show a high concordance of Idylla with NGS 
for NRAS testing. These finding support the hypothesis and are the first study to evaluate 
the system for KRAS or NRAS testing.  
 
4.5 Discussion 
There were two discordant test results in the Idylla KRAS Mutation Test diagnostic study, 
lowering the specificity slightly. In addition, the CIs were wider than anticipated. This likely 
reflects the fact that, despite a formal sample size calculation, in hindsight a bigger sample 
size would have improved the analysis. The discordant tests were further analysed with 
ddPCR, which showed one to be a true result by Idylla and the other to be a false positive 
call. Including these data in the analysis improves the CIs, the specificity is greater and the 
accuracy is within the realms of acceptability. These results were also reassured by the 
perfect concordance between Idylla and NGS for KRAS testing.  
 
The discordant results were not affected by which mutations were covered in either assay 
as the codon changes which were detected are covered by both Idylla and Cobas. In the 
case of the false positive Idylla result, this could have been due to contamination (although 
highly unlikely given the protocol) or the mutation being present in only a small clonal 
population of cells within the tumour. Although ddPCR is far more analytically sensitive 
(detects a lower mutation burden within the DNA pool) than Idylla, there is a possibility that 
a small clone could have been cut out in the later sections tested with ddPCR. This is 
extremely unlikely however. The clinical significance of a false positive or negative test in 
this circumstance is uncertain. The treatment with anti-EGFR mAb therapy is palliative 
anyway and small clonal populations would eventually be selected for once exposed to 
therapy. Therefore, while either inaccurate result would not be clinically ideal, neither offers 
greater accuracy over any reasonably available commercial assay used for standard 
testing. On balance then, the accuracy between the two systems (Idylla and Cobas) is 
probably comparable enough for the Idylla System to be safe for clinical use. There were 
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no failed Idylla tests in the KRAS part of the study and this probably reflects some of the 
improvements made on the system from the feedback given after the BRAF testing.  
 
The Idylla NRAS-BRAF-EGFRS492R Mutation Assay showed complete concordance but 
a further diagnostic study of the assay should be undertaken before taking the test fully into 
clinical practice. This is a crucial step for the Idylla System for use in CRC, as NRAS testing 
could become routine. There was one failed assay due to an initial software issue. This 
was fully resolved with a system update and really only reflected that the fact that the NRAS 
assay had only just been released. 
 
An important limitation of Ras tests on the Idylla system is the difference in coverage of 
some rare mutations when compared with Cobas or NGS (see Table 7). For example, the 
Idylla KRAS Mutation Test lacks coverage of the KRAS G13C mutation. This is a rare 
mutation and the clinical implications of this are not fully known,330 but this might be shown 
to be an important mutation in CRC in the future as more data become apparent. Similarly, 
there are some NRAS mutations not covered by Idylla but are by NGS. The converse is 
also true; some Ras codon changes are covered by Idylla but not the other conventional 
tests investigated here. The clinical implications of this issue are not currently known but 
again, this could be important in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similar methods, data, statistical analysis and some points of discussion presented in this 
Chapter are also presented in publications and posters arising from this work.1-8 Non-
integer values are rounded to one decimal point. For all statistical analysis formulae, see 
Appendix 4.  
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Chapter 5: Discussion 
5.1 Main findings 
In this thesis the results have shown that the Idylla System is able to detect mutations in 
BRAF, KRAS and NRAS with a very high degree of accuracy, confirming the hypothesis 
set out in Chapter 1. Only one Idylla result out of 180 molecular assay comparisons carried 
out in this thesis was shown to be a false result (one KRAS Mutation Test result). The Idylla 
BRAF Mutation Test was shown to be specific and potentially more sensitive that the Cobas 
equivalent test. The Idylla KRAS Mutation Test was shown to be at least as sensitive and 
specific as the Cobas equivalent test and have other benefits which are discussed below. 
The NRAS-BRAF-EGFRS492R Mutation Assay had a high level of concordance with 
standard care testing and further clinical evaluation would be useful.  
 
5.2 Potential benefits of automated PCR 
There are several potential benefits of the Idylla System over conventional PCR or NGS 
approaches. First of all the Idylla System is fully automated and was found to be very easy 
to use in this study. No specialist training is needed and no specialist setting is required to 
house the system. In contrast, the typical NHS histopathology laboratory does not have the 
specialist training or facilities needed in order to run molecular tests such as conventional 
PCR or NGS. The Idylla System is unique in that all the processes are automated and 
carried out on-board the system; no other commercially available system can do this. These 
facts eliminate a whole range of practical, legal and administrative issues around sending 
tissue out of the department. It also streamlines the diagnostic process, reduces the risk of 
losing cases to follow-up and cuts down the turnaround time.  
 
The speed of the Idylla System is also an attractive benefit. Standard tests can take at least 
a week to get a result and often this can be so variable and unpredictable that several 
attempts to check for results are often needed. The Idylla System will give a result within 
three hours of the histopathologist requesting it. Therefore the turnaround time is cut 
significantly. This has several knock–on benefits. Firstly, should patients meet the criteria 
at time of diagnosis for Ab therapy, the system can minimise any delay in treatment. This 
may potentially be of clinical benefit as well as help improve patient satisfaction. Cutting 
the turnaround time also has benefits for the department as well. One single report 
(histological and molecular result) can be signed out by a consultant on the same day, 
eliminating the need to wait, continually chase results and authorise additional reports 
(which could be missed by the clinician). A prospective clinical follow-up study would be 
needed to confirm these hypotheses however.  
 
The Idylla BRAF assays cover a greater range of clinically relevant targets than most 
conventional tests and the Idylla Ras assays cover some codon changes not covered by 
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the comparison tests. Although none of these rare mutations were encountered in this 
study, the extra coverage offed by Idylla could increase the number of mutant cancers 
identified in routine practice and this could help direct therapy towards those patients who 
are most likely to benefit. More clinical data however are needed to support this particular 
hypothesis.  
 
In a publically funded healthcare system, the financial implications of any new technology 
introduced is of great interest. This study suggests that The Idylla System is more cost-
effective than standard care tests in current use. The audit and cost estimates showed 
significant savings for each individual test. In the real-life clinical scenario combinations of 
tests change the actual overall costings. It is likely that most centers at the moment would 
want to use the Idylla BRAF Mutation Test and the Idylla KRAS Mutation Test. In this study 
(an average-sized cancer centre) 284 CRC cases were reported each year. From these 44 
were eligible for BRAF testing and all 284 were eligible for KRAS testing. From calculations 
in Chapters 3 and 4, annual Cobas testing was estimated to cost £59,040 overall. The Idylla 
in contrast was projected to cost £47,156 overall, thus offering a potential saving of 
£11,884. In centres where there is limited funding for molecular testing despite 
recommendations, such savings could be very clinically impactful. Alternatively, if Ion 
Torrent NGS is being used in a centre (around £300 per case, each assay covering both 
KRAS and BRAF thus all 284 cases are tested but only once) the total annual cost could 
be estimated at £85,200, offering a far greater potential saving of £38,949 with Idylla in this 
scenario. Testing numbers may change however, based on new NICE guidelines to screen 
all CRC patients for LS.269  
 
Some centers are now routinely testing for NRAS mutations and this is usually with NGS. 
In this scenario the estimated cost for Ion Torrent NGS remains the same at £85,200 per 
year. In contrast, testing with the KRAS Mutation Test in combination with the NRAS-BRAF-
EGFRS492R Mutation Assay (calculated costs in Chapter 4) to cover all three targets 
would be £102,524 per year, potentially an additional expense of £13,324 per year with the 
Idylla System. This is not cost effective and the other benefits of the test would need to be 
weighed when deciding on whether to use the system. The figures here are based on list 
prices however, and the cost per test falls with larger orders.  
 
Another factor which is difficult to assess is the overall cost of the system, which for Idylla 
with one processing unit is around £40,000 purchased outright; subscription deal on a test-
by-test basis are also possible. NGS and Cobas cost many times this, but most molecular 
centres will already have such systems – meaning to introduce Idylla testing may incur an 
additional outlay cost. A center may decide however that being able to offer a both detailed 
NGS-based technologies and rapid on-demand PCR testing may cater for a wider range 
of clinical scenarios. There are also roles the Idylla may play in the future and therefore 
acquiring the system in the short-term could be useful for new developments in molecular 
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diagnostics in the long run. There are some cartridges in development that will allow testing 
of tiny amounts of unfixed cytological (loose single cells) material. This would allow very 
rapid genetic testing of tumours which are amenable to fine needle aspiration (FNA), such 
as thyroid and lung cancers,331,332 and, as will be mentioned later in Section 5.5, the existing 
cartridge may work with tissue other than FFPE.333 Minimally invasive molecular testing 
could be carried out in the clinic while the patient waited and any treatment started 
immediately without delay. There are also test cartridges in development that will be able 
to test blood samples for circulating tumour cell DNA (ctDNA) or free plasma DNA. One 
such cartridge was released prior to this thesis as already discussed in Chapter 1, the Idylla 
ctBRAF Mutation Assay,190 and a further similar assay, the Idylla ctKRAS Mutation Assay, 
has been released since.334 Testing for ctDNA mutations is an increasingly popular method 
of monitoring patients for relapse but also could be a potential method for detecting 
mutations within the tumour, faster and with less invasive procedures.335,336 The most 
significant benefit of this testing method in CRC would probably be in detecting 
KRAS/NRAS mutations in patients who later develop metastatic disease. In this scenario, 
because of inter-tumour heterogeneity, original testing results may not reflect the true 
genotype of the metastatic cell population.320 These patients often do not undergo biopsy 
of their secondary tumour, either because it wrongly assumed not to be diagnostically 
useful or because it is technically challenging and risky (e.g. brain metastases). Also, once 
a patient has developed metastases, there is an urgent need to start targeted therapy and 
standard molecular testing takes too long. Therefore, KRAS/NRAS mutations are often 
excluded only on the primary tumour tissue.337 Some data have suggested there is a 
reasonably high (92%) rate of genotype concordance between primary and secondary 
tumours,316 however other studies have mixed findings.315,317-319 In the envisioned future of 
precision medicine, testing secondary tumours will surely be insisted upon,338 and will allow 
the clinical impact of this to be evaluated in drug trials based on metastatic tumour tissue 
Ras testing. If the Idylla ctKRAS Mutation Assay proves to be accurate, this would 
potentially be more informative that current primary tumour testing and facilitate better-
informed treatment decisions while causing very minimal delays in starting treatment.  
 
5.3 Potential drawbacks of automated PCR 
There are several potential drawbacks to the Idylla System. While the cost of the PCR in 
our institution would be lower with the Idylla System, in other institutions this may not be 
the case. The Cobas system is batched and the cost per test is variable depending upon 
the number of cases being tested. Therefore the Cobas system may be cheaper in some 
institutions. In addition, the introduction of Idylla may result in a fall in use of the Cobas 
system and therefore this may result in underutilisation of an valuable system that is 
expensive to maintain (and can’t be decommissioned as it is needed for other tests in the 
Trust). There may also be a risk of increasing the waiting times and cost per test for other 
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Cobas tests as the numbers of cases for batching falls. There is also the risk of de-skilling 
staff who run the Cobas system.  
 
The Cobas system is not so much of a ‘black box’ set up as the Idylla System is. With 
Cobas, the user can examine the processes of the analyser and the sample preparation 
and can adjust the protocol if needed (for example testing different kinds of tissues may 
need slight changes in the system settings). This cannot be done with the Idylla System. 
Also the results of the Cobas system can be interrogated and many values such as the Cq 
value (discussed in Chapter 1) can be read and the melting curve can be manually 
examined. Interrogating these variables can be useful when verifying results and can give 
an indication of how confident the user should be of a mutation. In contrast NGS can give 
additional information such as an indication of the frequency of mutated cells within the 
tissue tested. None of these can be easily achieved with the Idylla System and while this 
makes the test less subjective, it can potentially limit the ability to quality control the results 
produced.  
 
An important point to consider with any new technology is the potential for hardware or 
software failure. There were several failed Idylla tests but these however appeared to be 
teething problems. Only one cartridge failed under normal working conditions (true failure 
rate <1%), which is probably within the margin of acceptability. Commonly, molecular tests 
may fail because of poor quality samples. Biocartis state that they Idylla assays can be run 
on just a single FFPE section. For the majority of cases in this thesis this was true. Only 
two tests were reported as insufficient material and these were paucicellular (<10% tumour 
cells) mucinous tumours where the recommended single section was obviously not enough 
for sufficient DNA yield. Had further tissue sections been available (in clinical practice this 
would have been the case, however repeating the tests was not possible in the study 
setting due to limited funding), these cases could have been tested with multiple tissue 
sections and would probably have been successful. This is an interesting point in general 
for molecular testing of mucinous tumours, which although not highlighted in the literature, 
is anecdotally a known problem amongst laboratory staff. Mucinous tumours by nature 
secrete huge amounts of mucin-like material and the cells often sit singly or in small islands 
within a sea of acellular stroma. Mucinous tumours then need many sections or tissue 
punches in order to get enough DNA for testing. In contrast, the percentage of cells within 
these samples that are tumour is usually very high as there is little inflammatory or stromal 
cell content.   
 
Already discussed (see Section 4.5) earlier was the issue about mutation coverage. There 
are some mutations not covered by Idylla and others that are only covered by Idylla (see 
Table 7). These are in general very rare codon changes and no such mutation was 
encountered in this study, however the clinical implications of these may end up being 
important in the future and so any lack of coverage by the Idylla is a potential drawback of 
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the system. Also important to note is that the Idylla does not always distinguish between 
particular types of codon changes and often just reports a mutation from a group of several 
related changes (also see Table 7). For example, the KRAS Q61L mutation cannot be 
distinguished from the KRAS Q61R mutation and is reported as a ‘KRAS Q61L/R’ mutation. 
This is probably due to a limitation with the primers and reporting probes. It is generally not 
clinically useful to know which particular codon change has taken place but, once again, 
the clinical implications for targeted or other therapy of rare mutations may not be fully 
known and so the ideal would be to know exactly which codon change has taken place. 
Therefore, this is also a potential limitation of the Idylla system. 
 
As alluded to in the earlier discussion about cost-effectiveness, to be useful in CRC 
molecular diagnostics the Idylla System needs to be able to offer the complete package of 
tests needed in clinical practice. Most guidelines mentioned call for BRAF and KRAS 
testing currently and the Idylla has CE-IVD marked assays for both of these. NRAS is 
however likely to play a greater role in the future of CRC targeted therapy guidance. At the 
time of planning this thesis the only assay which covered NRAS was the Idylla NRAS-
BRAF-EGFRS492R Mutation Assay and this was RUO, not CE-IVD marked. Since this 
thesis work was undertaken, a CE-IVD approved Idylla assay for NRAS and BRAF testing 
has been released, the Idylla NRAS-BRAF Mutation Test.339 This appears to be a final 
version of the NRAS-BRAF-EGFRS492R Mutation Assay, but without the EGFR testing 
component, probably as the clinical use for this was not warranted. This thesis has 
validated the BRAF and NRAS components of this test as a proof-of-concept and a full 
clinical evaluation of its accuracy would now be helpful. This is crucial for the system and 
if this cannot be demonstrated clinicians will probably opt for NGS gene panel testing 
because all three gene targets are easily covered by NGS and this technology has been 
extensively validated. 
 
As mentioned, the Idylla NRAS-BRAF-EGFRS492R Mutation Assay also tests for 
mutations in the EGFR gene. Currently, management guidelines do not recommend routine 
testing for this mutation, however this may change in the future and this part of the assay 
could be released in a CE-IVD approved test at some point. Therefore, technical validation 
of this component would still be useful and this should also be followed up by a clinical 
study.259-261,340,341 At this time, no commercial PCR or NGS-based tests are available for 
the S492R mutation but gene sequencing could be used to validate any findings. It may be 
difficult to identify positive cases though in the short-term.  
 
The rivalry of NGS with PCR-based platforms has been mentioned already several times 
but this should not be underestimated. The cost of whole genome and targeted NGS is 
rapidly falling, but only a limited number of such tests are clinically validated and approved 
so far; those that have been approved remain expensive (around £1000 per sample). The 
situation is very fluid though. It is probably reasonable to anticipate that the cost of targeted 
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panels and indeed WGS will fall in coming years. In addition, many newer assays are in 
development and while not generally clinically approved or validated yet, may in the near 
future offer superior turnaround times and at a lower cost. Therefore, Biocartis will need to 
be quick to market and offer flexible pricing in order to make the test viable in the long-
term. In the short-term, for centres only requiring BRAF and KRAS testing, the system 
could be acquired on a licence arrangement and be cost effective. 
 
5.4 Findings in the context of the recent literature 
When this project was conceived there were no publications for the Idylla System in the 
literature. Since this work was started however, a number of publications have arisen in 
and it is worth considering the results of this thesis along side those publications.  
 
The first study appear in the literature was presented online as an epublication initially in 
mid 2015, when the BRAF work of this thesis was well underway. This evaluated the Idylla 
System in a Respiratory Panel for blood testing. The paper presents a technical feasibility 
study which attempts to derive Idylla Cq values from conventional PCR comparisons. The 
study has little relevance to mutation testing in cancer however and no data on clinical 
diagnostic accuracy was presented.328 
 
The next study published with Idylla was a detailed and thorough technical evaluation of 
the Idylla BRAF Mutation Test, published in late 2015 when the KRAS data started to be 
collected for this thesis. The authors test the Idylla System with a number of known 
commercially available control sample cells lines and show a high degree of validity when 
compared with a range of PCR and NGS-based tests. The system is further evaluated in a 
set of commercially available FFPE control tumour samples. The final stage in the paper 
was a clinical evaluation at a major teaching hospital. 100 patients were selected with 
differing tumour sites (including skin, colorectum, ovary, thyroid) and the Idylla was 
compared with an in-house PCR. A detailed discussion of how the cases were selected 
was not provided and although it appears that an attempt to replicate the true clinical setting 
made, the potential for selection bias cannot be excluded. Overall the authors quote 
concordance rates between 95% and 100% and diagnostic accuracy is not established for 
any tumour type. Although there are limitations to this study, the findings are in keeping 
with the results of this thesis.326 
 
The next study published compared the Idylla BRAF Mutation Test with ‘reference 
laboratory results’ (this is not defined) in 148 patients with melanoma. This was published 
just after the previous study discussed in late 2015. The cases were said to be from those 
with ‘left over FFPE’ tissue and it is likely there was significant selection bias with this 
approach. The concordance was quoted by the authors as between 97% and 100% but the 
sensitivity and specificity were not calculated. Despite these limitations, the findings are 
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overall in keeping with the results presented in this thesis. The reference list in the paper 
suggests there are two pending studies which are in press, however further details of these 
could not be found.327  
 
At around the same time as the above publications in late 2015, there were a number of 
Biocartis sponsored posters presented. One of these investigated the role of Idyla in 
detecting BRAF mutations in circulating tumour DNA (the Idylla ctBRAF Mutation Assay 
already mentioned), finding a high level of concordance with standard methods.324 A 
second poster investigated the same assay and found similar results.342 Although in 
keeping with the results of this thesis, this is of less relevance as this work was carried out 
on blood samples. Another poster was the first to present KRAS and NRAS data with 
comparisons of the Idylla KRAS Mutation Test and the Idylla NRAS-BRAF-EGFRS492R 
Mutation Assay with Cobas PCR and NGS. This demonstrated high concordance, again in 
keeping with the findings of this thesis.325 
 
The first study for KRAS mutations to be published on the Idylla was the next to appear in 
the literature. In this study pancreatic cancer samples were tested using the Idylla KRAS 
Mutation Test. A common test to diagnose lesions in the pancreas is with cytology is a 
FNA. This is a challenging test to interpret however and detecting KRAS mutations in FNA 
specimens (indicating malignancy) is clinically helpful in difficult cases. The study actually 
used extracted DNA inserted directly into the cartridge, as FFPE material is not easily 
derived from FNA specimens. This worked in 49 of 52 cases and showed a specificity of 
100% when compared with Sanger sequencing and NGS, very much in keeping with the 
KRAS assay findings in this thesis. The sensitivity however was much lower at 55.1%, but 
this was similar to NGS and is probably explained by the low cellularity of cytology 
specimens rather than a direct result of poor Idylla performance. These results demonstrate 
a novel use of the system in a different tissue type that can reliably rule out the presence 
of KRAS mutations (i.e. almost rule out malignancy) in a challenging area of diagnostic 
pathology.333 Around the same time of this publication, appeared a study investigating the 
BRAF Mutation Test in melanoma patients, comparing with conventional PCR, NGS and 
IHC. This found high concordance with molecular testing but interestingly like this thesis 
also ran into difficulties with IHC comparisons, especially with disagreements between 
scorers of VE1 Ab staining.343 
 
A large multicenter study looking at BRAF mutations in a variety of tissue (52 CRC cases) 
types was the next to be published. This found concordance of the Idylla BRAF Mutation 
Test with pyrosequencing and NGS at 96.6%.344 This was shortly followed up by a 
publication of the Idylla ctBRAF Mutation Assay345 and a publication of a prototype Idylla 
EGFR assay, 346 both showing high concordance. A further study with the Idylla BRAF 
Mutation Test was next published, this time looking at thyroid tumours. The presence of 
BRAF mutations in thyroid tumours can aid the diagnosis of papillary carcinoma, are 
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prognostic and may direct therapy for these patients. The study used 110 highly selected 
cases and this may have introduced bias, however they found that the sensitivity was 
98.8% and a specificity of 100% when compared with a combination of PCR and 
pyrosequencing, very much in keeping with the findings of this thesis.347  
 
The data from this thesis comparing the Idylla KRAS Mutation Test with PCR (Subsection 
4.3.2) was combined with similar data for CRC cases from other centers across Europe 
and published as one large cohort (375 cases). The overall combined study design was 
not that of a diagnostic accuracy study and the publication appropriately therefore did not 
report sensitivity and specificity etc. However the concordance with a combination of other 
methods, such as PCR, ddPCR, pyrosequencing and NGS, was found to be 98.9%, very 
much in keeping with the overall results (including other validations herein) for KRAS 
testing found in this thesis.3 
 
Recent publications for Idylla included an evaluation of a prototype Ebola virus assay that 
showed 95.9% concordance with standard testing methods348 and an evaluation of the 
Idylla EGFR Mutation Assay in lung cancer, finding 87.5% concordance with NGS but 
poorer results compared with ddPCR (27.8% concordance) for one particular codon 
change (T790M).349 Other recent evidence available is from several poster presentations. 
The first was an AstraZeneca sponsored poster abstract, co-authored by Biocartis, of a 
small study of 56 samples (cell lines) comparing the performance of 12 different 
technologies. This included conventional PCR and NGS, for detecting KRAS mutations. In 
this study Idylla detected the correct result in 96% of cases, outperforming many of the 
existing technologies, including Cobas and Ion Torrent.350 The second poster was also co-
authored by Biocartis and evaluated the Idylla NRAS-BRAF-EGFRS492R Mutation Assay. 
The results showed agreement with sequencing in 98.9% (NRAS), 99.6% (BRAF) and 
100% (EGFR, n=1) of cases, again very much in keeping with the results of this project.351 
The third poster evaluated the Idylla EGFR Mutation Assay and found this to have 99.4% 
agreement with NGS.352 Although the results from both of these posters are likely not peer-
reviewed and there are potential conflicts with the authors, the results are in keeping with 
the findings of this thesis.  
 
Since this thesis was started a wide range of publications and posters have become 
available presenting evidence for the Idylla System. The data from this thesis has also been 
published and presented in posters, although (other than the KRAS data) these 
publications and posters have been omitted from the above discussion of the recent 
literature, for obvious reasons.1-8 Although some of the evidence discussed here is in poster 
format and sponsored by Biocartis, the majority of it has been later published in peer-
reviewed journals. Furthermore, the overall findings for Idylla are consistent throughout all 
the evidence identified. In this thesis, the findings match the overall picture that the Idylla 
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can accurately detect BRAF, KRAS and NRAS mutations and is in some respects superior 
to the other systems used in routine practice.  
 
5.5 Study limitations and potential future work 
The results presented in this thesis have addressed the hypothesis. The primary outcome 
has been addressed and the accuracy of the Idylla System has been demonstrated to be 
high. The study was carried out and reported following conventional evidence-based 
medicine principles and satisfies the Standards for Reporting Diagnostic Accuracy 
(STARD) statement.237,249 The secondary outcomes and research questions have been 
partially addressed and this thesis has demonstrated the system to be easy to use and 
potentially cost effective. There are a number of limitations of this work however and there 
are further issues to be addressed.  
 
Firstly, a Biomedical Scientist would carry out testing in the real-life context. While this does 
not pose any issue with technical ability, there may be issues with workflow, staff time to 
run the test and actual space in the working laboratory (although small the only space 
available for this study was in a storage area) for the machine and cartridges. In this sense 
the feasibility of using the system in daily practice has only been partially assessed. 
Furthermore, the cost analysis set out is an estimate and an actual prospective cost-impact 
study has not been carried out fully. This may be an area of further work. Likewise, the 
expected impact upon turn-around time is speculative and an audit or similar study of use 
would be needed to provide empirical evidence of this.  
 
A criticism of this study could be that retrospective cases were assessed. Although bias 
was minimised by blinding and consecutive/unselected case testing, a prospective study 
will always have a lower risk of bias. In addition, the use of the system in the long term may 
see test failures once the full spectrum of cases with variable tissue qualities have been 
attempted with the machine over a sustained period of use. Several failed tests were 
encountered early on, due to a combination of user error and design faults. Once these 
were overcome, no further failed tests were encountered – however once placed in a busy 
laboratory and under constant use by numerous staff, further failed tests are likely to be 
seen. Therefore, a sensible next step is to trial the system for a sustained period of time 
and subject the service to audit. A further step could be to assess the actual clinical 
outcome in these patients and determine how testing with the Idylla System impacted upon 
clinical care and patient outcome.  
 
There are some specific problems with the use of Idylla in CRC. In CRC the routine 
molecular targeted testing is focused on BRAF, KRAS and NRAS and therefore any new 
system introduced will need to be able to cater for all three targets. The Idylla System has 
been demonstrated to be valid for use in BRAF and KRAS here, however there remains 
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work to be carried out for NRAS. More work is needed to clinically evaluate the accuracy 
of Idylla NRAS testing.  
 
In the current state, at least two test runs/cartridges are needed to provide a full 
assessment for CRC and in this sense a single cartridge which covered all the mutations 
for CRC would be far more preferential. Biocartis have communicated that this is planned 
in the future and this could be a further area for research in terms of validation and 
estimating accuracy. Microsatellite status is also increasingly being requested in clinical 
practice. For most centers this involves MMR protein expression evaluation by IHC but 
some centers use molecular testing with conventional PCR. To improve the Idylla System 
and to make it more appealing to those institutions with a large molecular preference, the 
inclusion of MSI testing within a cartridge would be very beneficial. Biocartis have 
communicated that such a prototype is in development and this would be an area of further 
work for validation and accuracy assessment.  
 
This thesis does not evaluate the reproducibility of the Idylla System, neither by repeating 
samples nor by carrying out assessments at different testing sites. This is an important 
piece of work which should be carried out.  
 
Finally, since this thesis was undertaken a number of new assays have been released on 
the Idylla. As mentioned the Idylla NRAS-BRAF Mutation Test339 and the Idylla EGFR 
Mutation Assay (with a wider coverage than just the S492R codon change and mainly 
focused at lung cancer testing)353 have been developed and in addition an Idylla ctKRAS 
Mutation Assay (aimed at identifying circulating tumour KRAS mutations in various 
cancers, including CRC) has now been released.334 It would be of value to investigate the 
accuracy of these new tests, especially the ctKRAS test in CRC for reasons discussed 
earlier about circulating tumour DNA in Section 5.2  
 
5.6 Recommendations for practice and closing remarks 
Based on the evidence presented here, the Idylla System can be recommended for clinical 
use in detecting BRAF and KRAS mutations in FFPE tissue from colorectal 
adenocarcinomas. For centres only requiring KRAS and BRAF testing this system would 
be as accurate or more accurate that current tests and would offer significant potential 
patient benefits such as reduced turn-around time and costs. For centres requiring NRAS 
testing the system in principle is valid but not yet fully evaluated. Therefore, it is 
recommended the Idylla System is used cautiously for NRAS mutation detection in the 
clinical setting.  
 
 
Similar conclusions and points of discussion presented in this Chapter are also presented 
in publications and posters arising from this work.1-8 
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Study Title:  Expression pattern of C-type lectins in Health and Disease. 
Internal Reference No: 04/Q1604/21 
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Date and Version No: 07.01.2015  Version 12 
 
              
 
Chief Investigator: Dr Elizabeth Soilleux 
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Lecturer 
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Tel. 01865 220535 (secretary 01865 220499) 
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E-mail: Elizabeth.soilleux@ndcls.ox.ac.uk 
Sponsor:  Oxford University  
Funder (if 
applicable): 
Oxford University Medical Research Fund 
Signatures:  The approved protocol should be signed by author(s) 
and/or person(s) authorised to sign the protocol 
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Tel. 01865 220535 (secretary 01865 220499) 
Fax. 01865 220519 
E-mail: Elizabeth.soilleux@ndcls.ox.ac.uk 
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APPENDIX 2 – Tissue Regulations  
   Oxford Centre for Histopathology Research application (14/A209) 
 
Section 1 Applicant details 
Research group / department Cellular Pathology & NDCLS 
Lead applicant (e.g. Head 
of Department or Group, 
or clinical trial PI) 
Name Dr Elizabeth Soilleux 
Job Title Consultant Histopathologist 
Address Dept of Cellular Pathology, OUH Trust 
Tel No. 01865 220535 
Email elizabeth.soilleux@ndcls.ox.ac.uk 
Contact person 
(if different from above)  
(i.e. the person who will 
coordinate the request(s) 
with OCHRe) 
Name Dr Richard Colling 
Job Title Academic Clinical Fellow 
Address Dept of Cellular Pathology, OUH Trust 
Tel No. 01865 220581 
Email rtcolling@gmail.com 
Shipping details  
(if different from above)  
Name Dr Richard Colling 
Address  
Tel No.   
Section 2 Funding details 
Research funder (e.g. commercial company, 
NHS or University) 
Oxfordshire Health Services Research 
Committee 
Contact person for quotation / funding 
questions 
Dr Richard Colling 
Section 3 Approval details 
Ethical approval details 
(if applicable)  
A copy of the approval 
letter should be submitted 
with this application 
Reference No.  04lQ1604l21  
Title Expression pattern of C-type lectins in 
Health and Disease 
Approval date 04.06.2004 
Expiry date 04.06.2019 
R&D approval details  
A copy of the approval 
letter should be submitted 
with this application 
Approval body Oxford University 
Reference no.  
(if applicable) 
04lQ1604l21 
Other 
information 
Confirmatory paperwork/ e-mails available 
from Dr Elizabeth Soilleux 
Sponsor  Organisation University of Oxford 
Section 4 Project details 
Research project title Immunohistochemical testing of BRAF 
mutation for Lynch Syndrome screening in 
colorectal carcinoma 
Lay summary (this may be made available on 
the OCHRe website, please advise if 
confidential) 
Colon cancer is the fourth most common 
cancer in the UK and a leading cause of 
cancer death. Whilst most cancers are 
sporadic, there are a group of patients for 
whom cancer runs in the family. Lynch 
syndrome accounts for a large proportion of 
these inherited colon cancers and is also 
known to cause other tumours, for example 
of the uterus and stomach. In Lynch 
syndrome there are inherited mutations in 
genes which control the repair of damaged 
DNA; this puts carriers at an increased risk 
of developing cancers..  
 
A number of centers in the UK and 
internationally have begun to screen for 
Lynch syndrome in those patients with colon 
cancer that are at high risk. This can be done 
using a test which is carried out in hospital 
pathology departments on tissue samples 
from tumours removed surgically. Patients 
with a positive test are then followed up in 
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clinical genetics departments for further 
diagnostic tests.  
 
More recently, the screening process has 
been refined by testing for a mutation in a 
gene called BRAF. This gene is unrelated to 
Lynch syndrome and patients with this 
mutation almost never have Lynch 
syndrome, meaning they do not need follow 
up in the genetics clinic. This has helped 
streamline the screening process. However, 
the standard BRAF test requires specialist 
techniques, is time consuming and 
expensive. Recently, new simpler and faster 
BRAF tests have been developed. There are 
currently two different new tests 
commercially available and only one has 
been tested on colon cancer. This proposed 
study would compare the accuracy of both 
of these tests in colon cancer and evaluate 
the practical and financial feasibility of 
introducing this in to routine practice.    
 
Aims and objectives  
(Scientific background, plan of 
investigation, methodology and any pilot data) 
Background:  
 
Colorectal adenocarcinoma is the fourth 
most common malignancy in the UK and 
around 25% of cases occur in an inherited 
context. Lynch syndrome is the most 
common inherited cancer syndrome leading 
to colorectal carcinoma and is caused by 
loss-of-function germ line mutations in 
mismatch repair (MMR) genes. Currently 
patients with colorectal carcinoma at high 
risk for Lynch syndrome are screened by 
pathologists for MMR mutations using 
immunohistochemistry (IHC) on resection 
tissue. Those patients with loss-of-
expression of the MLH1 or PMS2 type MMR 
proteins on IHC are then screened for BRAF 
mutations using PCR. The patients without 
BRAF mutations are at highest risk of Lynch 
syndrome and are referred to specialist 
clinical genetics follow up. Many centers do 
not have the funding or facilities to carry out 
PCR analysis (including Oxford) and so the 
potential for IHC detection of BRAF 
mutations needs investigation. There are 
currently two commercial antibodies, only 
one of which has been evaluated in 
colorectal carcinoma.  
 
Aims:  
 
The aim of this study is to validate the two 
commercially available antibodies in 
detecting BRAF V600E mutations by 
immunohistochemistry (IHC) against 
standard polymerase chain reaction (PCR) 
mutational analysis within the context of 
Lynch syndrome (LS) screening. 
Furthermore, the practical and financial 
feasibility of these tests will be investigated 
in order to inform practice locally.  
 
Methodology: 
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Cases of colorectal carcinoma with MSI and 
known BRAF V600E mutation status (as 
determined by PCR) will be drawn from the 
diagnostic archive. In total, 20 cases will be 
selected – 10 with BRAF mutations on PCR 
and 10 without. Cases will be anonymised 
and two x 4 micron sections will be cut from 
each.  The anti-BRAF antibodies (Roche 
and NewEast Bioscience) will be optimized 
for immunostaining on an Ultra Discovery 
Immunostainer (Roche-Ventanna) using 
sections of colorectal carcinoma known on 
the basis of PCR results to be either positive 
or negative for the BRAF V600E mutation. 
Immunostaining for BRAF V600E will be 
performed using the Ultra Discovery 
Immunostainer (Roche) and results will be 
assessed by two observers blind to the PCR 
results.   
 
 
External Peer Review (confirm if project has 
been subject to external peer review) 
Reviewed by the Oxfordshire Health 
Services Research Committee  
NHS Pathologist (advise if you have 
discussed this with an NHS pathologist – if 
applicable) 
Dr Elizabeth Soilleux (ES) and Dr Richard 
Colling (RC) are both NHS pathologists. Dr 
Lai Mun Wang (LMW) is also collaborating.  
Section 5 Samples, service and data 
Sample requirements 
(Sample numbers if known or description of 
samples required) 
We require 10 cases of BRAF V600E 
mutated colorectal carcinoma and 10 
unmutated cases.  20 appropriate cases will 
be selected from the Cellular Pathology 
diagnostic archive by RC and ES. One block 
from each case will be selected for histology. 
There will be 20 blocks in total, 1 per case. 
A list will be provided to OCHRe once 
application is approved. 
Full details of histology services 
(e.g. number of sections required, staining, 
processing) 
OCHRe to check consent status of cases 
requested. OCHRe to provide 10 unstained 
FFPE sections of a colorectal carcinoma 
case with known BRAF V600E mutation for 
optimization. Subsequently, we will require 
40 unstained FFPE sections (i.e. two 
sections of each of the 20 blocks) on coated 
slides suitable for immunostaining. 
Therefore 50 unstained sections are 
required in total. Immunostaining will be 
performed by RC and ES once the Ventana 
Discovery Ultra Immunostainer arrives 
(17.11.14). 
How will material be used? 
(How will you use the materials requested in 
this application?) 
To validate two anti-BRAF V600E mutation 
antibodies for subsequent clinical diagnostic 
use. 
Data requirements  
(Specify any accompanying data you require 
e.g. copy of pathology reports) 
Cases will be anonymous. BRAF V600E 
mutation status by PCR will be requested on 
each case. 
 
 
Thank you for completing this OCHRe Part 2 application form.  Please remember to provide 
electronic or paper copies of ethics and R&D approval documents when you submit it to OCHRe. 
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Oxford Centre for Histopathology Research application (15/A041) 
 
Section 1 Applicant details 
Research group / 
department 
Cellular Pathology & NDCLS 
Lead 
applican
t (e.g. 
Head of 
Departm
ent or 
Group, or 
clinical 
trial PI) 
Name Dr Elizabeth Soilleux 
Job Title Consultant Histopathologist 
Address Dept of Cellular Pathology, OUH Trust 
Tel No. 01865 220535 
Email elizabeth.soilleux@ndcls.ox.ac.uk 
Contact 
person 
(if 
different 
from 
above)  
(i.e. the 
person 
who will 
coordinat
e the 
request(s
) with 
OCHRe) 
Name Dr Richard Colling 
Job Title Academic Clinical Fellow 
Address Dept of Cellular Pathology, OUH Trust 
Tel No. 01865 220581 
Email rtcolling@gmail.com 
Shipping 
details  
(if 
different 
from 
above)  
Name Dr Richard Colling 
Address  
Tel No.   
Section 2 Funding details 
Research funder (e.g. 
commercial company, NHS 
or University) 
Oxfordshire Health Services Research Committee 
Contact person for 
quotation / funding 
questions 
Dr Richard Colling 
Section 3 Approval details 
Ethical 
approval 
details (if 
applicabl
e)  
A copy of 
the 
approval 
letter 
should be 
submitted 
with this 
applicatio
n 
Reference No.  04lQ1604l21  
Title Expression pattern of C-type lectins in Health and Disease 
Approval date 04.06.2004 
Expiry date 04.06.2019 
R&D 
approval 
details  
A copy of 
the 
approval 
letter 
should be 
submitted 
with this 
Approval body Oxford University 
Reference no.  
(if applicable) 
04lQ1604l21 
Other 
information 
Confirmatory paperwork/ e-mails available from Dr 
Elizabeth Soilleux 
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applicatio
n 
Sponsor  Organisation University of Oxford 
Section 4 Project details 
Research project title Automated PCR testing of BRAF and KRAS mutation in 
colorectal carcinoma 
Lay summary (this may be 
made available on the 
OCHRe website, please 
advise if confidential) 
Colon cancer is the fourth most common cancer in the UK 
and a leading cause of cancer death. It is not routine 
practice to test for the presence of BRAF and KRAS 
mutations in some patients with these tumours. BRAF 
mutations have important prognostic value and targeted 
therapies against this mutation are in development. In 
addition, BRAF mutation testing is recommended in the 
screening of Lynch Syndrome in these patients. KRAS 
mutations hold important prognostic value and are also 
used now clinically to guide therapy.  
 
The standard BRAF and KRAS mutation tests require 
specialist techniques and for most small district general 
hospitals this poses a problem. The tests are time 
consuming and expensive. Recently, a new simple, fast 
and cheap automated machine has become available for 
use in BRAF and KRAS testing. The machine offers a 
potential benefit for those smaller and remote sites where 
standard testing methods are difficult. This proposed 
study would compare the accuracy of this new testing 
method in colon cancer and evaluate the practical and 
financial feasibility of introducing this in to routine practice 
in smaller hospitals.    
 
Aims and objectives  
(Scientific background, plan 
of 
investigation, methodology 
and any pilot data) 
Background:  
 
Colorectal adenocarcinoma is the fourth most common 
malignancy in the UK and around 25% of cases occur in 
an inherited context. It has become routine practice to 
investigate these tumours for BRAF and KRAS mutations. 
BRAF mutations give prognostic information and while 
anti-BRAF therapy is not currently used in colon cancer, 
this may be a possibility in the future. BRAF mutational 
analysis is also used as routine in the screening for Lynch 
Syndrome in colorectal cancer patients. KRAS mutations 
also impart prognostic information and are used to guide 
the therapy given in current oncology practice. Current 
practice is to carry out mutational analysis using real-time 
polymerase chain reaction (PCR). Many small, district 
general centres do not have the facilities to carry out 
traditional PCR analysis and so the potential for other 
options for detection of BRAF mutations needs 
investigation. One such solution for these centres is an 
automated PCR approach.  
 
Aims:  
 
The aim of this study is to validate the Idylla automated 
PCR in detecting BRAF mutations against standard PCR 
analysis, within the context of Lynch syndrome (LS) 
screening. Furthermore, the practical and financial 
feasibility of these tests will be investigated in order to 
inform practice locally.  
 
Methodology: 
 
Cases of colorectal carcinoma with known BRAF and 
KRAS mutation status (as determined by Cobas z480 
PCR) will be drawn from the diagnostic archive. In total, 
around 100 cases will be selected for BRAF and KRAS; 
50 BRAF/KRAS + mutations on PCR and 50 BRAF/KRAS 
-. In many instances, these will be the same cases for both 
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BRAF and KRAS. Cases will be anonymised and 
unstained sections will be cut from each. We will use 
scrolls cut at 10 microns where possible. Otherwise we 
will request 4 micron sections on glass slides for 
macrodissection. Automated PCR will be performed using 
the Idylla platform (BioCartis) BRAF and KRAS cartridges. 
This platform is being provided on loan with all the 
reagents for free by BioCartis. This will be placed in 
Cellular Pathology on Level 1 (permission already granted 
by Sharon Roberts-Gant). A loan agreement will be in 
place via Clinical Engineering, who will carry out a system 
electrical check. A health and safety assessment will be 
carried out by RC and ES.  
 
External Peer Review 
(confirm if project has been 
subject to external peer 
review) 
Reviewed by the Oxfordshire Health Services Research 
Committee  
NHS Pathologist (advise if 
you have discussed this with 
an NHS pathologist – if 
applicable) 
Dr Elizabeth Soilleux (ES) and Dr Richard Colling (RC) are 
both NHS pathologists. Dr Lai Mun Wang (LMW) is also 
collaborating.  
Section 5 Samples, service and data 
Sample requirements 
(Sample numbers if known or 
description of samples 
required) 
Cases will be selected from the Cellular Pathology 
diagnostic archive by RC and ES. One block from each 
case will be selected for PCR. There will be 50 cases in 
total. A list will be provided to OCHRe once application is 
approved. 
Full details of histology 
services 
(e.g. number of sections 
required, staining, 
processing) 
OCHRe to check consent status of cases requested. 
OCHRe to provide an unstained FFPE sections from each 
block (one or two depending on if the case can be used 
for both KRAS and BRAF testing. As this is for PCR the 
usual molecular precautions will be needed (cleaning of 
the blade/water bath between blocks as appropriate etc.) 
Where possible we will request 10 micron scrolls. Where 
macrodissection is needed we will request sections on 
uncoated slides. The automated PCR will be performed 
by RC on the Idylla System within the Cellular Pathology 
laboratory on Level 1. 
How will material be used? 
(How will you use the 
materials requested in this 
application?) 
To validate automated Idylla BRAF/KRAS PCR.  
Data requirements  
(Specify any accompanying 
data you require e.g. copy of 
pathology reports) 
Cases will be anonymous. BRAF and KRAS mutation 
status by Cobas z480 PCR (already performed) will be 
requested on each case. We would like to use the same 
anonymised system OCHRe have used for our previous 
BRAF IHC application so we can match cases and 
compare while not breaking the  anonymisation process if 
this is possible.  
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Oxford Centre for Histopathology Research application (16/A002) 
 
Section 1 Applicant details 
Research group / department Cellular Pathology & NDCLS 
Lead applicant 
(e.g. Head of 
Department or 
Group, or 
clinical trial PI) 
Name Dr Elizabeth Soilleux 
Job Title Consultant Histopathologist 
Address Dept of Cellular Pathology, OUH Trust 
Tel No. 01865 220535 
Email elizabeth.soilleux@ndcls.ox.ac.uk 
Contact 
person 
(if different from 
above)  
(i.e. the person 
who will 
coordinate the 
request(s) with 
OCHRe) 
Name Dr Richard Colling 
Job Title Academic Clinical Fellow 
Address Dept of Cellular Pathology, OUH Trust 
Tel No. 01865 220581 
Email rtcolling@gmail.com 
Shipping 
details  
(if different from 
above)  
Name Dr Richard Colling 
Address  
Tel No.   
Section 2 Funding details 
Research funder (e.g. commercial 
company, NHS or University) 
Oxfordshire Health Services Research 
Committee 
Contact person for quotation / 
funding questions 
Dr Richard Colling 
Section 3 Approval details 
Ethical 
approval 
details (if 
applicable)  
A copy of the 
approval letter 
should be 
submitted with 
this application 
Reference No.  04lQ1604l21  
Title Expression pattern of C-type lectins in Health 
and Disease 
Approval date 04.06.2004 
Expiry date 04.06.2019 
R&D approval 
details  
A copy of the 
approval letter 
should be 
submitted with 
this application 
Approval body Oxford University 
Reference no.  
(if applicable) 
04lQ1604l21 
Other 
information 
Confirmatory paperwork/ e-mails available from 
Dr Elizabeth Soilleux 
Sponsor  Organisation University of Oxford 
Section 4 Project details 
Research project title Automated PCR testing of KRAS, NRAS and 
EGFR mutations in colorectal carcinoma 
Lay summary (this may be made 
available on the OCHRe website, 
please advise if confidential) 
This is an amendment of the previous 
application (15/A041) for a small extension of 
the project to include NRAS and EGFR 
mutation testing. Previous work in this study 
has validated the Idylla System for the 
detection of BRAF and KRAS mutations.  
 
Lay Summary: 
 
Colon cancer is the fourth most common 
cancer in the UK and a leading cause of cancer 
death. It is routine practice to test for the 
presence of NRAS/EGFR mutations in some 
patients with these tumours. NRAS/EGFR 
mutations hold important prognostic value and 
are also used now clinically to guide therapy.  
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The standard NRAS/EGFR mutation tests 
require specialist techniques and for most small 
district general hospitals this poses a problem. 
The tests are time consuming and expensive. 
Recently, a new simple, fast and cheap 
automated machine has become available for 
use in NRAS/EGFR testing. The machine 
offers a potential benefit for those smaller and 
remote sites where standard testing methods 
are difficult. This proposed study would 
compare the accuracy of this new testing 
method in colon cancer and evaluate the 
practical and financial feasibility of introducing 
this in to routine practice in smaller hospitals.    
 
Aims and objectives  
(Scientific background, plan of 
investigation, methodology and any 
pilot data) 
Background:  
 
Colorectal adenocarcinoma (CRC) is the fourth 
most common malignancy in the UK. It has 
become routine practice locally and 
increasingly, nationally, to investigate these 
tumours for NRAS/EGFR mutations as these 
impart prognostic information and are used to 
guide the therapy given in current oncology 
practice. Until recently KRAS mutation status 
was sufficient to predict response with anti-
EGFR therapy in these patients, however it is 
increasingly recognised that mutations in 
NRAS and EGFR contribute to anti-EGFR 
therapy resistance; therefore testing of KRAS 
with NRAS and EGFR is becoming routine. 
Current practice is to carry out mutational 
analysis using NGS gene panels for 
KRAS/NRAS/EGFR. Many small, district 
general centres do not have the facilities to 
carry out NGS analyses and so the potential for 
other options for detection of mutations needs 
investigation. One such solution for these 
centres is an automated PCR approach. The 
previous work in this study validated a new 
platform called ‘Idylla’ which provides 
automated and simple standalone PCR which 
can be run in any lab. We validated this for 
BRAF mutations in CRC paitents (as part of the 
Lynch syndrome screening pathway) and 
KRAS mutations (for reasons mentioned 
above). The system has now launched a new 
assay which tests KRAS/NRAS/EGFR in 
combination. There is no evidence or validation 
data published for this system as yet.  
 
Aims:  
 
This is an amendment to the previous 
application for an additional small validation 
study for the Idylla KRAS/NRAS/EGFR test.   
 
Methodology: 
 
Cases of colorectal carcinoma with known 
KRAS/NRAS/EGFR mutation status (as 
determined by Ion torrent NGS cancer panel) 
will be drawn from the diagnostic archive. In 
total, 30 cases will be selected (estimate). 
Cases will be anonymised and unstained 
sections will be cut from each. Automated PCR 
will be performed using the Idylla platform 
(BioCartis) KRAS/NRAS/EGFR cartridges. 
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This platform is being provided on loan with all 
the reagents for free by BioCartis. This is 
already placed in Cellular Pathology on Level 1 
(permission already granted by Sharon 
Roberts-Gant). A loan agreement will be in 
place. Clinical Engineering, have already 
carried out a system electrical check. A health 
and safety assessment has been carried out by 
RC.  
 
External Peer Review (confirm if 
project has been subject to external 
peer review) 
Reviewed by the Oxfordshire Health Services 
Research Committee  
NHS Pathologist (advise if you 
have discussed this with an NHS 
pathologist – if applicable) 
Dr Elizabeth Soilleux (ES) and Dr Richard 
Colling (RC) are both NHS pathologists. Dr Lai 
Mun Wang (LMW) is also collaborating (NHS 
Consultant Histopathologist at OUH).  
Section 5 Samples, service and data 
Sample requirements 
(Sample numbers if known or 
description of samples required) 
Cases will be selected from the Cellular 
Pathology diagnostic archive by RC. One block 
from each case will be selected for PCR. There 
will be 30 cases in total (estimate). A list will be 
provided to OCHRe once application is 
approved. Extra sections will be provided for 
discordant results if needed.  
Full details of histology services 
(e.g. number of sections required, 
staining, processing) 
OCHRe to check consent status of cases 
requested. OCHRe to provide a single 5 micron 
unstained FFPE sections from each block on 
uncoated glass slides for macrodissection. We 
will need sections cut with PCR protocol 
(cleaning blade and water bath between 
cases). The automated PCR will be performed 
by RC on the Idylla System within the Cellular 
Pathology laboratory on Level 1.  
How will material be used? 
(How will you use the materials 
requested in this application?) 
To validate automated Idylla 
KRAS/NRAS/EGFR PCR.  
Data requirements  
(Specify any accompanying data 
you require e.g. copy of pathology 
reports) 
Cases will be anonymous. We would like to use 
the same anonymised system OCHRe have 
used for our previous applications (15/A041) 
i.e. case number only on slide. 
 
Thank you for completing this OCHRe Part 2 application form.  Please remember to provide 
electronic or paper copies of ethics and R&D approval documents when you submit it to OCHRe. 
 
NDCLS, Level 4, Academic Block, University of Oxford, John Radcliffe Hospital Headington, 
Oxford, OX3 9DU Email: ochre@ndcls.ox.ac.uk Tel: 01865 220557 Fax: 01865 222776 
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APPENDIX 3 – Risk Assessment (COSHH) 
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APPENDIX 4 – Statistical Formulae  
In this appendix below the formulae used in this work are given. These are well established 
methods documented elsewhere. 235,250,251,288  
 
Sample Size Estimations: 
 
The nomogram and instructions can be found at:  
 
URL:http://emj.bmj.com/content/22/3/180/suppl/DC1?ck=nck [Accessed 21/04/2016] 
 
 
The sample size (n) is estimated by:  
𝑛 =
DP
P
 
 
 
 
Where P is the prevalence of disease, DP (disease positive) is calculated as: 
 
 
 
DP = 𝑧2
𝑆𝑛 (1 −  𝑆𝑛)
W2
 
 
 
 
Where Sn is the predicted sensitivity, W is the desired confidence interval (0.05 for 95%) 
and z (representing z1-α/2) is taken from the standard Normal distribution (1.96 at the 95% 
CI). 
 
 
Statistical Analysis (accuracy): 
 
Prevalence (P): 
 
 
𝑃 =
𝐷𝑖𝑠𝑒𝑎𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
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Accuracy data are presented in 2 x 2 tables: 
 
 Disease present Disease absent 
Test Positive 
 
True Positive test 
result 
(TP) 
False Positive test result 
(FP) 
Test Negative 
 
False Negative test 
result 
(FN) 
True Negative test 
results 
(TN) 
 
 
 
Concordance (C) / accuracy:  
 
𝐶 =
(𝑇𝑃 + 𝑇𝑁)
(𝑇𝑃 + 𝐹𝑃 + 𝑇𝑁 + 𝐹𝑁)
 
 
 
 
Sensitivity (Sn): 
 
𝑆𝑛 =
𝑇𝑃
(𝑇𝑃 + 𝐹𝑁)
 
 
 
Specificity (Sp) 
 
𝑆𝑝 =
𝑇𝑁
(𝐹𝑃 + 𝑇𝑁)
  
 
 
 
Positive predictive value (PPV): 
 
𝑃𝑃𝑉 =
𝑇𝑃
(𝑇𝑃 + 𝐹𝑃)
 
 
 
 
Negative predictive value (NPV): 
 
𝑁𝑃𝑉 =
𝑇𝑁
(𝑇𝑁 + 𝐹𝑁)
 
 
 
 
 
 
 
Likelihood ratio positive (LH+) and negative (LH-): 
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𝐿𝐻+ =
𝑆𝑛
(1 − 𝑆𝑝)
 
 
and 
 
𝐿𝐻− =
(1 −  𝑆𝑛)
𝑆𝑝
 
 
 
Statistical Analysis (reproducibility): 
 
 
Reproducibility data are presented in 2 x 2 tables: 
 
 
 
 Reviewer 2 
positive 
Reviewer 2 
negative 
Reviewer 1 
positive 
Positive agreement 
(PA) 
Positive/negative 
disagreement 
(PND) 
Reviewer 2 
negative 
Negative/positive 
disagreement 
(NPD) 
Negative agreement 
(NA) 
 
 
Firstly, the proportion of cases in which the observers agree (Ag): 
 
𝐴𝑔 =
𝐴 + 𝐷
𝑇𝑜𝑡𝑎𝑙 𝑐𝑎𝑠𝑒𝑠
 
 
Probability (R) of the observer (O1 or O2) having produced the results randomly (i.e. by guessing), 
for each observer: 
 
RO1 =
𝐴+𝐵
𝑇𝑜𝑡𝑎𝑙 𝑐𝑎𝑠𝑒𝑠
 
 
RO2 =
𝐴+𝐶
𝑇𝑜𝑡𝑎𝑙 𝑐𝑎𝑠𝑒𝑠
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Probability of both randomly agreeing the result is positive (R+) and both randomly 
agreeing the result is negative (R-): 
 
R+ =     RO1    ×   RO2 
R-  =     (1 – RO1)    ×   (1 – RO2) 
 
The overall probability of agreeing (Ra): 
 
Ra  =     R+    +   R- 
 
Cohen’s kappa (k) statistic: 
𝑘 =
𝐴𝑔 − 𝑅𝑎
1 − 𝑅𝑎
 
 
 
0.0           → agreement only by chance 
0.0 – 0.2 → poor agreement 
0.2 – 0.4 → fair agreement  
0.4 – 0.6 → moderate agreement 
0.6 – 0.8 → good agreement 
0.8 – 1.0 → very good agreement 
 
 
Confidence intervals (CI): 
Wilson’s method: 
 
𝐶𝐼 =     
(𝐴 − 𝐵)
𝐶
      𝑡𝑜     
𝐴 + 𝐵
𝐶
   
 
Where 
 
𝐴 = 2𝑟 + 𝑧2 
𝐵 = 𝑧√𝑧2 + 4𝑟𝑞 
𝐶 = 2(𝑛 + 𝑧2) 
 
And 
 
𝑞 = 1 − 𝑝 
𝑝 =
𝑟
𝑛
 
 
 
Given that n is the sample size and r is the proportion in question.  
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